|
|
| Zeile 1: |
Zeile 1: |
| | | | |
| | cont as [[TempP(1)]] | | cont as [[TempP(1)]] |
| − |
| |
| − | {{tp|p=32628145|t=2020. Blocking angiotensin earlier with RAS blockers, statins, and heparin in high-risk COVID-19 patients: Is the remedy here?|pdf=|usr=012}}
| |
| − | {{tp|p=32634024|t=2020. How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32646061|t=2020. Could Ergothioneine Aid in the Treatment of Coronavirus Patients?|pdf=|usr=012}}
| |
| − | {{tp|p=32638906|t=2020. Controle do Intervalo QT para Prevencao de Torsades de Pointes Durante uso de Hidroxicloroquina e/ou Azitromicina em Pacientes com COVID 19.|pdf=|usr=012}}
| |
| − | {{tp|p=32645994|t=2020. Ten-Year Research Update Review: Antiviral Activities from Marine Organisms.|pdf=|usr=012}}
| |
| − | {{tp|p=32649880|t=2020. Need for Speed: From Human SARS-CoV-2 Samples to Protective and Efficacious Antibodies in Weeks.|pdf=|usr=012}}
| |
| − | {{tp|p=32641681|t=2020. Is hydroxychloroquine beneficial for COVID-19 patients?|pdf=|usr=012}}
| |
| − | {{tp|p=32638908|t=2020. Double-edged sword: Granulocyte colony stimulating factors in cancer patients during the COVID-19 era.|pdf=|usr=012}}
| |
| − | {{tp|p=32646869|t=2020. Challenges in evaluating SARS-CoV-2 vaccines during the COVID-19 pandemic.|pdf=|usr=012}}
| |
| − | {{tp|p=32646499|t=2020. Effect of favipiravir and an anti-inflammatory strategy for COVID-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32631373|t=2020. Clarifying the controversial risk-benefit profile of soluble ACE2 in COVID-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32620147|t=2020. Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series.|pdf=|usr=012}}
| |
| − | {{tp|p=32618691|t=2020. A Centrally Acting Antihypertensive, Clonidine, Sedates Patients Presenting With Acute Respiratory Distress Syndrome Evoked by Severe Acute Respiratory Syndrome-Coronavirus 2.|pdf=|usr=012}}
| |
| − | {{tp|p=32640414|t=2020. Vitamin D deficiency in patients with diabetes and COVID- 19 infection.|pdf=|usr=012}}
| |
| − | {{tp|p=32634717|t=2020. Application of Artificial Intelligence in COVID-19 drug repurposing.|pdf=|usr=012}}
| |
| − | {{tp|p=32639233|t=2020. Concentration-dependent mortality of chloroquine in overdose.|pdf=|usr=012}}
| |
| − | {{tp|p=32619390|t=2020. Shotgun proteomics analysis of SARS-CoV-2-infected cells and how it can optimize whole viral particle antigen production for vaccines.|pdf=|usr=012}}
| |
| − | {{tp|p=32615862|t=2020. Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry.|pdf=|usr=012}}
| |
| − | {{tp|p=32616599|t=2020. Potential of regulatory T cell-based therapies in the management of severe COVID-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32640331|t=2020. Analysis of the intricate effects of polyunsaturated fatty acids and polyphenols on inflammatory pathways in health and disease.|pdf=|usr=012}}
| |
| − | {{tp|p=32621202|t=2020. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.|pdf=|usr=012}}
| |
| − | {{tp|p=32638628|t=2020. Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2.|pdf=|usr=012}}
| |
| − | {{tp|p=32622993|t=2020. Prophylactic (hydroxy)chloroquine in COVID-19: potential relevance for cardiac arrhythmia risk.|pdf=|usr=012}}
| |
| − | {{tp|p=32621881|t=2020. INCIDENCE OF ARRHYTHMIAS AND ELECTROCARDIOGRAPHIC ABNORMALITIES IN SYMPTOMATIC PEDIATRIC PATIENTS WITH PCR POSITIVE SARS-CoV-2 INFECTION INCLUDING DRUG INDUCED CHANGES IN THE CORRECTED QT INTERVAL (QTc).|pdf=|usr=012}}
| |
| − | {{tp|p=32641876|t=2020. Curcumin: a Wonder Drug as a Preventive Measure for COVID19 Management.|pdf=|usr=012}}
| |
| − | {{tp|p=32641874|t=2020. Hydroxychloroquine and Covid-19: A Cellular and Molecular Biology Based Update.|pdf=|usr=012}}
| |
| − | {{tp|p=32643111|t=2020. Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease.|pdf=|usr=012}}
| |
| − | {{tp|p=32640381|t=2020. Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches.|pdf=|usr=012}}
| |
| − | {{tp|p=32642806|t=2020. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.|pdf=|usr=012}}
| |
| − | {{tp|p=32645633|t=2020. An update on antiviral antibody-based biopharmaceuticals.|pdf=|usr=012}}
| |
| − | {{tp|p=32645632|t=2020. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32634603|t=2020. COVID-19 Treatment: Close to a Cure? - A Rapid Review of Pharmacotherapies for the Novel Coronavirus.|pdf=|usr=012}}
| |
| − | {{tp|p=32646770|t=2020. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.|pdf=|usr=012}}
| |
| − | {{tp|p=32639711|t=2020. CNS Penetration Ability: A Critical Factor for Drugs in the Treatment of SARS-CoV-2 Brain Infection.|pdf=|usr=012}}
| |
| − | {{tp|p=32619190|t=2020. Passive immunization: Paradoxical and traditional method for new pandemic challenge COVID-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32648245|t=2020. COVID-19 and Mesenchymal Stem Cell Treatment; Mystery or Not.|pdf=|usr=012}}
| |
| − | {{tp|p=32628223|t=2020. Very Long-acting Antivirals as Chemovaccines for Preventing Viral Infections.|pdf=|usr=012}}
| |
| − | {{tp|p=32640172|t=2020. Poly(ADP-ribose) Polymerase Inhibition in Acute Lung Injury: A Re-emerging Concept.|pdf=|usr=012}}
| |
| − | {{tp|p=32634026|t=2020. COVID-19 Clinical Trials: Unravelling a Methodological Gordian Knot.|pdf=|usr=012}}
| |
| − | {{tp|p=32628535|t=2020. Regulatory T Cells for Treating Patients With COVID-19 and Acute Respiratory Distress Syndrome: Two Case Reports.|pdf=|usr=012}}
| |
| − | {{tp|p=32647027|t=2020. Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study.|pdf=|usr=012}}
| |
| − | {{tp|p=32632035|t=2020. Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD.|pdf=|usr=012}}
| |
| − | {{tp|p=32632034|t=2020. COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study.|pdf=|usr=012}}
| |
| − | {{tp|p=32632030|t=2020. Response to: 'COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study' by Cuceoglu et al.|pdf=|usr=012}}
| |
| − | {{tp|p=32620597|t=2020. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.|pdf=|usr=012}}
| |
| − | {{tp|p=32641296|t=2020. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.|pdf=|usr=012}}
| |
| − | {{tp|p=32631826|t=2020. Clinical trials of repurposed antivirals for SARS-CoV-2.|pdf=|usr=012}}
| |
| − | {{tp|p=32639103|t=2020. Trainee Led Collaboratives, Clinical Trials And New Opportunities In The Covid-19 Era.|pdf=|usr=012}}
| |
| − | {{tp|p=32644876|t=2020. Nutrients in prevention, treatment, and management of viral infections; special focus on Coronavirus.|pdf=|usr=012}}
| |
| − | {{tp|p=32646867|t=2020. Vaccines, convalescent plasma, and monoclonal antibodies for covid-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32631851|t=2020. Urgent call for greater multilateralism and coordination of covid-19 trials.|pdf=|usr=012}}
| |
| − | {{tp|p=32631850|t=2020. Covid-19: research methods must be flexible in a crisis.|pdf=|usr=012}}
| |
| − | {{tp|p=32620554|t=2020. Dexamethasone in the management of covid -19.|pdf=|usr=012}}
| |
| − | {{tp|p=32611587|t=2020. Covid-19: Lopinavir-ritonavir does not benefit hospitalised patients, UK trial finds.|pdf=|usr=012}}
| |
| − | {{tp|p=32641344|t=2020. COVID-19 clinical trials: see it big and keep it simple.|pdf=|usr=012}}
| |
| − | {{tp|p=32639062|t=2020. Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32627226|t=2020. Potential role of IL-17 blocking agents in the treatment of severe COVID-19?|pdf=|usr=012}}
| |
| − | {{tp|p=32645204|t=2020. Double-bright (CD56bright/CD16bright) NK cell adoptive immunotherapy for SARS-CoV-2.|pdf=|usr=012}}
| |
| − | {{tp|p=32621754|t=2020. COVID-19 pandemic and management of GIMEMA clinical trials: changes and challenges.|pdf=|usr=012}}
| |
| − | {{tp|p=32639031|t=2020. Proteinase-activated receptor 1 (PAR1): A target for repurposing in the treatment of COVID-19?|pdf=|usr=012}}
| |
| − | {{tp|p=32640179|t=2020. Current Therapies Under Investigation for COVID-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32633733|t=2020. Interaction of hydroxychloroquine with SARS-CoV2 functional proteins using all-atoms non-equilibrium alchemical simulations.|pdf=|usr=012}}
| |
| − | {{tp|p=32613971|t=2020. Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection.|pdf=|usr=012}}
| |
| − | {{tp|p=32621392|t=2020. Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalised with COVID-19 are associated with greater disease severity.|pdf=|usr=012}}
| |
| − | {{tp|p=32640049|t=2020. Immune checkpoint inhibition in the era of COVID-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32640019|t=2020. Proposing minimum requirements for announcing clinical trial results during the COVID-19 pandemic.|pdf=|usr=012}}
| |
| − | {{tp|p=32628748|t=2020. Evaluating use cases for human challenge trials in accelerating SARS-CoV-2 vaccine development.|pdf=|usr=012}}
| |
| − | {{tp|p=32648959|t=2020. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.|pdf=|usr=012}}
| |
| − | {{tp|p=32634894|t=2020. Smoking in critically ill patients with COVID-19: the Australian experience.|pdf=|usr=012}}
| |
| − | {{tp|p=32628049|t=2020. Analytical Methods on Determination in Pharmaceuticals and Biological Materials of Chloroquine as Available for the Treatment of COVID-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32619167|t=2020. Effect of the Phytochemical Agents Against the SARS-CoV and Selected Some of them for Application to COVID-19: A Mini-Review.|pdf=|usr=012}}
| |
| − | {{tp|p=32634080|t=2020. Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19).|pdf=|usr=012}}
| |
| − | {{tp|p=32634079|t=2020. The role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.|pdf=|usr=012}}
| |
| − | {{tp|p=32628591|t=2020. Elucidating the Pivotal Role of Immune Players in the Management of COVID-19: Focus on Mesenchymal Stem Cells and Inflammation.|pdf=|usr=012}}
| |
| − | {{tp|p=32648845|t=2020. Therapeutic targets and computational approaches on drug development for COVID-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32621718|t=2020. Shape-based Machine Learning Models for the potential Novel COVID-19 protease inhibitors assisted by Molecular Dynamics Simulation.|pdf=|usr=012}}
| |
| − | {{tp|p=32643448|t=2020. Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32632960|t=2020. Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review.|pdf=|usr=012}}
| |
| − | {{tp|p=32629169|t=2020. Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges.|pdf=|usr=012}}
| |
| − | {{tp|p=32616659|t=2020. BET 2: Hydroxychloroquine in the treatment of COVID-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32616658|t=2020. BET 1: Lopinavir-ritonavir and COVID-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32641191|t=2020. Bacillus Calmette-Guerin vaccination and clinical characteristics and outcomes of COVID-19 in Rhode Island, United States: a cohort study.|pdf=|usr=012}}
| |
| − | {{tp|p=32648935|t=2020. SGLT2 inhibition and COVID-19: The road not taken.|pdf=|usr=012}}
| |
| − | {{tp|p=32620680|t=2020. Do psychotropic drugs used during COVID-19 therapy have an effect on the treatment process?|pdf=|usr=012}}
| |
| − | {{tp|p=32631083|t=2020. Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32643980|t=2020. Predictor of poor prognosis of COVID-19 patients----liver injury.|pdf=|usr=012}}
| |
| − | {{tp|p=32649840|t=2020. Liver injury in severe COVID-19 infection: current insights and challenges.|pdf=|usr=012}}
| |
| − | {{tp|p=32639083|t=2020. Balancing infection control and frailty prevention during and after the COVID-19 pandemic: Introduction of the NCGG Home Exercise Program for Older People 2020.|pdf=|usr=012}}
| |
| − | {{tp|p=32645727|t=2020. Isopathic Remedy Prepared from Convalescent Plasma as a Therapeutic Option for COVID-19?|pdf=|usr=012}}
| |
| − | {{tp|p=32643512|t=2020. Thinking more about therapy with convalescent plasma for COVID-19 patients.|pdf=|usr=012}}
| |
| − | {{tp|p=32633162|t=2020. Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature.|pdf=|usr=012}}
| |
| − | {{tp|p=32643997|t=2020. Effect of recombinant human granulocyte colony-stimulating factor on lymphocyte subsets in patients with COVID-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32615877|t=2020. Suggestions for Combatting COVID-19 by Natural Means in the Absence of Standard Medical Regimens.|pdf=|usr=012}}
| |
| − | {{tp|p=32649272|t=2020. Combating COVID-19 and Building Immune Resilience: A Potential Role for Magnesium Nutrition?|pdf=|usr=012}}
| |
| − | {{tp|p=32643552|t=2020. Identification of bioactive molecule from Withania somnifera (Ashwagandha) as SARS-CoV-2 main protease inhibitor.|pdf=|usr=012}}
| |
| − | {{tp|p=32643550|t=2020. Potential of NO donor furoxan as SARS-CoV-2 main protease (M(pro)) inhibitors: in silico analysis.|pdf=|usr=012}}
| |
| − | {{tp|p=32643529|t=2020. Natural-like products as potential SARS-CoV-2 M(pro) inhibitors: in-silico drug discovery.|pdf=|usr=012}}
| |
| − | {{tp|p=32627715|t=2020. Screening of phytochemical compounds of Tinospora cordifolia for their inhibitory activity on SARS-CoV-2: an in silico study.|pdf=|usr=012}}
| |
| − | {{tp|p=32627689|t=2020. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.|pdf=|usr=012}}
| |
| − | {{tp|p=32619162|t=2020. Bacterial protein azurin and derived peptides as potential anti-SARS-CoV-2 agents: insights from molecular docking and molecular dynamics simulations.|pdf=|usr=012}}
| |
| − | {{tp|p=32619134|t=2020. Epitope based peptide vaccine against SARS-COV2: an immune-informatics approach.|pdf=|usr=012}}
| |
| − | {{tp|p=32618198|t=2020. Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights.|pdf=|usr=012}}
| |
| − | {{tp|p=32643158|t=2020. Excavating SARS-coronavirus 2 genome for epitope-based subunit vaccine synthesis using immunoinformatics approach.|pdf=|usr=012}}
| |
| − | {{tp|p=32643200|t=2020. Convalescent plasma therapy in patients with COVID-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32647045|t=2020. Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making.|pdf=|usr=012}}
| |
| − | {{tp|p=32644254|t=2020. Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management.|pdf=|usr=012}}
| |
| − | {{tp|p=32644224|t=2020. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection.|pdf=|usr=012}}
| |
| − | {{tp|p=32644208|t=2020. Erythropoietin Induced Hemoglobin Sub-Unit Beta may Stimulate Innate Immune RNA Virus Pattern Recognition, Suppress Reactive Oxygen Species, Reduce ACE2 Viral Doorway Opening and Neutrophil Extracellular Traps against Covid-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32633865|t=2020. A retrospective review of memantine use and COVID-19-associated mortality from a national database.|pdf=|usr=012}}
| |
| − | {{tp|p=32633831|t=2020. RNA-dependent RNA Polymerase of SARS-CoV-2 as a Therapeutic Target.|pdf=|usr=012}}
| |
| − | {{tp|p=32621621|t=2020. Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: a retrospective matched-pair cohort study.|pdf=|usr=012}}
| |
| − | {{tp|p=32617989|t=2020. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.|pdf=|usr=012}}
| |
| − |
| |
| − | {{tp|p=32634602|t=2020. Corticosteroid therapy for patients with CoVID-19 pneumonia: a before-after study.|pdf=|usr=012}}
| |
| − | {{tp|p=32629115|t=2020. A pharmacological perspective of Chloroquine in SARS-CoV-2 infection.|pdf=|usr=012}}
| |
| − | {{tp|p=32619764|t=2020. Case reports study of the first five patients COVID-19 treated with remdesivir in France.|pdf=|usr=012}}
| |
| − | {{tp|p=32634589|t=2020. Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapy.|pdf=|usr=012}}
| |
| − | {{tp|p=32623082|t=2020. Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32623080|t=2020. An Observational Cohort Study of Hydroxychloroquine and Azithromycin for COVID-19: (Can't Get No) Satisfaction.|pdf=|usr=012}}
| |
| − | {{tp|p=32629817|t=2020. Influence of Herbal Medicines on HMGB1 Release, SARS-CoV-2 Viral Attachment, Acute Respiratory Failure, and Sepsis. A Literature Review.|pdf=|usr=012}}
| |
| − | {{tp|p=32617855|t=2020. Phylogenetic Analysis and Structural Perspectives of RNA-Dependent RNA-Polymerase Inhibition from SARs-CoV-2 with Natural Products.|pdf=|usr=012}}
| |
| − | {{tp|p=32627127|t=2020. Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.|pdf=|usr=012}}
| |
| − | {{tp|p=32623068|t=2020. Nucleic Acid Approaches to Antibody-based Therapeutics for COVID-19: A Perspective.|pdf=|usr=012}}
| |
| − | {{tp|p=32634126|t=2020. SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy.|pdf=|usr=012}}
| |
| − | {{tp|p=32629768|t=2020. Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives.|pdf=|usr=012}}
| |
| − | {{tp|p=32630746|t=2020. SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening.|pdf=|usr=012}}
| |
| − | {{tp|p=32622963|t=2020. Mesenchymal stromal cells and their secreted extracellular vesicles as therapeutic tools for COVID-19 pneumonia? ().|pdf=|usr=012}}
| |
| − | {{tp|p=32622008|t=2020. Azithromycin and SARS-CoV-2 infection: where we are now and where we are going.|pdf=|usr=012}}
| |
| − | {{tp|p=32636240|t=2020. BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy.|pdf=|usr=012}}
| |
| − | {{tp|p=32611687|t=2020. On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32627442|t=2020. Convalescent Plasma Therapy in Coronavirus Disease 2019: a Case Report and Suggestions to Overcome Obstacles.|pdf=|usr=012}}
| |
| − | {{tp|p=32638109|t=2020. Mild COVID-19 infection in an NMO patient treated with tocilizumab: a confirmation of anti-IL-6 protective role?|pdf=|usr=012}}
| |
| − | {{tp|p=32646487|t=2020. Evolving geographic diversity in SARS-CoV2 and in silico analysis of replicating enzyme 3CL(pro) targeting repurposed drug candidates.|pdf=|usr=012}}
| |
| − | {{tp|p=32635935|t=2020. Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach.|pdf=|usr=012}}
| |
| − | {{tp|p=32631442|t=2020. Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19).|pdf=|usr=012}}
| |
| − | {{tp|p=32650019|t=2020. Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32629788|t=2020. Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy.|pdf=|usr=012}}
| |
| − | {{tp|p=32610445|t=2020. Microbial Natural Products as Potential Inhibitors of SARS-CoV-2 Main Protease (M(pro)).|pdf=|usr=012}}
| |
| − | {{tp|p=32634550|t=2020. Aptamers, the bivalent agents as probes and therapies for coronavirus infections: A systematic review.|pdf=|usr=012}}
| |
| − | {{tp|p=32641037|t=2020. Caspase1/11 signaling affects muscle regeneration and recovery following ischemia, and can be modulated by chloroquine.|pdf=|usr=012}}
| |
| − | {{tp|p=32647131|t=2020. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice.|pdf=|usr=012}}
| |
| − | {{tp|p=32648153|t=2020. The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine.|pdf=|usr=012}}
| |
| − | {{tp|p=32641560|t=2020. COVID-19 and vitamin D deficiency, a fatal combination?|pdf=|usr=012}}
| |
| − | {{tp|p=32645974|t=2020. SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings.|pdf=|usr=012}}
| |
| − | {{tp|p=32619723|t=2020. Edaravone: A potential treatment for the COVID-19-induced inflammatory syndrome?|pdf=|usr=012}}
| |
| − | {{tp|p=32622723|t=2020. Chinese herbal medicine for coronavirus disease 2019: A systematic review and meta-analysis.|pdf=|usr=012}}
| |
| − | {{tp|p=32629137|t=2020. Ultraviolet-based Biophotonic Technologies and COVID-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32641511|t=2020. Discovery of potent thrombin inhibitors from a protease-focused DNA-encoded chemical library.|pdf=|usr=012}}
| |
| − | {{tp|p=32621829|t=2020. Letter to the editor regarding "Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable".|pdf=|usr=012}}
| |
| − | {{tp|p=32638884|t=2020. Primum non nocere - Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?|pdf=|usr=012}}
| |
| − | {{tp|p=32616763|t=2020. A candidate multi-epitope vaccine against SARS-CoV-2.|pdf=|usr=012}}
| |
| − | {{tp|p=32638647|t=2020. Alternative management of Covid-19 infection.|pdf=|usr=012}}
| |
| − | {{tp|p=32636116|t=2020. First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia.|pdf=|usr=012}}
| |
| − | {{tp|p=32645478|t=2020. Hydroxychloroquine safety: A meta-analysis of randomized controlled trials.|pdf=|usr=012}}
| |
| − | {{tp|p=32629139|t=2020. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".|pdf=|usr=012}}
| |
| − | {{tp|p=32635353|t=2020. Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute Respiratory Distress: A Case Report and Literature Review.|pdf=|usr=012}}
| |
| − | {{tp|p=32640619|t=2020. Prospects and Challenges in the Development of Universal Influenza Vaccines.|pdf=|usr=012}}
| |
| − | {{tp|p=32635180|t=2020. Immunoinformatic Analysis of T- and B-Cell Epitopes for SARS-CoV-2 Vaccine Design.|pdf=|usr=012}}
| |
| − | {{tp|p=32621841|t=2020. Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2.|pdf=|usr=012}}
| |
| − | {{tp|p=32629804|t=2020. Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.|pdf=|usr=012}}
| |
| − | {{tp|p=32620700|t=2020. Low Dose Radiation to COVID-19 Patients to Ease the Disease Course and Reduce the Need of Intensive Care.|pdf=|usr=012}}
| |
| − | {{tp|p=32623965|t=2020. Are we aware of potential interactions between drugs used in lung cancer and drugs used in the treatment of COVID-19?|pdf=|usr=012}}
| |
| − | {{tp|p=32628262|t=2020. The Development of COVID-19 Vaccines: Safeguards Needed.|pdf=|usr=012}}
| |
| − | {{tp|p=32628244|t=2020. Developing a SARS-CoV-2 Vaccine at Warp Speed.|pdf=|usr=012}}
| |
| − | {{tp|p=32614442|t=2020. Evolution of Altered Sense of Smell or Taste in Patients With Mildly Symptomatic COVID-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32613691|t=2020. Editorial - Nutritional Status Affects COVID-19 Patient Outcomes.|pdf=|usr=012}}
| |
| − | {{tp|p=32613660|t=2020. Evaluation of Nutritional Risk and its Association With Mortality Risk in Severe and Critically Ill COVID-19 Patients.|pdf=|usr=012}}
| |
| − | {{tp|p=32619276|t=2020. Low dose radiation as a treatment for COVID-19 pneumonia: a threat or real opportunity?|pdf=|usr=012}}
| |
| − | {{tp|p=32619669|t=2020. Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease.|pdf=|usr=012}}
| |
| − | {{tp|p=32633860|t=2020. Safety of Plasma Infusions in Parkinson's Disease.|pdf=|usr=012}}
| |
| − | {{tp|p=32649078|t=2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.|pdf=|usr=012}}
| |
| − | {{tp|p=32649077|t=2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.|pdf=|usr=012}}
| |
| − | {{tp|p=32649076|t=2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.|pdf=|usr=012}}
| |
| − | {{tp|p=32649075|t=2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.|pdf=|usr=012}}
| |
| − | {{tp|p=32649074|t=2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.|pdf=|usr=012}}
| |
| − | {{tp|p=32643410|t=2020. Bioactive compounds from marine resources against novel corona virus (2019-nCoV): in silico study for corona viral drug.|pdf=|usr=012}}
| |
| − | {{tp|p=32636505|t=2020. COVID-19 platform trial delivers.|pdf=|usr=012}}
| |
| − | {{tp|p=32623442|t=2020. Going back in time for an antibody to fight COVID-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32645305|t=2020. Golden Anniversary of the Nicotinic Receptor.|pdf=|usr=012}}
| |
| − | {{tp|p=32618794|t=2020. Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19).|pdf=|usr=012}}
| |
| − | {{tp|p=32615642|t=2020. Is povidone-iodine mouthwash effective against SARS-CoV-2? First in vivo tests.|pdf=|usr=012}}
| |
| − | {{tp|p=32613637|t=2020. Naringenin, a flavanone with antiviral and anti-inflammatory effects: A promising treatment strategy against COVID-19.|pdf=|usr=012}}
| |
| − | {{tp|p=32648294|t=2020. COVID-19: Phylogenetic approaches may help in finding resources for natural cure.|pdf=|usr=012}}
| |
| − | {{tp|p=32647056|t=2020. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19).|pdf=|usr=012}}
| |
| − | {{tp|p=32648313|t=2020. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.|pdf=|usr=012}}
| |
| − | {{tp|p=32614102|t=2020. Using heat to kill SARS-CoV-2.|pdf=|usr=012}}
| |
| − | {{tp|p=32646977|t=2020. Can interferons stop COVID-19 before it takes hold?|pdf=|usr=012}}
| |
| − | {{tp|p=32649367|t=2020. Potential Immunotherapeutic Targets For Hypoxia Due to COVI-FLU.|pdf=|usr=012}}
| |
| − | {{tp|p=32619318|t=2020. COVID-19 drug repurposing: Summary statistics on current clinical trials and promising untested candidates.|pdf=|usr=012}}
| |
| − | {{tp|p=32627216|t=2020. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation.|pdf=|usr=012}}
| |
| − | {{tp|p=32639598|t=2020. SARS-CoV2 and immunosuppression: a double-edged sword.|pdf=|usr=012}}
| |
| − | {{tp|p=32629531|t=2020. Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib.|pdf=|usr=012}}
| |
| − | {{tp|p=32614684|t=2020. Review of the SARS-CoV-2 in Wuhan and Analysis as Well as Prediction of Therapeutic Drugs.|pdf=|usr=012}}
| |
| − |
| |
| − | {{tp|p=32388537|t=2020. Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease M(pro).|pdf=|usr=009}}
| |
| − | {{tp|p=32532959|t=2020. The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin.|pdf=|usr=009}}
| |
| − | {{tp|p=32423553|t=2020. Angiotensin converting enzyme: A review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infection.|pdf=|usr=009}}
| |
| − | {{tp|p=32531235|t=2020. Role of the GTNGTKR motif in the N-terminal receptor-binding domain of the SARS-CoV-2 spike protein.|pdf=|usr=009}}
| |
| − | {{tp|p=32430279|t=2020. Gut microbiota and Covid-19- possible link and implications.|pdf=|usr=009}}
| |
| − | {{tp|p=32416259|t=2020. On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2.|pdf=|usr=009}}
| |
| − | {{tp|p=32558150|t=2020. Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation.|pdf=|usr=010}}
| |
| − | {{tp|p=32585135|t=2020. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.|pdf=|usr=010}}
| |
| − | {{tp|p=32546195|t=2020. Micronutrient status of COVID-19 patients: a critical consideration.|pdf=|usr=010}}
| |
| − | {{tp|p=32559343|t=2020. Rationale for targeting Complement in COVID-19.|pdf=|usr=010}}
| |
| − | {{tp|p=32543705|t=2020. Evolutionary relationships and sequence-structure determinants in human SARS coronavirus-2 spike proteins for host receptor recognition.|pdf=|usr=010}}
| |
| − | {{tp|p=32592394|t=2020. A role for selenium-dependent GPX1 in SARS-CoV-2 virulence.|pdf=|usr=010}}
| |
| − | {{tp|p=32590326|t=2020. Pulmonary surfactant itself must be a strong defender against SARS-CoV-2.|pdf=|usr=010}}
| |
| − | {{tp|p=32562814|t=2020. Statins and other drugs: Facing COVID-19 as a vascular disease.|pdf=|usr=010}}
| |
| − | {{tp|p=32424591|t=2020. COVID-19, acute respiratory distress syndrome (ARDS), and hyperbaric oxygen therapy (HBOT): what is the link?|pdf=|usr=011}}
| |
| − | {{tp|p=32598884|t=2020. Alterations in Fecal Fungal Microbiome of Patients With COVID-19 During Time of Hospitalization until Discharge.|pdf=|usr=011}}
| |
| − | {{tp|p=32481719|t=2020. The Role of MicroRNA in the Airway Surface Liquid Homeostasis.|pdf=|usr=011}}
| |
| − | {{tp|p=32534506|t=2020. Bradykinin as a Probable Aspect in SARS-Cov-2 Scenarios: Is Bradykinin Sneaking out of Our Sight?|pdf=|usr=011}}
| |
| − | {{tp|p=32600316|t=2020. The cholinergic anti-inflammatory pathway alleviates acute lung injury.|pdf=|usr=011}}
| |
| − | {{tp|p=32537478|t=2020. Airways Expression of SARS-CoV-2 Receptor, ACE2, and TMPRSS2 Is Lower in Children Than Adults and Increases with Smoking and COPD.|pdf=|usr=011}}
| |
| − | {{tp|p=32595361|t=2020. Gut-lung axis and dysbiosis in COVID-19.|pdf=|usr=011}}
| |
| − | {{tp|p=32591496|t=2020. Door to the cell for COVID-19 opened, leading way to therapies.|pdf=|usr=011}}
| |
| − | {{tp|p=32602262|t=2020. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series.|pdf=|usr=011}}
| |
| − | {{tp|p=32555145|t=2020. Targeting the entry step of SARS-CoV-2: a promising therapeutic approach.|pdf=|usr=011}}
| |
| − | {{tp|p=32594085|t=2020. Early Hemoperfusion for Cytokine Removal May Contribute to Prevention of Intubation in Patients Infected with COVID-19.|pdf=|usr=011}}
| |
| − | {{tp|p=32582574|t=2020. ACE2, Much More Than Just a Receptor for SARS-COV-2.|pdf=|usr=011}}
| |
| − | {{tp|p=32545271|t=2020. Relative Abundance of SARS-CoV-2 Entry Genes in the Enterocytes of the Lower Gastrointestinal Tract.|pdf=|usr=011}}
| |
| − | {{ttp|p=32593832|t=2020. Why is SARS-CoV-2 infection more severe in obese men? The gut lymphatics - Lung axis hypothesis.|pdf=|usr=011}}
| |
| − | {{tp|p=32573788|t=2020. Elucidation of Cellular Targets and Exploitation of the Receptor Binding Domain of SARS-CoV-2 for vaccine and monoclonal antibody synthesis.|pdf=|usr=011}}
| |
| − | {{tp|p=32551652|t=2020. Critical Differences Between the Binding Features of the Spike Proteins of SARS-CoV-2 and SARS-CoV.|pdf=|usr=011}}
| |
| − | {{tp|p=32551648|t=2020. The Discovery of a Putative Allosteric Site in the SARS-CoV-2 Spike Protein Using an Integrated Structural/Dynamic Approach.|pdf=|usr=011}}
| |
| − | {{tp|p=32571797|t=2020. Identification of common deletions in the spike protein of SARS-CoV-2.|pdf=|usr=011}}
| |
| − | {{tp|p=32606248|t=2020. Genomic discovery of an evolutionarily programmed modality for small-molecule targeting of an intractable protein surface.|pdf=|usr=011}}
| |
| − | {{tp|p=32602627|t=2020. Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection.|pdf=|usr=011}}
| |
| − |
| |
| − | {{tp|p=32417594|t=2020. Supplements for COVID-19: A modifiable environmental risk.|pdf=|usr=011}}
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=32665809|t=2020. Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment.|pdf=|usr=014}}
| |
| − | {{tp|p=32665808|t=2020. Exploiting Existing Molecular Scaffolds for Long-Term COVID Treatment.|pdf=|usr=014}}
| |
| − | {{tp|p=32667191|t=2020. Hard Nanomaterials in Time of Viral Pandemics.|pdf=|usr=014}}
| |
| − | {{tp|p=32717094|t=2020. Cannabis terapeutico y COVID-19: entre el oportunismo y la infoxicacion.|pdf=|usr=014}}
| |
| − | {{tp|p=32711735|t=2020. Reverse genetic systems: Rational design of coronavirus live attenuated vaccines with immune sequelae.|pdf=|usr=014}}
| |
| − | {{tp|p=32705585|t=2020. Associations between hypovitaminosis D and COVID-19: a narrative review.|pdf=|usr=014}}
| |
| − | {{tp|p=32653224|t=2020. BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic?|pdf=|usr=014}}
| |
| − | {{tp|p=32687406|t=2020. Inhibiting Fusion with Cellular Membrane System: Therapeutic Options to Prevent Severe Acute Respiratory Syndrome Coronavirus-2 Infection.|pdf=|usr=014}}
| |
| − | {{tp|p=32653550|t=2020. Treating hypoxemic COVID-19 "ARDS" patients with almitrine: The earlier the better?|pdf=|usr=014}}
| |
| − | {{tp|p=32673060|t=2020. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial.|pdf=|usr=014}}
| |
| − | {{tp|p=32673059|t=2020. The Saga of Hydroxychloroquine and COVID-19: A Cautionary Tale.|pdf=|usr=014}}
| |
| − | {{tp|p=32667853|t=2020. Update Alert: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32653425|t=2020. Does androgen deprivation therapy protect against severe complications from COVID-19?|pdf=|usr=014}}
| |
| − | {{tp|p=32692238|t=2020. Tongue diagnosis and treatment in traditional Chinese medicine for severe COVID-19: a case report.|pdf=|usr=014}}
| |
| − | {{tp|p=32660993|t=2020. Safety, pharmacokinetics, and activity of high-dose ivermectin and chloroquine against the liver-stage of Plasmodium cynomolgi infection in Rhesus Macaques.|pdf=|usr=014}}
| |
| − | {{tp|p=32708578|t=2020. The Role of Glutathione in Protecting against the Severe Inflammatory Response Triggered by COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32679055|t=2020. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.|pdf=|usr=014}}
| |
| − | {{tp|p=32659293|t=2020. Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.|pdf=|usr=014}}
| |
| − | {{tp|p=32659292|t=2020. Immunoglobulin fragment F(ab')2 against RBD potently neutralizes SARS-CoV-2 in vitro.|pdf=|usr=014}}
| |
| − | {{tp|p=32660794|t=2020. Response to: Amantadine Treatment for People with COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32682671|t=2020. Nutrition management for critically and acutely unwell hospitalised patients with coronavirus disease 2019 (COVID-19) in Australia and New Zealand.|pdf=|usr=014}}
| |
| − | {{tp|p=32710969|t=2020. Approaching Coronavirus Disease 2019: mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.|pdf=|usr=014}}
| |
| − | {{tp|p=32688139|t=2020. PARP-inhibitors in a non-oncological indication as COVID-19: Are we aware about its potential role as anti-thrombotic drugs? The discussion is open.|pdf=|usr=014}}
| |
| − | {{tp|p=32679775|t=2020. Deamidated Human Triosephosphate Isomerase is a Promising Druggable Target.|pdf=|usr=014}}
| |
| − | {{tp|p=32665234|t=2020. Drug treatments affecting ACE2 in COVID-19 infection: a systematic review protocol.|pdf=|usr=014}}
| |
| − | {{tp|p=32717399|t=2020. Purinergic signaling in infectious diseases of the central nervous system.|pdf=|usr=014}}
| |
| − | {{tp|p=32679175|t=2020. Regional differences in use of immune-modulating catechins should be investigated regarding COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32679174|t=2020. Reply to the Letter to the Editor: Regional differences in dietary use of immune-modulating catechins should be investigated regarding COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32615072|t=2020. Ivermectin: potential candidate for the treatment of Covid 19.|pdf=|usr=014}}
| |
| − | {{tp|p=32717278|t=2020. The Multiple Effects of SGLT2 Inhibitors Suggest Potential Benefit in COVID-19 Patients.|pdf=|usr=014}}
| |
| − | {{tp|p=32643141|t=2020. Ion channel inhibition against COVID-19: A novel target for clinical investigation.|pdf=|usr=014}}
| |
| − | {{tp|p=32645327|t=2020. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.|pdf=|usr=014}}
| |
| − | {{tp|p=32714563|t=2020. Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro.|pdf=|usr=014}}
| |
| − | {{tp|p=32707096|t=2020. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.|pdf=|usr=014}}
| |
| − | {{tp|p=32668216|t=2020. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice.|pdf=|usr=014}}
| |
| − | {{tp|p=32711111|t=2020. Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32710890|t=2020. The minimal effect of zinc on the survival of hospitalized patients with Covid-19: an observational study.|pdf=|usr=014}}
| |
| − | {{tp|p=32676976|t=2020. Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial.|pdf=|usr=014}}
| |
| − | {{tp|p=32632717|t=2020. In Silico Screening of Potential Chinese Herbal Medicine Against COVID-19 by Targeting SARS-CoV-2 3CLpro and Angiotensin Converting Enzyme II Using Molecular Docking.|pdf=|usr=014}}
| |
| − | {{tp|p=32665783|t=2020. Current strategies against COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32667534|t=2020. Pandemia de COVID19: implicacoes para (in)seguranca alimentar e nutricional.|pdf=|usr=014}}
| |
| − | {{tp|p=32661912|t=2020. Tocilizumab, Adipokines and Severe Complications of COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32661911|t=2020. Authors' Reply to: Tocilizumab, Adipokines and Severe Complications of COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32707089|t=2020. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous n-acetylcysteine.|pdf=|usr=014}}
| |
| − | {{tp|p=32673711|t=2020. mTORC inhibitor Sirolimus deprograms monocytes in "cytokine storm" in SARS-CoV2 secondary hemophagocytic lymphohistiocytosis- like syndrome.|pdf=|usr=014}}
| |
| − | {{tp|p=32663514|t=2020. Intestinal microbiome transfer, a novel therapeutic strategy for COVID-19 induced hyperinflammation?: In reply to, 'COVID-19: Immunology and treatment options', Felsenstein, Herbert McNamara et al. 2020'.|pdf=|usr=014}}
| |
| − | {{tp|p=32675166|t=2020. COVID-19, hydroxychloroquine and the eighth alternative.|pdf=|usr=014}}
| |
| − | {{tp|p=32717568|t=2020. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.|pdf=|usr=014}}
| |
| − | {{tp|p=32705604|t=2020. Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?|pdf=|usr=014}}
| |
| − | {{tp|p=32709544|t=2020. COVID-19 and hydroxychloroquine: Let the available data speak for themselves.|pdf=|usr=014}}
| |
| − | {{tp|p=32668460|t=2020. COVID-19 Therapeutics: Making Sense of It All.|pdf=|usr=014}}
| |
| − | {{tp|p=32662982|t=2020. Calcium Channel Blockers: A Possible Potential Therapeutic Strategy for the Treatment of Alzheimer's Dementia Patients with SARS-CoV-2 Infection.|pdf=|usr=014}}
| |
| − | {{tp|p=32687696|t=2020. Old drugs for a new virus: repurposed approaches for combating COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32686128|t=2020. Montelukast in children with allergic rhinitis amid COVID-19 pandemic.|pdf=|usr=014}}
| |
| − | {{tp|p=32696443|t=2020. The Role of Hyperbaric Oxygen Treatment for COVID-19: A Review.|pdf=|usr=014}}
| |
| − | {{tp|p=32716768|t=2020. The Regulation of COVID-19 "Challenge" Studies.|pdf=|usr=014}}
| |
| − | {{tp|p=32709838|t=2020. Unusual Early Recovery of a Critical COVID-19 Patient After Administration of Intravenous Vitamin C.|pdf=|usr=014}}
| |
| − | {{tp|p=32661220|t=2020. First-in-Man: Case Report of Selective C-Reactive Protein Apheresis in a Patient with SARS-CoV-2 Infection.|pdf=|usr=014}}
| |
| − | {{tp|p=32694294|t=2020. Nutrition Support in the ICU-A Refresher in the Era of COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32668178|t=2020. Inhaled Corticosteroids and COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32668164|t=2020. Reply to: Inhaled Corticosteroids and COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32711585|t=2020. More Studies are Needed on the Link between Metformin and Decreased Mortality in Diabetic COVID-19 Patients.|pdf=|usr=014}}
| |
| − | {{tp|p=32705976|t=2020. Artemisia Spp. Derivatives for COVID-19 Treatment: Anecdotal Use, Political Hype, Treatment Potential, Challenges, and Road Map to Randomized Clinical Trials.|pdf=|usr=014}}
| |
| − | {{tp|p=32663348|t=2020. Current status of COVID-19 (pre)clinical vaccine development.|pdf=|usr=014}}
| |
| − | {{tp|p=32692580|t=2020. Repurposing Existing Drugs for the Treatment of COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32687756|t=2020. Remdesivir improved time to recovery in adults hospitalized with COVID-19 and lower respiratory tract involvement.|pdf=|usr=014}}
| |
| − | {{tp|p=32661006|t=2020. Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial.|pdf=|usr=014}}
| |
| − | {{tp|p=32686943|t=2020. Potential role of Bacillus Calmette-Guerin (BCG) vaccination in COVID-19 pandemic mortality: Epidemiological and Immunological aspects.|pdf=|usr=014}}
| |
| − | {{tp|p=32713288|t=2020. Chloroquine in fighting COVID-19: good, bad, or both?|pdf=|usr=014}}
| |
| − | {{tp|p=32692801|t=2020. COVID-19 Docking Server: A meta server for docking small molecules, peptides and antibodies against potential targets of COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32663708|t=2020. Reckoning a fungal metabolite, Pyranonigrin A as a potential Main protease (M(pro)) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation.|pdf=|usr=014}}
| |
| − | {{tp|p=32699011|t=2020. Intensive immunosuppression reduces deaths in covid-19-associated cytokine storm syndrome, study finds.|pdf=|usr=014}}
| |
| − | {{tp|p=32698999|t=2020. Are we responsible for the racial inequalities of covid-19?|pdf=|usr=014}}
| |
| − | {{tp|p=32665225|t=2020. Covid-19: Experts criticise claim that remdesivir cuts death rates.|pdf=|usr=014}}
| |
| − | {{tp|p=32693436|t=2020. Model-Informed Drug Repurposing: Viral Kinetic Modeling to Prioritize Rational Drug Combinations for COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32692462|t=2020. ABNORMAL LABORATORY FINDINGS AND PLASMA CONCENTRATION MONITORING OF LOPINAVIR AND RITONAVIR IN COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32687645|t=2020. Clinical outcomes and adverse events in patients hospitalised with COVID -19, treated with off- label hydroxychloroquine and azithromycin.|pdf=|usr=014}}
| |
| − | {{tp|p=32656822|t=2020. Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials.|pdf=|usr=014}}
| |
| − | {{tp|p=32652563|t=2020. Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection.|pdf=|usr=014}}
| |
| − | {{tp|p=32713358|t=2020. COVID-19 and Misinformation: How an Infodemic Fueled the prominence of Vitamin D.|pdf=|usr=014}}
| |
| − | {{tp|p=32703328|t=2020. THE RATIONALE FOR A MULTI-STEP THERAPEUTIC APPROACH BASED ON ANTIVIRALS, DRUGS, AND NUTRIENTS WITH IMMUNOMODULATORY ACTIVITY IN PATIENTS WITH CORONAVIRUS-SARS2-INDUCED DISEASE OF DIFFERENT SEVERITY.|pdf=|usr=014}}
| |
| − | {{tp|p=32700336|t=2020. Non-steroidal anti-inflammatory drugs, prostaglandins and COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32681537|t=2020. Safety perspectives on presently considered drugs for the treatment of COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32671829|t=2020. Targeting zinc metalloenzymes in COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32713374|t=2020. Clozapine treatment and risk of COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32662814|t=2020. Integrative pharmacological mechanism of vitamin C combined with glycyrrhizic acid against COVID-19: findings of bioinformatics analyses.|pdf=|usr=014}}
| |
| − | {{tp|p=32717117|t=2020. Peptidyl Acyloxymethyl Ketones as Activity-Based Probes for the Main Protease of SARS-CoV-2.|pdf=|usr=014}}
| |
| − | {{tp|p=32700795|t=2020. Targeting SARS-CoV-2 RBD interface: a supervised computational data-driven approach to identify potential modulators.|pdf=|usr=014}}
| |
| − | {{tp|p=32702997|t=2020. IL-6 Blockade and QTc Prolongation in COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32671847|t=2020. In response to: Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalised with COVID-19 are associated with greater disease severity.|pdf=|usr=014}}
| |
| − | {{tp|p=32710937|t=2020. Micronutrients as immunomodulatory tools for COVID-19 management.|pdf=|usr=014}}
| |
| − | {{tp|p=32706859|t=2020. Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care.|pdf=|usr=014}}
| |
| − | {{tp|p=32674126|t=2020. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial.|pdf=|usr=014}}
| |
| − | {{tp|p=32671407|t=2020. Long-term outcome of short-course high-dose glucocorticoids for SARS: a 17-year follow-up in SARS survivors.|pdf=|usr=014}}
| |
| − | {{tp|p=32667978|t=2020. Treatment of COVID-19 - Evidence-Based or Personalized Medicine?|pdf=|usr=014}}
| |
| − | {{tp|p=32651997|t=2020. Tocilizumab for treatment of mechanically ventilated patients with COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32687630|t=2020. Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.|pdf=|usr=014}}
| |
| − | {{tp|p=32674594|t=2020. Endpoints for randomized controlled clinical trials for COVID-19 treatments.|pdf=|usr=014}}
| |
| − | {{tp|p=32666816|t=2020. Highly efficient clinical trial designs for reliable screening of under-performing treatments: Application to the COVID-19 Pandemic.|pdf=|usr=014}}
| |
| − | {{tp|p=32650672|t=2020. Clinical trials in the time of a pandemic.|pdf=|usr=014}}
| |
| − | {{tp|p=32650671|t=2020. Editorial: Clinical trial design in the era of COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32651961|t=2020. Updates on the Pharmacology of Chloroquine against Coronavirus Disease 2019 (COVID-19): A Perspective on its Use in the General and Geriatric Population.|pdf=|usr=014}}
| |
| − | {{tp|p=32675717|t=2020. Role for antimalarials in the management of COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32674732|t=2020. Ligand- and structure-based virtual screening of Lamiaceae diterpenes with potential activity against a novel coronavirus (2019-nCoV).|pdf=|usr=014}}
| |
| − | {{tp|p=32686260|t=2020. Insights in chloroquine action: perspectives and implications in Malaria and COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32692700|t=2020. Plasma-derived therapy: can the survivors of COVID-19 help the defenseless?|pdf=|usr=014}}
| |
| − | {{tp|p=32690491|t=2020. Dexamethasone for COVID-19: preliminary findings.|pdf=|usr=014}}
| |
| − | {{tp|p=32705683|t=2020. High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection.|pdf=|usr=014}}
| |
| − | {{tp|p=32688337|t=2020. Growth hormone therapy at the time of Covid-19 pandemic: adherence and drug supply issues.|pdf=|usr=014}}
| |
| − | {{tp|p=32706089|t=2020. Potential usefulness of pentoxifylline, a non-specific phosphodiesterase inhibitor with anti-inflammatory, anti-thrombotic, antioxidant, and anti-fibrogenic properties, in the treatment of SARS-CoV-2.|pdf=|usr=014}}
| |
| − | {{tp|p=32706087|t=2020. A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients.|pdf=|usr=014}}
| |
| − | {{tp|p=32700604|t=2020. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications.|pdf=|usr=014}}
| |
| − |
| |
| − | {{tp|p=32658735|t=2020. Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach.|pdf=|usr=014}}
| |
| − | {{tp|p=32698853|t=2020. Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence.|pdf=|usr=014}}
| |
| − | {{tp|p=32693829|t=2020. Chinese herbal experience for the 2019 novel coronavirus.|pdf=|usr=014}}
| |
| − | {{tp|p=32690059|t=2020. Convalescent plasma to treat critically ill patients with COVID-19: framing the need for randomised clinical trials.|pdf=|usr=014}}
| |
| − | {{tp|p=32684169|t=2020. Neuromuscular blocking agents (NMBA) for COVID-19 acute respiratory distress syndrome: a multicenter observational study.|pdf=|usr=014}}
| |
| − | {{tp|p=32682440|t=2020. Blocking IL-1 to prevent respiratory failure in COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32680535|t=2020. Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series.|pdf=|usr=014}}
| |
| − | {{tp|p=32664996|t=2020. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation.|pdf=|usr=014}}
| |
| − | {{tp|p=32653043|t=2020. Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia.|pdf=|usr=014}}
| |
| − | {{tp|p=32653015|t=2020. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.|pdf=|usr=014}}
| |
| − | {{tp|p=32656044|t=2020. Pulse Therapy With Corticosteroids and Intravenous Immunoglobulin in the Management of Severe Tocilizumab-Resistant COVID-19: A Report of Three Clinical Cases.|pdf=|usr=014}}
| |
| − | {{tp|p=32661859|t=2020. Can Vitamins, as Epigenetic Modifiers, Enhance Immunity in COVID-19 Patients with Non-communicable Disease?|pdf=|usr=014}}
| |
| − | {{tp|p=32665127|t=2020. Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?|pdf=|usr=014}}
| |
| − | {{tp|p=32683320|t=2020. Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19).|pdf=|usr=014}}
| |
| − | {{tp|p=32696429|t=2020. Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.|pdf=|usr=014}}
| |
| − | {{tp|p=32696108|t=2020. Pharmaco-Immunomodulatory Therapy in COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32655654|t=2020. Coronavirus disease 2019 (COVID-19): latest developments in potential treatments.|pdf=|usr=014}}
| |
| − | {{tp|p=32691021|t=2020. Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia.|pdf=|usr=014}}
| |
| − | {{tp|p=32662949|t=2020. Modulation of the acute defence reaction by eplerenone prevents cardiac disease progression in viral myocarditis.|pdf=|usr=014}}
| |
| − | {{tp|p=32696234|t=2020. Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies.|pdf=|usr=014}}
| |
| − | {{tp|p=32653152|t=2020. Waste in COVID-19 clinical trials conducted in western Europe.|pdf=|usr=014}}
| |
| − | {{tp|p=32651040|t=2020. Linking hydroxychloroquine to hemolysis in a 'suspected' glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection - a critical appraisal.|pdf=|usr=014}}
| |
| − | {{tp|p=32693294|t=2020. Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses.|pdf=|usr=014}}
| |
| − | {{tp|p=32668312|t=2020. A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection.|pdf=|usr=014}}
| |
| − | {{tp|p=32682787|t=2020. Advances in the possible treatment of COVID-19: A review.|pdf=|usr=014}}
| |
| − | {{tp|p=32700671|t=2020. Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2.|pdf=|usr=014}}
| |
| − | {{tp|p=32707160|t=2020. An overview of safety assessment of the medicines currently used in the treatment of COVID-19 disease.|pdf=|usr=014}}
| |
| − | {{tp|p=32679367|t=2020. Selenium - associated gene signatures within the SARS-CoV-2 - host genomic interaction interface.|pdf=|usr=014}}
| |
| − | {{tp|p=32653511|t=2020. Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32714335|t=2020. Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine.|pdf=|usr=014}}
| |
| − | {{tp|p=32695123|t=2020. GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response.|pdf=|usr=014}}
| |
| − | {{tp|p=32670297|t=2020. Severe COVID-19: NLRP3 Inflammasome Dysregulated.|pdf=|usr=014}}
| |
| − | {{tp|p=32705405|t=2020. Traditional Chinese medicine for combating COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32651936|t=2020. The role played by traditional Chinese medicine in preventing and treating COVID-19 in China.|pdf=|usr=014}}
| |
| − | {{tp|p=32714938|t=2020. Physical Exercise Potentials Against Viral Diseases Like COVID-19 in the Elderly.|pdf=|usr=014}}
| |
| − | {{tp|p=32671084|t=2020. Randomized Controlled Study Evaluating Efficiency of Low Intensity Transcranial Direct Current Stimulation (tDCS) for Dyspnea Relief in Mechanically Ventilated COVID-19 Patients in ICU: The tDCS-DYSP-COVID Protocol.|pdf=|usr=014}}
| |
| − | {{tp|p=32714193|t=2020. Turning the Tide: Natural Products and Natural-Product-Inspired Chemicals as Potential Counters to SARS-CoV-2 Infection.|pdf=|usr=014}}
| |
| − | {{tp|p=32698626|t=2020. Anti-COVID drugs: repurposing existing drugs or search for new complex entities, strategies and perspectives.|pdf=|usr=014}}
| |
| − | {{tp|p=32672061|t=2020. Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics.|pdf=|usr=014}}
| |
| − | {{tp|p=32662664|t=2020. N-acetylcysteine as a potential treatment for novel coronavirus disease 2019.|pdf=|usr=014}}
| |
| − | {{tp|p=32682763|t=2020. Association between famotidine use and COVID-19 severity in Hong Kong: a territory-wide study.|pdf=|usr=014}}
| |
| − | {{tp|p=32717321|t=2020. Genomics approaches to synthesis plant-based biomolecules for therapeutic applications to combat SARS-CoV-2.|pdf=|usr=014}}
| |
| − | {{tp|p=32703797|t=2020. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial.|pdf=|usr=014}}
| |
| − | {{tp|p=32703791|t=2020. Complement C5 inhibition in patients with COVID-19 - a promising target?|pdf=|usr=014}}
| |
| − | {{tp|p=32676695|t=2020. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.|pdf=|usr=014}}
| |
| − | {{tp|p=32712334|t=2020. Ribavirin Therapy For Severe COVID-19: A Retrospective Cohort Study.|pdf=|usr=014}}
| |
| − | {{tp|p=32712333|t=2020. Tocilizumab for severe COVID-19: a systematic review and meta-analysis.|pdf=|usr=014}}
| |
| − | {{tp|p=32708322|t=2020. Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19?|pdf=|usr=014}}
| |
| − | {{tp|p=32717282|t=2020. The Lord of the NanoRings: cyclodextrins and the battle against SARS-CoV-2.|pdf=|usr=014}}
| |
| − | {{tp|p=32711037|t=2020. Radiation Therapy as a Treatment for COVID-19?|pdf=|usr=014}}
| |
| − | {{tp|p=32707264|t=2020. Low-dose Whole-lung Irradiation for COVID-19 Pneumonia: Short Course Results.|pdf=|usr=014}}
| |
| − | {{tp|p=32713677|t=2020. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.|pdf=|usr=014}}
| |
| − | {{tp|p=32707230|t=2020. Differential immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung and intestinal cells: implications for treatment with IFN-beta and IFN inducer.|pdf=|usr=014}}
| |
| − | {{tp|p=32662677|t=2020. The combination of artificial intelligence and systems biology for intelligent vaccine design.|pdf=|usr=014}}
| |
| − | {{tp|p=32693646|t=2020. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.|pdf=|usr=014}}
| |
| − | {{tp|p=32693650|t=2020. Tocilizumab for patients with severe COVID-19: a retrospective, multi-centre study.|pdf=|usr=014}}
| |
| − | {{tp|p=32693652|t=2020. Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection.|pdf=|usr=014}}
| |
| − | {{tp|p=32662690|t=2020. The Use of IV vitamin C for patients with COVID-19: a single center observational study.|pdf=|usr=014}}
| |
| − | {{tp|p=32700398|t=2020. Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study.|pdf=|usr=014}}
| |
| − | {{tp|p=32657483|t=2020. Pharmacological agents under investigation in the treatment of coronavirus disease 2019 and the importance of melatonin.|pdf=|usr=014}}
| |
| − | {{tp|p=32691927|t=2020. Drug interactions with potential antivirals used for COVID-19 in older persons.|pdf=|usr=014}}
| |
| − | {{tp|p=32701395|t=2020. Designing Pull Funding For A COVID-19 Vaccine.|pdf=|usr=014}}
| |
| − | {{tp|p=32706599|t=2020. A Social and Behavioral Research Agenda to Facilitate COVID-19 Vaccine Uptake in the United States.|pdf=|usr=014}}
| |
| − | {{tp|p=32703069|t=2020. Promise and challenges in the development of COVID-19 vaccines.|pdf=|usr=014}}
| |
| − | {{tp|p=32703064|t=2020. COVID-19 - Recent advancements in identifying novel vaccine candidates and current status of upcoming SARS-CoV-2 vaccines.|pdf=|usr=014}}
| |
| − | {{tp|p=32693665|t=2020. COVID-19 - Important considerations for developing and using a vaccine.|pdf=|usr=014}}
| |
| − | {{tp|p=32663051|t=2020. An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein.|pdf=|usr=014}}
| |
| − | {{tp|p=32710535|t=2020. MMR Vaccine and Covid-19: A Myth or a Low Risk-High Reward Preventive Measure?|pdf=|usr=014}}
| |
| − | {{tp|p=32713336|t=2020. Chloroquine as chemoprophylaxis for COVID-19: Will this work?|pdf=|usr=014}}
| |
| − | {{tp|p=32673140|t=2020. Re: Low-dose radiation therapy for COVID-19 pneumonia: is there any supportive evidence?|pdf=|usr=014}}
| |
| − | {{tp|p=32674673|t=2020. COVID-19 and Vitamin D deficiency; the two pandemics. Are they correlated?|pdf=|usr=014}}
| |
| − | {{tp|p=32666683|t=2020. COVID-19 and chronic obstructive pulmonary disease: therapeutic potential of blocking SARS-CoV2 adhesion factors.|pdf=|usr=014}}
| |
| − | {{tp|p=32673081|t=2020. Chinese Herbal Medicines During the Covid-19 Pandemic: A Role for Observational Studies.|pdf=|usr=014}}
| |
| − | {{tp|p=32659175|t=2020. Can Vitamin D and L-Cysteine Co-Supplementation Reduce 25(OH)-Vitamin D Deficiency and the Mortality Associated with COVID-19 in African Americans?|pdf=|usr=014}}
| |
| − | {{tp|p=32688374|t=2020. Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients.|pdf=|usr=014}}
| |
| − | {{tp|p=32720578|t=2020. Identification of some novel oxazine substituted 9-anilinoacridines as SARS-CoV-2 inhibitors for COVID-19 by molecular docking, free energy calculation and molecular dynamics studies.|pdf=|usr=014}}
| |
| − | {{tp|p=32720577|t=2020. Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2 via RNA-dependent RNA polymerase (RdRp) inhibition: an in-silico analysis.|pdf=|usr=014}}
| |
| − | {{tp|p=32720571|t=2020. Investigating the binding affinity, interaction, and structure-activity-relationship of 76 prescription antiviral drugs targeting RdRp and Mpro of SARS-CoV-2.|pdf=|usr=014}}
| |
| − | {{tp|p=32715956|t=2020. Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2.|pdf=|usr=014}}
| |
| − | {{tp|p=32705962|t=2020. Molecular docking and dynamics study of natural compound for potential inhibition of main protease of SARS-CoV-2.|pdf=|usr=014}}
| |
| − | {{tp|p=32705953|t=2020. Identification of a potential SARS-CoV2 inhibitor via molecular dynamics simulations and amino acid decomposition analysis.|pdf=|usr=014}}
| |
| − | {{tp|p=32705952|t=2020. In-Silico approach for identification of effective and stable inhibitors for COVID-19 main protease (M(pro)) from flavonoid based phytochemical constituents of Calendula officinalis.|pdf=|usr=014}}
| |
| − | {{tp|p=32705942|t=2020. Computational drug repurposing for the identification of SARS-CoV-2 main protease inhibitors.|pdf=|usr=014}}
| |
| − | {{tp|p=32698693|t=2020. Dual inhibitors of SARS-CoV-2 proteases: pharmacophore and molecular dynamics based drug repositioning and phytochemical leads.|pdf=|usr=014}}
| |
| − | {{tp|p=32698689|t=2020. Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in silico study for drug development.|pdf=|usr=014}}
| |
| − | {{tp|p=32696720|t=2020. Antimalarial-agent artemisinin and derivatives portray more potent binding to Lys353 and Lys31-binding hotspots of SARS-CoV-2 spike protein than hydroxychloroquine: potential repurposing of artenimol for COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32696718|t=2020. Comparative molecular investigation of the potential inhibitors against SARS-CoV-2 main protease: a molecular docking study.|pdf=|usr=014}}
| |
| − | {{tp|p=32692306|t=2020. Virtual screening, molecular dynamics and structure-activity relationship studies to identify potent approved drugs for Covid-19 treatment.|pdf=|usr=014}}
| |
| − | {{tp|p=32691697|t=2020. Natural derivatives with dual binding potential against SARS-CoV-2 main protease and human ACE2 possess low oral bioavailability: a brief computational analysis.|pdf=|usr=014}}
| |
| − | {{tp|p=32691680|t=2020. Cyanobacterial metabolites as promising drug leads against the M(pro) and PL(pro) of SARS-CoV-2: an in silico analysis.|pdf=|usr=014}}
| |
| − | {{tp|p=32684114|t=2020. In-silico drug repurposing and molecular dynamics puzzled out potential SARS-CoV-2 main protease inhibitors.|pdf=|usr=014}}
| |
| − | {{tp|p=32684109|t=2020. Targeting virus-host interaction by novel pyrimidine derivative: an in silico approach towards discovery of potential drug against COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32679006|t=2020. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL(pro)).|pdf=|usr=014}}
| |
| − | {{tp|p=32677591|t=2020. The latitude hypothesis, vitamin D, and SARS-Co-V2.|pdf=|usr=014}}
| |
| − | {{tp|p=32677545|t=2020. Approach to the mechanism of action of hydroxychloroquine on SARS-CoV-2: a molecular docking study.|pdf=|usr=014}}
| |
| − | {{tp|p=32677533|t=2020. Designing a multi-epitope vaccine against SARS-CoV-2: an immunoinformatics approach.|pdf=|usr=014}}
| |
| − | {{tp|p=32672528|t=2020. Computer-aided screening for potential TMPRSS2 inhibitors: a combination of pharmacophore modeling, molecular docking and molecular dynamics simulation approaches.|pdf=|usr=014}}
| |
| − | {{tp|p=32666910|t=2020. Computational investigation of potential inhibitors of novel coronavirus 2019 through structure-based virtual screening, molecular dynamics and density functional theory studies.|pdf=|usr=014}}
| |
| − | {{tp|p=32662333|t=2020. Computational discovery of small drug-like compounds as potential inhibitors of SARS-CoV-2 main protease.|pdf=|usr=014}}
| |
| − | {{tp|p=32657643|t=2020. Identification of potential drugs against SARS-CoV-2 non-structural protein 1 (nsp1).|pdf=|usr=014}}
| |
| − | {{tp|p=32697000|t=2020. Corticosteroids-induced osteonecrosis in COVID-19: a call for caution.|pdf=|usr=014}}
| |
| − | {{tp|p=32658005|t=2020. Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality.|pdf=|usr=014}}
| |
| − | {{tp|p=32700555|t=2020. Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia.|pdf=|usr=014}}
| |
| − | {{tp|p=32692858|t=2020. Stem cell therapies for COVID-19: Strategy and application.|pdf=|usr=014}}
| |
| − | {{tp|p=32687345|t=2020. Structure-based virtual screening to discover potential lead molecules for the SARS-CoV-2 main protease.|pdf=|usr=014}}
| |
| − | {{tp|p=32678588|t=2020. SARS-CoV-2 Main Protease: A Molecular Dynamics Study.|pdf=|usr=014}}
| |
| − | {{tp|p=32694358|t=2020. Hydroxychloroquine and Chloroquine in COVID-19: A Survey of Prescription Patterns Among Rheumatologists.|pdf=|usr=014}}
| |
| − | {{tp|p=32700580|t=2020. Pharmacotherapy in COVID-19 patients: A review of ACE2-raising drugs and their clinical safety.|pdf=|usr=014}}
| |
| − | {{tp|p=32677610|t=2020. Antiviral and virucidal effects of curcumin on transmissible gastroenteritis virus in vitro.|pdf=|usr=014}}
| |
| − | {{tp|p=32651218|t=2020. A Case for Targeting Th17 Cells and IL-17A in SARS-CoV-2 Infections.|pdf=|usr=014}}
| |
| − | {{tp|p=32702095|t=2020. Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy.|pdf=|usr=014}}
| |
| − | {{tp|p=32651586|t=2020. Do Not Minimize the Impact of Cellular Immunity in the Development of Vaccines and Therapeutics for COVID-19.|pdf=|usr=014}}
| |
| − |
| |
| − | {{tp|p=32666357|t=2020. Vitamin D and COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32685369|t=2020. Early use of tocilizumab in respiratory failure associated with acute COVID -19 pneumonia in recipients with solid organ transplantation.|pdf=|usr=014}}
| |
| − | {{tp|p=32677493|t=2020. Obesity, COVID-19 and immunotherapy: the complex relationship!|pdf=|usr=014}}
| |
| − | {{tp|p=32664810|t=2020. Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.|pdf=|usr=014}}
| |
| − | {{tp|p=32651941|t=2020. That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32656668|t=2020. SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus.|pdf=|usr=014}}
| |
| − | {{tp|p=32683296|t=2020. Immune and bioinformatics identification of T cell and B cell epitopes in the protein structure of SARS-CoV-2: A systematic review.|pdf=|usr=014}}
| |
| − | {{tp|p=32687949|t=2020. Chloroquine and Hydroxychloroquine in Coronavirus Disease 2019 (COVID-19). Facts, Fiction & the Hype. A Critical Appraisal.|pdf=|usr=014}}
| |
| − | {{tp|p=32674929|t=2020. Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?|pdf=|usr=014}}
| |
| − | {{tp|p=32674928|t=2020. Review of: "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949.|pdf=|usr=014}}
| |
| − | {{tp|p=32693122|t=2020. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.|pdf=|usr=014}}
| |
| − | {{tp|p=32682041|t=2020. Design of a multi-epitope vaccine against SARS-CoV-2 using immunoinformatics approach.|pdf=|usr=014}}
| |
| − | {{tp|p=32698494|t=2020. Self-Amplifying RNA Viruses as RNA Vaccines.|pdf=|usr=014}}
| |
| − | {{tp|p=32674481|t=2020. Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy.|pdf=|usr=014}}
| |
| − | {{tp|p=32691002|t=2020. A consensus guideline of herbal medicine for coronavirus disease 2019.|pdf=|usr=014}}
| |
| − | {{tp|p=32691000|t=2020. Herbal medicine for the management of COVID-19 during the medical observation period: A review of guidelines.|pdf=|usr=014}}
| |
| − | {{tp|p=32652231|t=2020. Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma.|pdf=|usr=014}}
| |
| − | {{tp|p=32652194|t=2020. Retrospective Analysis of Dermatological Adverse Events Associated with Hydroxychloroquine Reported to the United States Food and Drug Administration.|pdf=|usr=014}}
| |
| − | {{tp|p=32674834|t=2020. Plasma Therapies and Parabiosis in the COVID-19 Era.|pdf=|usr=014}}
| |
| − | {{tp|p=32690352|t=2020. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.|pdf=|usr=014}}
| |
| − | {{tp|p=32694923|t=2020. Blood Targets of Adjuvant Drugs Against COVID19.|pdf=|usr=014}}
| |
| − | {{tp|p=32713161|t=2020. The potential effects of DPP-4 inhibitors on cardiovascular system in COVID-19 patients.|pdf=|usr=014}}
| |
| − | {{tp|p=32677763|t=2020. Lessons from SARS and MERS remind us of the possible therapeutic effects of implementing a siRNA strategy to target COVID-19: Shoot the messenger!|pdf=|usr=014}}
| |
| − | {{tp|p=32672454|t=2020. Bioactivity Profile Similarities to Expand the Repertoire of COVID-19 Drugs.|pdf=|usr=014}}
| |
| − | {{tp|p=32655741|t=2020. First Reported Use of Highly Adsorptive Hemofilter in Critically Ill COVID-19 Patients in the USA.|pdf=|usr=014}}
| |
| − | {{tp|p=32683212|t=2020. Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32680687|t=2020. Therapeutic plasma exchange in life-threatening COVID-19 and associated cytokine release syndrome.|pdf=|usr=014}}
| |
| − | {{tp|p=32682930|t=2020. Could Bordetella pertussis vaccine protect against coronavirus COVID-19?|pdf=|usr=014}}
| |
| − | {{tp|p=32695833|t=2020. Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development.|pdf=|usr=014}}
| |
| − | {{tp|p=32652164|t=2020. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.|pdf=|usr=014}}
| |
| − | {{tp|p=32666875|t=2020. Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients.|pdf=|usr=014}}
| |
| − | {{tp|p=32654098|t=2020. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.|pdf=|usr=014}}
| |
| − | {{tp|p=32661074|t=2020. Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines.|pdf=|usr=014}}
| |
| − | {{tp|p=32702590|t=2020. Intermolecular interaction among Remdesivir, RNA and RNA-dependent RNA polymerase of SARS-CoV-2 analyzed by fragment molecular orbital calculation.|pdf=|usr=014}}
| |
| − | {{tp|p=32682142|t=2020. Neuromyelitis optica practice and prescribing changes in the setting of Covid19: A survey of neurologists.|pdf=|usr=014}}
| |
| − | {{tp|p=32684166|t=2020. Withaferin A: a potential therapeutic agent against COVID-19 infection.|pdf=|usr=014}}
| |
| − | {{tp|p=32685234|t=2020. Prophetic Medicine-Nigella Sativa (Black cumin seeds) - Potential herb for COVID-19?|pdf=|usr=014}}
| |
| − | {{tp|p=32658489|t=2020. Michael Acceptors Tuned by the Pivotal Aromaticity of Histidine to Block COVID-19 Activity.|pdf=|usr=014}}
| |
| − | {{tp|p=32653646|t=2020. SARS-CoV and SARS-CoV-2 main protease residue interaction networks change when bound to inhibitor N3.|pdf=|usr=014}}
| |
| − | {{tp|p=32718719|t=2020. Interacciones medicamentosas potenciales en pacientes COVID 19 en tratamiento con lopinavir/ritonavir.|pdf=|usr=014}}
| |
| − | {{tp|p=32718715|t=2020. Reacciones adversas a farmacos utilizados en el tratamiento especifico de la infeccion por SARS-CoV-2.|pdf=|usr=014}}
| |
| − | {{tp|p=32712223|t=2020. Commentary. Eliminating Vitamin D Deficiency During the COVID-19 Pandemic: A Call to Action.|pdf=|usr=014}}
| |
| − | {{tp|p=32712272|t=2020. Blood nitrate and nitrite modulating nitric oxide bioavailability: potential therapeutic functions in COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32708526|t=2020. Selenium Deficiency Is Associated with Mortality Risk from COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32709055|t=2020. Polymorphism and Selection Pressure of SARS-CoV-2 Vaccine and Diagnostic Antigens: Implications for Immune Evasion and Serologic Diagnostic Performance.|pdf=|usr=014}}
| |
| − | {{tp|p=32707768|t=2020. Two Examples of RNA Aptamers with Antiviral Activity. Are Aptamers the Wished Antiviral Drugs?|pdf=|usr=014}}
| |
| − | {{tp|p=32713784|t=2020. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review.|pdf=|usr=014}}
| |
| − | {{tp|p=32703528|t=2020. Replica: Ivermectina en COVID-19. inverted question markArgumentum ad ignorantiam?|pdf=|usr=014}}
| |
| − | {{tp|p=32719454|t=2020. Identification of key interactions between SARS-CoV-2 main protease and inhibitor drug candidates.|pdf=|usr=014}}
| |
| − | {{tp|p=32652766|t=2020. The link between Vitamin D and Covid-19: distinguishing facts from fiction.|pdf=|usr=014}}
| |
| − | {{tp|p=32662708|t=2020. SARS-CoV-2 in the first trimester of pregnancy: potential interference in placentation.|pdf=|usr=014}}
| |
| − | {{tp|p=32692176|t=2020. Lung protection by cathepsin C inhibition: a new hope for COVID-19 and ARDS?|pdf=|usr=014}}
| |
| − | {{tp|p=32716073|t=2020. Vitamin D insufficiency as a potential culprit in critical COVID-19 patients.|pdf=|usr=014}}
| |
| − | {{tp|p=32691896|t=2020. Hydroxychloroquine, dermatology, and SARS-CoV-2: Updating an old association.|pdf=|usr=014}}
| |
| − | {{tp|p=32691875|t=2020. SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.|pdf=|usr=014}}
| |
| − | {{tp|p=32681650|t=2020. SARS-CoV-2 replicating in non-primate mammalian cells probably have critical advantages for COVID-19 vaccines due to anti-Gal antibodies: A minireview and proposals.|pdf=|usr=014}}
| |
| − | {{tp|p=32672860|t=2020. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study.|pdf=|usr=014}}
| |
| − | {{tp|p=32658304|t=2020. Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).|pdf=|usr=014}}
| |
| − | {{tp|p=32651248|t=2020. Management of patients with generalised myasthenia gravis and COVID-19: four case reports.|pdf=|usr=014}}
| |
| − | {{tp|p=32680924|t=2020. Oncology-inspired treatment options for COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32710111|t=2020. Vitamin D and COVID-19: Lessons from Spaceflight Analogs.|pdf=|usr=014}}
| |
| − | {{tp|p=32705690|t=2020. Benzothiazoles as potential antiviral agents.|pdf=|usr=014}}
| |
| − | {{tp|p=32650355|t=2020. Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept.|pdf=|usr=014}}
| |
| − | {{tp|p=32699094|t=2020. Type I and Type III IFN Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.|pdf=|usr=014}}
| |
| − | {{tp|p=32675436|t=2020. Tailoring steroids in the treatment of COVID-19 pneumonia assisted by CT scans: Three case reports.|pdf=|usr=014}}
| |
| − | {{tp|p=32717043|t=2020. Pooling Data From Individual Clinical Trials in the COVID-19 Era.|pdf=|usr=014}}
| |
| − | {{tp|p=32662848|t=2020. COVID-19 Antibody Trials Have Begun.|pdf=|usr=014}}
| |
| − | {{tp|p=32716474|t=2020. Setting Expectations for Clinical Research During the COVID-19 Pandemic.|pdf=|usr=014}}
| |
| − | {{tp|p=32720612|t=2020. [Steroid pulse -therapy in patients With coronAvirus Pneumonia (COVID-19), sYstemic inFlammation And Risk of vEnous thRombosis and thromboembolism (WAYFARER Study)].|pdf=|usr=014}}
| |
| − | {{tp|p=32702300|t=2020. Encouraging results from phase 1/2 COVID-19 vaccine trials.|pdf=|usr=014}}
| |
| − | {{tp|p=32702299|t=2020. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.|pdf=|usr=014}}
| |
| − | {{tp|p=32663575|t=2020. Tackling the cytokine storm in COVID-19, challenges and hopes.|pdf=|usr=014}}
| |
| − | {{tp|p=32720605|t=2020. In silico study to evaluate the antiviral activity of novel structures against 3C-like protease of Novel Coronavirus (COVID-19) and SARS-CoV.|pdf=|usr=014}}
| |
| − | {{tp|p=32679430|t=2020. Eicosapentaenoic free fatty acid to treat patients with SARS-Cov2 infection.|pdf=|usr=014}}
| |
| − | {{tp|p=32678815|t=2020. Lopinavir-ritonavir para COVID-19: una revision sistematica viva.|pdf=|usr=014}}
| |
| − | {{tp|p=32721082|t=2020. A Computational Approach to Identify Potential Novel Inhibitors against the Coronavirus SARS-CoV-2.|pdf=|usr=014}}
| |
| − | {{tp|p=32696772|t=2020. Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data.|pdf=|usr=014}}
| |
| − | {{tp|p=32658332|t=2020. COVID-19 in MuSK Myasthenia Gravis: A Case Report.|pdf=|usr=014}}
| |
| − | {{tp|p=32706953|t=2020. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32706553|t=2020. Audio Interview: Dexamethasone and Covid-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32678530|t=2020. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report.|pdf=|usr=014}}
| |
| − | {{tp|p=32668131|t=2020. Audio Interview: Covid-19 Vaccine Development.|pdf=|usr=014}}
| |
| − | {{tp|p=32668109|t=2020. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. Reply.|pdf=|usr=014}}
| |
| − | {{tp|p=32668108|t=2020. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32668107|t=2020. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32668106|t=2020. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32669667|t=2020. How computational immunology changed the face of COVID-19 vaccine development.|pdf=|usr=014}}
| |
| − | {{tp|p=32651581|t=2020. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.|pdf=|usr=014}}
| |
| − | {{tp|p=32669664|t=2020. COVID-19 vaccine development and a potential nanomaterial path forward.|pdf=|usr=014}}
| |
| − | {{tp|p=32699321|t=2020. Controlling the SARS-CoV-2 spike glycoprotein conformation.|pdf=|usr=014}}
| |
| − | {{tp|p=32661423|t=2020. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.|pdf=|usr=014}}
| |
| − | {{tp|p=32707573|t=2020. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.|pdf=|usr=014}}
| |
| − | {{tp|p=32698191|t=2020. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.|pdf=|usr=014}}
| |
| − | {{tp|p=32698190|t=2020. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2.|pdf=|usr=014}}
| |
| − | {{tp|p=32668443|t=2020. Potently neutralizing and protective human antibodies against SARS-CoV-2.|pdf=|usr=014}}
| |
| − | {{tp|p=32694847|t=2020. Coronavirus vaccines get a biotech boost.|pdf=|usr=014}}
| |
| − | {{tp|p=32667989|t=2020. COVID-19 and tobacco - more questions than answers.|pdf=|usr=014}}
| |
| − | {{tp|p=32679589|t=2020. Supplementation with vitamin D in the COVID-19 pandemic?|pdf=|usr=014}}
| |
| − | {{tp|p=32653930|t=2020. Dietary recommendations during the COVID-19 pandemic.|pdf=|usr=014}}
| |
| − | {{tp|p=32677126|t=2020. Efficacy of povidone-iodine to reduce viral load.|pdf=|usr=014}}
| |
| − | {{tp|p=32660339|t=2020. Intranasal Antiviral Drug Delivery and Coronavirus Disease 2019 (COVID-19): A State of the Art Review.|pdf=|usr=014}}
| |
| − | {{tp|p=32677113|t=2020. The cardiovascular effects of treatment with hydroxychloroquine and azithromycin.|pdf=|usr=014}}
| |
| − | {{tp|p=32674177|t=2020. Therapie mit Dexamethason bei Patienten mit COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32674189|t=2020. DZK-Stellungnahme zu Tuberkulose, BCG und COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32699149|t=2020. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32699147|t=2020. Opinion: It's ethical to test promising coronavirus vaccines against less-promising ones.|pdf=|usr=014}}
| |
| − | {{tp|p=32662915|t=2020. Computer modelling of a potential agent against SARS-Cov-2 (COVID-19) protease.|pdf=|usr=014}}
| |
| − | {{tp|p=32696570|t=2020. Tocilizumab therapy in individuals with COVID-19 infection and hyperinflammatory state.|pdf=|usr=014}}
| |
| − | {{tp|p=32698247|t=2020. The effect of BCG vaccine in the era of COVID-19 pandemic.|pdf=|usr=014}}
| |
| − | {{tp|p=32657436|t=2020. Can medicinal mushrooms have prophylactic or therapeutic effect against COVID-19 and its pneumonic superinfection and complicating inflammation?|pdf=|usr=014}}
| |
| − | {{tp|p=32720847|t=2020. Is there really room for anti-rheumatic drugs in the treatment of COVID-19?|pdf=|usr=014}}
| |
| − | {{tp|p=32690628|t=2020. An alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates.|pdf=|usr=014}}
| |
| − |
| |
| − | {{tp|p=32691006|t=2020. Dietary therapy and herbal medicine for COVID-19 prevention: A review and perspective.|pdf=|usr=014}}
| |
| − | {{tp|p=32691005|t=2020. The antiviral and coronavirus-host protein pathways inhibiting properties of herbs and natural compounds - Additional weapons in the fight against the COVID-19 pandemic?|pdf=|usr=014}}
| |
| − | {{tp|p=32650788|t=2020. Energetics and IC50 based epitope screening in SARS CoV-2 (COVID 19) spike protein by immunoinformatic analysis implicating for a suitable vaccine development.|pdf=|usr=014}}
| |
| − | {{tp|p=32682081|t=2020. Fish Oil and Covid-19 Thromboses.|pdf=|usr=014}}
| |
| − | {{tp|p=32661140|t=2020. The SARS-CoV-2 N protein is a good component in a vaccine.|pdf=|usr=014}}
| |
| − | {{tp|p=32687267|t=2020. Chloroquine and hydroxychloroquine for the prevention and therapy of COVID-19: new hopes and old cardiovascular concerns.|pdf=|usr=014}}
| |
| − | {{tp|p=32702298|t=2020. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.|pdf=|usr=014}}
| |
| − | {{tp|p=32653520|t=2020. Computational insights into tetracyclines as inhibitors against SARS-CoV-2 M(pro) via combinatorial molecular simulation calculations.|pdf=|usr=014}}
| |
| − | {{tp|p=32679150|t=2020. Matrix metallopeptidase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis.|pdf=|usr=014}}
| |
| − | {{tp|p=32679148|t=2020. The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics.|pdf=|usr=014}}
| |
| − | {{tp|p=32684816|t=2020. Anti-inflammatory Properties of Stingless Bee Honey May Reduce the Severity of Pulmonary Manifestations in COVID-19 Infections?|pdf=|usr=014}}
| |
| − | {{tp|p=32703911|t=2020. Can Dietary Fatty Acids Affect the COVID-19 Infection Outcome in Vulnerable Populations?|pdf=|usr=014}}
| |
| − | {{tp|p=32663741|t=2020. Prospective vaccination of COVID-19 using shRNA-plasmid-LDH nanoconjugate.|pdf=|usr=014}}
| |
| − | {{tp|p=32683221|t=2020. Immuno-pathogenesis of nCOVID-19 and a possible host-directed therapy including anti-inflammatory and anti-viral prostaglandin (PG J2) for effective treatment and reduction in the death toll.|pdf=|usr=014}}
| |
| − | {{tp|p=32653736|t=2020. Surfactant-based prophylaxis and therapy against COVID-19: A possibility.|pdf=|usr=014}}
| |
| − | {{tp|p=32683219|t=2020. Transpulmonary electrotherapy for reduction of lung viral load of SARS-CoV-2 in patients with COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32670526|t=2020. Pidotimod in Paucisymptomatic SARS-CoV2 Infected Patients.|pdf=|usr=014}}
| |
| − | {{tp|p=32668701|t=2020. High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2.|pdf=|usr=014}}
| |
| − | {{tp|p=32663912|t=2020. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.|pdf=|usr=014}}
| |
| − | {{tp|p=32663910|t=2020. The Covid-19 Vaccine-Development Multiverse.|pdf=|usr=014}}
| |
| − | {{tp|p=32665542|t=2020. Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing.|pdf=|usr=014}}
| |
| − | {{tp|p=32661375|t=2020. Immune-mediated approaches against COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32694244|t=2020. The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report.|pdf=|usr=014}}
| |
| − | {{tp|p=32681986|t=2020. Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32655899|t=2020. Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic.|pdf=|usr=014}}
| |
| − | {{tp|p=32679784|t=2020. Immunologic Effects of Vitamin D on Human Health and Disease.|pdf=|usr=014}}
| |
| − | {{tp|p=32691007|t=2020. Countermeasures to Coronavirus Disease 2019: Are Immunomodulators Rational Treatment Options-A Critical Review of the Evidence.|pdf=|usr=014}}
| |
| − | {{tp|p=32671131|t=2020. Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32704455|t=2020. Small molecule therapeutics for COVID-19: repurposing of inhaled furosemide.|pdf=|usr=014}}
| |
| − | {{tp|p=32700247|t=2020. Cepharanthine: a review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32653650|t=2020. The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2.|pdf=|usr=014}}
| |
| − | {{tp|p=32653649|t=2020. Analysis on the current quality standards of Chinese materia Medica used in COVID-19 prevention and treatment.|pdf=|usr=014}}
| |
| − | {{tp|p=32675044|t=2020. Contribution of traditional Chinese medicine to the treatment of COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32706790|t=2020. Quantifying early COVID-19 outbreak transmission in South Africa and exploring vaccine efficacy scenarios.|pdf=|usr=014}}
| |
| − | {{tp|p=32706783|t=2020. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.|pdf=|usr=014}}
| |
| − | {{tp|p=32701969|t=2020. Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease.|pdf=|usr=014}}
| |
| − | {{tp|p=32661586|t=2020. COVID-19 and purinergic signaling: the need for investigation.|pdf=|usr=014}}
| |
| − | {{tp|p=32702730|t=2020. In silico Drug Repurposing to combat COVID-19 based on Pharmacogenomics of Patient Transcriptomic Data.|pdf=|usr=014}}
| |
| − | {{tp|p=32702732|t=2020. Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform.|pdf=|usr=014}}
| |
| − | {{tp|p=32702715|t=2020. Worldwide inverse correlation between Bacille Calmette-Guerin immunization and COVID-19 morbidity and mortality.|pdf=|usr=014}}
| |
| − | {{tp|p=32702731|t=2020. Hospitalized COVID-19 Patients treated with Convalescent Plasma in a Mid-size City in the Midwest.|pdf=|usr=014}}
| |
| − | {{tp|p=32670785|t=2020. Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis.|pdf=|usr=014}}
| |
| − | {{tp|p=32659271|t=2020. Pros and cons of corticosteroid therapy for COVID-19 patients.|pdf=|usr=014}}
| |
| − | {{tp|p=32696884|t=2020. Effects of four types of integrated Chinese and Western medicines for the treatment of COVID-19 in China: a network meta-analysis.|pdf=|usr=014}}
| |
| − | {{tp|p=32696862|t=2020. Use of remdesivir for patients with Covid-19: a review article.|pdf=|usr=014}}
| |
| − | {{tp|p=32696811|t=2020. Long-term positive severe acute respiratory syndrome coronavirus 2 ribonucleic acid and therapeutic effect of antivirals in patients with coronavirus disease: Case reports.|pdf=|usr=014}}
| |
| − | {{tp|p=32691011|t=2020. Structure-based drug designing and immunoinformatics approach for SARS-CoV-2.|pdf=|usr=014}}
| |
| − | {{tp|p=32661235|t=2020. Stress proteins: the biological functions in virus infection, present and challenges for target-based antiviral drug development.|pdf=|usr=014}}
| |
| − | {{tp|p=32660307|t=2020. RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery.|pdf=|usr=014}}
| |
| − | {{tp|p=32695804|t=2020. Cellular Therapy: Shafts of Light Emerging for COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32698898|t=2020. Mesenchymal stem cells: current clinical progress in ARDS and COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32678017|t=2020. A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report.|pdf=|usr=014}}
| |
| − | {{tp|p=32696426|t=2020. Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy.|pdf=|usr=014}}
| |
| − | {{tp|p=32661867|t=2020. Mesenchymal Stem Cell Derived Exosomes: a Nano Platform for Therapeutics and Drug Delivery in Combating COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32641644|t=2020. COVID-19 Pandemic: Can Maintaining Optimal Zinc Balance Enhance Host Resistance?|pdf=|usr=014}}
| |
| − | {{tp|p=32653199|t=2020. Immunomodulation for the management of corona virus disease (COVID-19).|pdf=|usr=014}}
| |
| − | {{tp|p=32631501|t=2020. Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?|pdf=|usr=014}}
| |
| − | {{tp|p=32620409|t=2020. Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia.|pdf=|usr=014}}
| |
| − | {{tp|p=32694044|t=2020. Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma.|pdf=|usr=014}}
| |
| − | {{tp|p=32694043|t=2020. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study.|pdf=|usr=014}}
| |
| − | {{tp|p=32684483|t=2020. A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a Framework for Accelerated Synthesis of Trial Evidence-FAST Evidence.|pdf=|usr=014}}
| |
| − | {{tp|p=32660611|t=2020. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.|pdf=|usr=014}}
| |
| − | {{tp|p=32682360|t=2020. The use of hydroxychloroquine plus azithromycin and early hospital admission are beneficial in Covid-19 patients: Turkey experience with real-life data.|pdf=|usr=014}}
| |
| − | {{tp|p=32654907|t=2020. Bacillus Calmette-Guerin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality.|pdf=|usr=014}}
| |
| − | {{tp|p=32653276|t=2020. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines.|pdf=|usr=014}}
| |
| − | {{tp|p=32620375|t=2020. Contingent assessment of the COVID-19 vaccine.|pdf=|usr=014}}
| |
| − | {{tp|p=32684499|t=2020. Planning for COVID-19 vaccines safety surveillance.|pdf=|usr=014}}
| |
| − | {{tp|p=32698423|t=2020. Identification and Analysis of Unstructured, Linear B-Cell Epitopes in SARS-CoV-2 Virion Proteins for Vaccine Development.|pdf=|usr=014}}
| |
| − | {{tp|p=32664505|t=2020. Significantly Improved COVID-19 Outcomes in Countries with Higher BCG Vaccination Coverage: A Multivariable Analysis.|pdf=|usr=014}}
| |
| − | {{tp|p=32666898|t=2020. Images in Vascular Medicine: Peripheral artery thrombosis in critically ill patients with COVID-19.|pdf=|usr=014}}
| |
| − | {{tp|p=32691699|t=2020. Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned.|pdf=|usr=014}}
| |
| − | {{tp|p=32696396|t=2020. A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial.|pdf=|usr=014}}
| |
| − | {{tp|p=32698440|t=2020. Tiotropium is Predicted to be a Promising Drug for COVID-19 Through Transcriptome-Based Comprehensive Molecular Pathway Analysis.|pdf=|usr=014}}
| |
| − |
| |
| − | head
| |
| − | {{tp|p=32718713|t=?. Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience.|pdf=|usr=015}}
| |
| − | {{tp|p=C7334972|t=?. Hydroxychloroquine in the treatment of COVID-19: How to use it waiting for conclusive scientific evidence?.|pdf=|usr=015}}
| |
| − | {{tp|p=C7242950|t=2020. Use of antimalarial drugs in the treatment of COVID-19: A window of opportunity??.|pdf=|usr=015}}
| |
| − | {{tp|p=C7303026|t=2020. ET-traps as a potential treatment for COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7266578|t=?. Vitamin D Levels and COVID-19 Susceptibility: Is there any Correlation?|pdf=|usr=015}}
| |
| − | {{tp|p=C7255206|t=?. BCG vaccination strategy implemented to reduce the impact of COVID-19: Hype or Hope?|pdf=|usr=015}}
| |
| − | {{tp|p=C7227543|t=2020. COVID-19 lockdown: de-risking exit by protecting the lung with leukaemia inhibitory factor (LIF).|pdf=|usr=015}}
| |
| − | {{tp|p=32721804|t=2020. Recombinant protein targeting and opsonizing spike glycoprotein for enhancing SARS-CoV-2 phagocytosis.|pdf=|usr=015}}
| |
| − | {{tp|p=32683222|t=2020. The immunomodulatory effects of exercise against COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=32663741|t=2020. Prospective vaccination of COVID-19 using shRNA-plasmid-LDH nanoconjugate.|pdf=|usr=015}}
| |
| − | {{tp|p=32683221|t=2020. Immuno-pathogenesis of nCOVID-19 and a possible host-directed therapy including anti-inflammatory and anti-viral prostaglandin (PG J2) for effective treatment and reduction in the death toll.|pdf=|usr=015}}
| |
| − | {{tp|p=C7340056|t=2020. Ibuprofen a traditional drug that may impact the course of COVID-19 new effective formulation in nebulizable solution.|pdf=|usr=015}}
| |
| − | {{tp|p=32683219|t=2020. Transpulmonary electrotherapy for reduction of lung viral load of SARS-CoV-2 in patients with COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7321662|t=2020. Reposition of montelukast either alone or in combination with levocetirizine against SARS-CoV-2.|pdf=|usr=015}}
| |
| − | {{tp|p=C7320867|t=2020. Rethinking interleukin-6 blockade for treatment of COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7320853|t=2020. Doxycycline or minocycline may be a viable treatment option against SARS-CoV-2.|pdf=|usr=015}}
| |
| − | {{tp|p=C7319607|t=2020. Why the lower reported prevalence of asthma in patients diagnosed with COVID-19 validates repurposing EDTA solutions to prevent and manage treat COVID-19 disease.|pdf=|usr=015}}
| |
| − | {{tp|p=C7318945|t=2020. Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms.|pdf=|usr=015}}
| |
| − | {{tp|p=C7309834|t=2020. Towards a pharmacochemical hypothesis of the prophylaxis of SARS-CoV-2 by psychoactive substances.|pdf=|usr=015}}
| |
| − | {{tp|p=C7301797|t=2020. Statins may be a key therapeutic for Covid-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7261222|t=?. Evaluating the potential of different inhibitors on RNA-dependent RNA polymerase of severe acute respiratory syndrome coronavirus 2: A molecular modeling approach.|pdf=|usr=015}}
| |
| − | {{tp|p=C7240261|t=?. Spectral domain optical coherence tomography?based prevalence of hydroxychloroquine maculopathy in Indian patients on hydroxychloroquine therapy: A utopia of underdiagnosis.|pdf=|usr=015}}
| |
| − | {{tp|p=32670526|t=2020. Pidotimod in Paucisymptomatic SARS-CoV2 Infected Patients.|pdf=|usr=015}}
| |
| − | {{tp|p=32670525|t=2020. Focusing On A Unique Innate Memory Cell Population Of Natural Killer Cells In The Fight Against COVID-19: Harnessing The Ubiquity Of Cytomegalovirus Exposure.|pdf=|usr=015}}
| |
| − | {{tp|p=32661375|t=?. Immune-mediated approaches against COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7313782|t=?. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7276122|t=?. Remdesivir investigational trials in COVID-19: a critical reappraisal.|pdf=|usr=015}}
| |
| − | {{tp|p=C7303619|t=?. Re. Early nutritional supplementation in non-critically ill patients hospitalized for the 2019 novel coronavirus disease (COVID-19): Rationale and feasibility of a shared pragmatic protocol.|pdf=|usr=015}}
| |
| − | {{tp|p=C7313521|t=2020. COVID-19 and the rush for self-medication and self-dosing with ivermectin: A word of caution.|pdf=|usr=015}}
| |
| − | {{tp|p=C7337805|t=?. Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7313774|t=?. Countermeasures to COVID-19: Are immunomodulators rational treatment options ? a critical review of the evidence.|pdf=|usr=015}}
| |
| − | {{tp|p=C7294877|t=?. Quest for a COVID-19 Cure by Repurposing Small-Molecule Drugs: Mechanism of Action Clinical Development Synthesis at Scale and Outlook for Supply.|pdf=|usr=015}}
| |
| − | {{tp|p=C7294886|t=?. Development of a Large-Scale Cyanation Process Using Continuous Flow Chemistry En Route to the Synthesis of Remdesivir.|pdf=|usr=015}}
| |
| − | {{tp|p=C7347483|t=?. Potential influence of Nagella sativa (Black Cumin) in reinforcing immune system: a hope to decelerate the COVID-19 pandemic.|pdf=|usr=015}}
| |
| − | {{tp|p=32675044|t=?. Contribution of traditional Chinese medicine to the treatment of COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7211506|t=?. Phytochemicals as Antiviral Agents: Recent Updates.|pdf=|usr=015}}
| |
| − | {{tp|p=C7267043|t=2020. Topological Indices of Some Chemical Structures Applied for the Treatment of COVID-19 Patients.|pdf=|usr=015}}
| |
| − | {{tp|p=C7341047|t=?. Psychiatric Aspects of Chloroquine and Hydroxychloroquine Treatment in the Wake of COVID-19: Psychopharmacological Interactions and Neuropsychiatric Sequelae.|pdf=|usr=015}}
| |
| − | {{tp|p=32661586|t=?. COVID-19 and purinergic signaling: the need for investigation.|pdf=|usr=015}}
| |
| − | {{tp|p=C7256487|t=?. Ethical rationale for better coordination of clinical research on COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=32702719|t=?. COVID-19: Famotidine Histamine Mast Cells and Mechanisms .|pdf=|usr=015}}
| |
| − | {{tp|p=32702734|t=?. Potentially repurposable drugs for COVID-19 identified from SARS-CoV-2 Host Protein Interactome.|pdf=|usr=015}}
| |
| − | {{tp|p=32702713|t=?. An in-silico approach to develop of a multi-epitope vaccine candidate against SARS-CoV-2 envelope (E) protein.|pdf=|usr=015}}
| |
| − | {{tp|p=32702733|t=?. A Novel RP-HPLC-DAD Method Development for Anti-Malarial and COVID-19 Hydroxy Chloroquine Sulfate Tablets and Profiling of In-Vitro Dissolution in Multimedia. .|pdf=|usr=015}}
| |
| − | {{tp|p=32702077|t=?. Identification of new drug treatments to combat COVID19: A signature-based approach using iLINCS .|pdf=|usr=015}}
| |
| − | {{tp|p=C7255263|t=2020. Use of corticosteroids in asthma and COPD patients with or without COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7308754|t=2020. Efficacy and safety of tocilizumab in critically ill adults with COVID-19 infection in Bahrain: A report of 5 cases.|pdf=|usr=015}}
| |
| − | {{tp|p=32659271|t=2020. Pros and cons of corticosteroid therapy for COVID-19 patients.|pdf=|usr=015}}
| |
| − | {{tp|p=32703528|t=?. Réplica: Ivermectina en COVID-19. ¿Argumentum ad ignorantiam?|pdf=|usr=015}}
| |
| − | {{tp|p=C7328629|t=2020. Hypothèse en Asie : protection du Covid et vaccin anti-encéphalite ?|pdf=|usr=015}}
| |
| − | {{tp|p=C7305479|t=2020. 5-(Perylen-3-ylethynyl)uracil Derivatives Inhibit Reproduction of Respiratory Viruses.|pdf=|usr=015}}
| |
| − | {{tp|p=C7286259|t=?. In silico screening of FDA approved drugs reveals ergotamine and dihydroergotamine as potential coronavirus main protease enzyme inhibitors.|pdf=|usr=015}}
| |
| − | {{tp|p=C7319274|t=?. Structure-based drug designing and immunoinformatics approach for SARS-CoV-2.|pdf=|usr=015}}
| |
| − | {{tp|p=32718560|t=?. Desperate Times Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7255217|t=?. Reply to Delirium sleep COVID-19 and melatonin .|pdf=|usr=015}}
| |
| − | {{tp|p=C7351559|t=?. Can HCQ Be Considered a ?Safe Weapon? for COVID-19 in the Indian Population?|pdf=|usr=015}}
| |
| − | {{tp|p=C7340747|t=?. Ozone (O3) and SARS-CoV-2: Physiological Bases and Their Therapeutic Possibilities According to COVID-19 Evolutionary Stage.|pdf=|usr=015}}
| |
| − | {{tp|p=C7320242|t=?. Ventricular Arrhythmia Risk Based on Ethnicity in COVID-19 Patients on Hydroxychloroquine and Azithromycin Combination: Viewpoint.|pdf=|usr=015}}
| |
| − | {{tp|p=32661867|t=?. Mesenchymal Stem Cell Derived Exosomes: a Nano Platform for Therapeutics and Drug Delivery in Combating COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=32669846|t=2020. Major Neurologic Adverse Drug Reactions Potential Drug?Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review.|pdf=|usr=015}}
| |
| − | {{tp|p=C7301821|t=2020. Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population consider N-acetylcysteine as early therapeutic intervention.|pdf=|usr=015}}
| |
| − | {{tp|p=32694044|t=?. Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma.|pdf=|usr=015}}
| |
| − | {{tp|p=C7283069|t=?. Convalescent plasma from COVID 19 patients enhances intensive care unit survival rate. A preliminary report.|pdf=|usr=015}}
| |
| − | {{tp|p=32703664|t=?. International Survey of Trials of Convalescent Plasma to Treat COVID-19 Infection.|pdf=|usr=015}}
| |
| − | {{tp|p=32684483|t=?. A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a Framework for Accelerated Synthesis of Trial Evidence?FAST Evidence.|pdf=|usr=015}}
| |
| − | {{tp|p=C7276128|t=2020. Compressed fluids and phytochemical profiling tools to obtain and characterize antiviral and anti-inflammatory compounds from natural sources.|pdf=|usr=015}}
| |
| − | {{tp|p=32654907|t=2020. Bacillus Calmette?Guérin vaccine antimalarial age and gender relation to COVID-19 spread and mortality.|pdf=|usr=015}}
| |
| − | {{tp|p=C7293477|t=?. A review on Promising vaccine development progress for COVID-19 disease.|pdf=|usr=015}}
| |
| − | {{tp|p=C7245990|t=?. Structure-based drug designing for potential antiviral activity of selected natural products from Ayurveda against SARS-CoV-2 spike glycoprotein and its cellular receptor.|pdf=|usr=015}}
| |
| − | {{tp|p=C7315151|t=2020. Hydroxychloroquine retinal toxicity: The bull s eye in the human eye.|pdf=|usr=015}}
| |
| − | {{tp|p=C7287468|t=2020. Exploration on the feasibility of moxibustion in prevention and treatment of COVID-19 from the perspective of modern medical mechanism.|pdf=|usr=015}}
| |
| − | {{tp|p=C7272237|t=?. Homeopathy combat against coronavirus disease (Covid-19).|pdf=|usr=015}}
| |
| − | head
| |
| − | {{tp|p=32674928|t=2020. Review of: ?Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010 DOI:10.1016/j.ijantimicag.2020.105949.|pdf=|usr=015}}
| |
| − | {{tp|p=32674929|t=2020. Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?|pdf=|usr=015}}
| |
| − | {{tp|p=32679328|t=2020. Application prospect of polysaccharides in the development of anti-novel coronavirus drugs and vaccines.|pdf=|usr=015}}
| |
| − | {{tp|p=C7292951|t=2020. Tandem mass spectrometry of small-molecule antiviral drugs: 3. antiviral agents against herpes influenza and other viral infections.|pdf=|usr=015}}
| |
| − | {{tp|p=C7335489|t=2020. A consensus guideline of herbal medicine for coronavirus disease 2019.|pdf=|usr=015}}
| |
| − | {{tp|p=C7328533|t=2020. Herbal medicine for the management of COVID-19 during the medical observation period: A review of guidelines.|pdf=|usr=015}}
| |
| − | {{tp|p=C7326427|t=2020. Allium fistulosum congee as a home remedy to ward off the corona virus at an early stage.|pdf=|usr=015}}
| |
| − | {{tp|p=C7323643|t=2020. COVID-19 ? Where should we go now?|pdf=|usr=015}}
| |
| − | {{tp|p=C7311349|t=2020. The potential benefits of Chinese integrative medicine for pregnancy women during the COVID-19 pandemic.|pdf=|usr=015}}
| |
| − | {{tp|p=C7280829|t=2020. The evaluation of online course of Traditional Chinese Medicine for MBBS international students during the COVID-19 epidemic period.|pdf=|usr=015}}
| |
| − | {{tp|p=C7262361|t=?. COVID?19: A review of therapeutics under investigation.|pdf=|usr=015}}
| |
| − | {{tp|p=32674834|t=2020. Plasma Therapies and Parabiosis in the COVID-19 Era.|pdf=|usr=015}}
| |
| − | {{tp|p=C7263178|t=?. The COVID 19 novel coronavirus pandemic 2020: seaweeds to the rescue? Why does substantial supporting research about the antiviral properties of seaweed polysaccharides seem to go unrecognized by the pharmaceutical community in these desperate times?|pdf=|usr=015}}
| |
| − | {{tp|p=32713677|t=?. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.|pdf=|usr=015}}
| |
| − | {{tp|p=32680602|t=?. Ayurvedic treatment of COVID-19/SARS-CoV-2: A case report.|pdf=|usr=015}}
| |
| − | {{tp|p=C7309301|t=2020. Leucoefdin a potential inhibitor against SARS CoV-2 Mpro.|pdf=|usr=015}}
| |
| − | {{tp|p=32661214|t=2020. Drug targets for COVID-19 therapeutics: Ongoing global efforts.|pdf=|usr=015}}
| |
| − | {{tp|p=32659363|t=?. Achieving Effective Informed Oversight by DMCs in COVID Clinical Trials.|pdf=|usr=015}}
| |
| − | {{tp|p=32682805|t=?. Are statins safe in patients with COVID-19?|pdf=|usr=015}}
| |
| − | {{tp|p=32683212|t=2020. Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7261216|t=?. Drug repurposing using computational methods to identify therapeutic options for COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=32680687|t=?. Therapeutic plasma exchange in life-threatening COVID-19 and associated cytokine release syndrome.|pdf=|usr=015}}
| |
| − | {{tp|p=C7313527|t=2020. Potential benefits of combination of Nigella sativa and Zn supplements to treat COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=32684351|t=?. An overview of the safety clinical application and antiviral research of the COVID-19 therapeutics.|pdf=|usr=015}}
| |
| − | {{tp|p=32670898|t=2020. Increasing Immunity to Fight against Novel COVID-19: Noninvasive Public Health Approach.|pdf=|usr=015}}
| |
| − | {{tp|p=C7323248|t=?. Hydroxychloroquine treatment in COVID?19: a descriptive observational analysis of 30 cases from a single center in Wuhan China.|pdf=|usr=015}}
| |
| − | {{tp|p=C7297697|t=2020. Immunoinformatics characterization of SARS-CoV-2 spike glycoprotein for prioritization of epitope based multivalent peptide vaccine.|pdf=|usr=015}}
| |
| − | {{tp|p=C7347502|t=2020. Inhibition of SARS-CoV-2 main protease 3CLpro by means of ?-ketoamide and pyridone-containing pharmaceuticals using in silico molecular docking.|pdf=|usr=015}}
| |
| − | {{tp|p=C7334662|t=2020. Computational evaluation of major components from plant essential oils as potent inhibitors of SARS-CoV-2 spike protein.|pdf=|usr=015}}
| |
| − | {{tp|p=C7309803|t=2020. Azafluorene derivatives as inhibitors of SARS CoV-2 RdRp: Synthesis physicochemical quantum chemical modeling and molecular docking analysis.|pdf=|usr=015}}
| |
| − | {{tp|p=C7266611|t=2020. Inhibitory activity of hydroxychloroquine on COVID-19 main protease: An insight from MD-simulation studies.|pdf=|usr=015}}
| |
| − | {{tp|p=C7293167|t=?. Is Vitamin D One of the Key Elements in COVID-19 Days?|pdf=|usr=015}}
| |
| − | {{tp|p=C7256177|t=?. Nutritional Considerations in Frail Older Patients with COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7319620|t=?. Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes.|pdf=|usr=015}}
| |
| − | {{tp|p=C7260602|t=2020. Dietary therapy and herbal medicine for COVID-19 prevention: A review and perspective.|pdf=|usr=015}}
| |
| − | {{tp|p=C7260130|t=2020. The antiviral and coronavirus-host protein pathways inhibiting properties of herbs and natural compounds - Additional weapons in the fight against the COVID-19 pandemic?|pdf=|usr=015}}
| |
| − | {{tp|p=32405422|t=2020. Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7331548|t=2020. Minimum costs to manufacture new treatments for COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7331506|t=2020. A review of the safety of favipiravir ? a potential treatment in the COVID-19 pandemic?|pdf=|usr=015}}
| |
| − | {{tp|p=C7331563|t=2020. Summary of the coronavirus disease 2019 (COVID-19) update from the 2020 Conference on Retroviruses and Opportunistic Infections 8?11 March 2020 Boston USA.|pdf=|usr=015}}
| |
| − | {{tp|p=C7296301|t=2020. Acute Cor Pulmonale in COVID-19-Related ARDS: Improvement With Almitrine Infusion.|pdf=|usr=015}}
| |
| − | {{tp|p=C7354765|t=?. Hydroxychloroquine-associated Hypoglycemia in Hemodialysis Patients with COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7298510|t=?. Steroids: A Therapeutic Option for COVID-19 Pneumonia Patients With ESRD?|pdf=|usr=015}}
| |
| − | {{tp|p=32673604|t=2020. Probiotics and COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=32673605|t=2020. Probiotics and COVID-19 ? Authors reply.|pdf=|usr=015}}
| |
| − | {{tp|p=32673603|t=2020. Probiotics and COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7333995|t=2020. Development of potential COVID-19 vaccines continues to accelerate.|pdf=|usr=015}}
| |
| − | {{tp|p=C7351406|t=?. Iloprost for COVID-19-related vasculopathy.|pdf=|usr=015}}
| |
| − | {{tp|p=C7316462|t=2020. Anakinra for patients with COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7316458|t=2020. Anakinra for patients with COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7316448|t=2020. Anakinra for patients with COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7316444|t=2020. Anakinra for patients with COVID-19 ? Authors reply.|pdf=|usr=015}}
| |
| − | {{tp|p=C7314456|t=2020. Tocilizumab in patients with severe COVID-19: a retrospective cohort study.|pdf=|usr=015}}
| |
| − | {{tp|p=C7314441|t=2020. Can tocilizumab calm the cytokine storm of COVID-19?|pdf=|usr=015}}
| |
| − | {{tp|p=C7272172|t=2020. Canakinumab in a subgroup of patients with COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7259909|t=2020. Anakinra for severe forms of COVID-19: a cohort study.|pdf=|usr=015}}
| |
| − | {{tp|p=C7241987|t=2020. Anakinra in COVID-19: important considerations for clinical trials.|pdf=|usr=015}}
| |
| − | {{tp|p=C7239618|t=2020. The immunology of COVID-19: is immune modulation an option for treatment?|pdf=|usr=015}}
| |
| − | {{tp|p=C7328610|t=2020. Calming the Cytokine Storm in Pneumonia by Biomimetic Nanoparticles.|pdf=|usr=015}}
| |
| − | {{tp|p=C7242942|t=2020. Calming Cytokine Storm in Pneumonia by Targeted Delivery of TPCA-1 Using Platelet-Derived Extracellular Vesicles.|pdf=|usr=015}}
| |
| − | {{tp|p=C7275157|t=2020. Clinical Trial End Points in Severe COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7275153|t=2020. Vitamin D Supplementation During the COVID-19 Pandemic.|pdf=|usr=015}}
| |
| − | {{tp|p=C7275146|t=2020. Famotidine Against SARS-CoV2: A Hope or Hype?|pdf=|usr=015}}
| |
| − | {{tp|p=C7237942|t=2020. Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection.|pdf=|usr=015}}
| |
| − | {{tp|p=C7334919|t=?. Deficiencies in the Designs and Interventions of COVID-19 Clinical Trials.|pdf=|usr=015}}
| |
| − | {{tp|p=C7235585|t=?. Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial.|pdf=|usr=015}}
| |
| − | {{tp|p=C7351402|t=?. Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia.|pdf=|usr=015}}
| |
| − | {{tp|p=32718719|t=?. Interacciones medicamentosas potenciales en pacientes COVID 19 en tratamiento con lopinavir/ritonavir.|pdf=|usr=015}}
| |
| − | {{tp|p=32718715|t=?. Reacciones adversas a fármacos utilizados en el tratamiento específico de la infección por SARS-CoV-2.|pdf=|usr=015}}
| |
| − | {{tp|p=C7346829|t=?. Agentes terapéuticos utilizados en 238 pacientes hospitalizados por COVID-19 y su relación con la mortalidad.|pdf=|usr=015}}
| |
| − | {{tp|p=C7332949|t=?. Abordaje terapéutico del SARS-CoV-2 (COVID-19) mediante células mesenquimales de médula ósea alogénica expandidas. Conceptos a propósito de un primer caso en España.|pdf=|usr=015}}
| |
| − | {{tp|p=C7351423|t=?. Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection?.|pdf=|usr=015}}
| |
| − |
| |
| − | {{tp|p=32167678|t=2020. Evaluation of glycoprotein E subunit and live attenuated varicella-zoster virus vaccines formulated with a single-strand RNA-based adjuvant.|pdf=|usr=015}}
| |
| − | {{tp|p=32405233|t=2020. The Promise and Peril of Natural Killer Cell Therapies in Pulmonary Infection.|pdf=|usr=015}}
| |
| − | {{tp|p=32400027|t=2020. Immunological fortification at our barrier organs: Protecting us as we age.|pdf=|usr=015}}
| |
| − | {{tp|p=25762305|t=2015. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus.|pdf=|usr=015}}
| |
| − | {{tp|p=32621997|t=2020. Which QTc correction formulae (Bazett, Framingham, or Fridericia) to use for Hydroxychloroquine induced QTc prolongation?|pdf=|usr=015}}
| |
| − | {{tp|p=32621996|t=2020. HCQ induced QT prolongation- Primum non nocere.|pdf=|usr=015}}
| |
| − | {{tp|p=32651941|t=2020. That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=32645630|t=2020. Evaluation of safety, efficacy, tolerability, and treatment-related outcomes of type I interferons for human coronaviruses (HCoVs) infection in clinical practice: An updated critical systematic review and meta-analysis.|pdf=|usr=015}}
| |
| − | {{tp|p=32430515|t=2020. Glucocorticoids inhibit type I IFN beta signaling and the upregulation of CD73 in human lung.|pdf=|usr=015}}
| |
| − | {{tp|p=32654006|t=2020. Emerging pharmacological therapies for ARDS: COVID-19 and beyond.|pdf=|usr=015}}
| |
| − | {{tp|p=32303896|t=2020. Therapeutic and prophylactic potential of anti-microbial peptides against coronaviruses.|pdf=|usr=015}}
| |
| − | {{tp|p=32622261|t=2020. Current Status of COVID-19 Therapies and Drug Repositioning Applications.|pdf=|usr=015}}
| |
| − | {{tp|p=32652194|t=2020. Retrospective Analysis of Dermatological Adverse Events Associated with Hydroxychloroquine Reported to the United States Food and Drug Administration.|pdf=|usr=015}}
| |
| − | {{tp|p=32339702|t=2020. Role of phototherapy in the era of biologics.|pdf=|usr=015}}
| |
| − | {{tp|p=32622513|t=2020. The roles of PPARgamma and its agonists in autoimmune diseases: A comprehensive review.|pdf=|usr=015}}
| |
| − | {{tp|p=32624376|t=2020. Ayurvedic clinical profile of COVID-19 - A preliminary report.|pdf=|usr=015}}
| |
| − | {{tp|p=32637368|t=2020. COVID-19: Introducing Low Dose Radiation as an Effective Treatment for Pneumonia that Shouldn't Induce Selective Pressure and New Mutations.|pdf=|usr=015}}
| |
| − | {{tp|p=32375574|t=2020. Repurposing of chloroquine and some clinically approved antiviral drugs as effective therapeutics to prevent cellular entry and replication of coronavirus.|pdf=|usr=015}}
| |
| − | {{tp|p=32306854|t=2020. Novel guanosine derivatives against MERS CoV polymerase: An in silico perspective.|pdf=|usr=015}}
| |
| − | {{tp|p=18442051|t=2008. Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors.|pdf=|usr=015}}
| |
| − | {{tp|p=32655741|t=2020. First Reported Use of Highly Adsorptive Hemofilter in Critically Ill COVID-19 Patients in the USA.|pdf=|usr=015}}
| |
| − | {{tp|p=32617428|t=2020. Statins as early therapy to mitigate COVID-19 (SARS-CoV-2)-associated ARDS and cytokine storm syndrome - time is of the essence.|pdf=|usr=015}}
| |
| − | {{tp|p=15693056|t=2005. SARS-CoV protease inhibitors design using virtual screening method from natural products libraries.|pdf=|usr=015}}
| |
| − | {{tp|p=32594451|t=2020. Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs.|pdf=|usr=015}}
| |
| − | {{tp|p=32535155|t=2020. The stress-inducible molecular chaperone GRP78 as potential therapeutic target for coronavirus infection.|pdf=|usr=015}}
| |
| − | {{tp|p=32652164|t=2020. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.|pdf=|usr=015}}
| |
| − | {{tp|p=28864360|t=2018. Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review.|pdf=|usr=015}}
| |
| − | {{tp|p=32654098|t=2020. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.|pdf=|usr=015}}
| |
| − | {{tp|p=18324609|t=2008. Metabolite identification of arbidol in human urine by the study of CID fragmentation pathways using HPLC coupled with ion trap mass spectrometry.|pdf=|usr=015}}
| |
| − | {{tp|p=32398885|t=2020. How materials can beat a virus.|pdf=|usr=015}}
| |
| − | {{tp|p=32398884|t=2020. Materials Science in the time of Coronavirus.|pdf=|usr=015}}
| |
| − | {{tp|p=32410212|t=2020. Acute kidney injury is associated with the mortality of coronavirus disease 2019.|pdf=|usr=015}}
| |
| − | {{tp|p=32628003|t=2020. Tocilizumab in patients with severe COVID-19: A single-center observational analysis.|pdf=|usr=015}}
| |
| − | {{tp|p=32617527|t=2020. Whole Genome Analysis and Targeted Drug Discovery Using Computational Methods and High Throughput Screening Tools for Emerged Novel Coronavirus (2019-nCoV).|pdf=|usr=015}}
| |
| − | {{tp|p=32301512|t=2020. Drug repositioning: a brief overview.|pdf=|usr=015}}
| |
| − | {{tp|p=32653646|t=2020. SARS-CoV and SARS-CoV-2 main protease residue interaction networks change when bound to inhibitor N3.|pdf=|usr=015}}
| |
| − | {{tp|p=32624302|t=2020. A case of cytokine hemofiltration and extracorporeal life support as treatment of coronavirus disease 2019 (COVID-19) respiratory failure.|pdf=|usr=015}}
| |
| − | {{tp|p=32642277|t=2020. Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label clinical trial.|pdf=|usr=015}}
| |
| − | {{tp|p=32642225|t=2020. Addressing the "What do we have to lose? Just give the drug" rationale: making the case for clinical trials and against off-label use in COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=32576276|t=2020. "Right-to-Try" experimental drugs: an overview.|pdf=|usr=015}}
| |
| − | {{tp|p=32650788|t=2020. Energetics and IC50 based epitope screening in SARS CoV-2 (COVID 19) spike protein by immunoinformatic analysis implicating for a suitable vaccine development.|pdf=|usr=015}}
| |
| − | {{tp|p=32188729|t=2020. Coronavirus Endoribonuclease and Deubiquitinating Interferon Antagonists Differentially Modulate the Host Response during Replication in Macrophages.|pdf=|usr=015}}
| |
| − | {{tp|p=18199635|t=2008. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge.|pdf=|usr=015}}
| |
| − | {{tp|p=32493486|t=2020. Alveolar lipids in pulmonary disease. A review.|pdf=|usr=015}}
| |
| − | {{tp|p=32653736|t=2020. Surfactant-based prophylaxis and therapy against COVID-19: A possibility.|pdf=|usr=015}}
| |
| − | {{tp|p=32423569|t=2020. Del empirismo a la evidencia cientifica en el tratamiento con antiviricos en los casos graves de infeccion por coronavirus en tiempos de epidemia.|pdf=|usr=015}}
| |
| − | {{tp|p=32599077|t=2020. Coronavirus vaccine-associated lung immunopathology-what is the significance?|pdf=|usr=015}}
| |
| − | {{tp|p=32600307|t=2020. The alpha7 nicotinic acetylcholine receptor agonist, GTS-21, attenuates hyperoxia-induced acute inflammatory lung injury by alleviating the accumulation of HMGB1 in the airways and the circulation.|pdf=|usr=015}}
| |
| − | {{tp|p=32579882|t=2020. Preparing for Pandemics: RNA Vaccines at the Forefront.|pdf=|usr=015}}
| |
| − | {{tp|p=32516954|t=2020. Antiviral Effects of Plant-Derived Essential Oils and Their Components: An Updated Review.|pdf=|usr=015}}
| |
| − | {{tp|p=32325742|t=2020. Advances on Antiviral Activity of Morus spp. Plant Extracts: Human Coronavirus and Virus-Related Respiratory Tract Infections in the Spotlight.|pdf=|usr=015}}
| |
| − | {{tp|p=32295300|t=2020. Natural Bioactive Compounds from Fungi as Potential Candidates for Protease Inhibitors and Immunomodulators to Apply for Coronaviruses.|pdf=|usr=015}}
| |
| − | {{tp|p=32459913|t=2020. Remdesivir - An Important First Step.|pdf=|usr=015}}
| |
| − | {{tp|p=32409740|t=2020. Type I and type III interferon in opposition?|pdf=|usr=015}}
| |
| − | {{tp|p=32636478|t=2020. Dexamethasone to the rescue.|pdf=|usr=015}}
| |
| − | {{tp|p=32378128|t=2020. Drug repurposing in cardiology.|pdf=|usr=015}}
| |
| − | {{tp|p=32651844|t=2020. The 'president's drug'.|pdf=|usr=015}}
| |
| − | {{tp|p=32643072|t=2020. An antiarrhythmic approach to hydroxychloroquine-induced QT prolongation.|pdf=|usr=015}}
| |
| − | {{tp|p=32474177|t=2020. Nicotinic acetylcholine receptors regulate clustering, fusion and acidification of the rat brain synaptic vesicles.|pdf=|usr=015}}
| |
| − | {{tp|p=32529044|t=2020. Better patient identification could help fight the coronavirus.|pdf=|usr=015}}
| |
| − | {{tp|p=32655899|t=2020. Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic.|pdf=|usr=015}}
| |
| − | {{tp|p=32579137|t=2020. New international guidance on quality, safety and efficacy of DNA vaccines.|pdf=|usr=015}}
| |
| − | {{tp|p=32579135|t=2020. WHO informal consultation on the guidelines for evaluation of the quality, safety, and efficacy of DNA vaccines, Geneva, Switzerland, December 2019.|pdf=|usr=015}}
| |
| − | {{tp|p=32536809|t=2020. Is a vitamin D fortification strategy needed?|pdf=|usr=015}}
| |
| − | {{tp|p=32349265|t=2020. Vitamin D and Immunity in Infants and Children.|pdf=|usr=015}}
| |
| − | {{tp|p=32344708|t=2020. A Novel Combination of Vitamin C, Curcumin and Glycyrrhizic Acid Potentially Regulates Immune and Inflammatory Response Associated with Coronavirus Infections: A Perspective from System Biology Analysis.|pdf=|usr=015}}
| |
| − | {{tp|p=32325790|t=2020. Key Vitamin D Target Genes with Functions in the Immune System.|pdf=|usr=015}}
| |
| − | {{tp|p=32325778|t=2020. Effects of an Omega-3 and Vitamin D Supplement on Fatty Acids and Vitamin D Serum Levels in Double-Blinded, Randomized, Controlled Trials in Healthy and Crohn's Disease Populations.|pdf=|usr=015}}
| |
| − | {{tp|p=32290296|t=2020. The Role of Selenium in Health and Disease: Emerging and Recurring Trends.|pdf=|usr=015}}
| |
| − | {{tp|p=32617169|t=2020. Hydroxychloroquine-induced Stevens-Johnson syndrome in COVID-19: a rare case report.|pdf=|usr=015}}
| |
| − | {{tp|p=32551127|t=2020. Covering coronavirus-emerging tools for the fight against the common enemy.|pdf=|usr=015}}
| |
| − | {{tp|p=32653463|t=2020. Vaccines for COVID-19: The current state of play.|pdf=|usr=015}}
| |
| − | {{tp|p=32630514|t=2020. Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection.|pdf=|usr=015}}
| |
| − | {{tp|p=32590098|t=2020. Global research on artemisinin and its derivatives: Perspectives from patents.|pdf=|usr=015}}
| |
| − | {{tp|p=32653650|t=2020. The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2.|pdf=|usr=015}}
| |
| − | {{tp|p=32653649|t=2020. Analysis on the current quality standards of Chinese materia Medica used in COVID-19 prevention and treatment.|pdf=|usr=015}}
| |
| − | {{tp|p=32384116|t=2020. Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus.|pdf=|usr=015}}
| |
| − | {{tp|p=32350142|t=2020. News Feature: To counter the pandemic, clinicians bank on repurposed drugs.|pdf=|usr=015}}
| |
| − | {{tp|p=17567736|t=2007. Crystallographic studies of the complexes of antiviral protein griffithsin with glucose and N-acetylglucosamine.|pdf=|usr=015}}
| |
| − | {{tp|p=17340634|t=2007. Crystallographic, thermodynamic, and molecular modeling studies of the mode of binding of oligosaccharides to the potent antiviral protein griffithsin.|pdf=|usr=015}}
| |
| − | {{tp|p=32540609|t=2020. Possible beneficial role of throat gargling in the coronavirus disease pandemic.|pdf=|usr=015}}
| |
| − | {{tp|p=32653040|t=2020. The need for fast-track, high-quality and low-cost studies about the role of the BCG vaccine in the fight against COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=32616298|t=2020. Ivermectina en COVID-19. inverted question markArgumentum ad ignorantiam?|pdf=|usr=015}}
| |
| − | {{tp|p=32636066|t=2020. Electrocardiographic/QT interval monitoring with a portable device in hospitalized patients with COVID-19: a protocol proposal.|pdf=|usr=015}}
| |
| − | {{tp|p=32593625|t=2020. Melatonin, coronavirus, cardiovascular disease, and the geriatric emergency: let's use everything we have!|pdf=|usr=015}}
| |
| − | {{tp|p=32622732|t=2020. The presence of heart disease worsens prognosis in patients with COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=32550880|t=2020. Recommandations EMA sur l'usage compassionnel du remdesivir.|pdf=|usr=015}}
| |
| − | {{tp|p=32537031|t=2020. Hochdosiertes Chloroquin bei COVID-19 gefahrlich.|pdf=|usr=015}}
| |
| − | {{tp|p=32577525|t=2020. A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques.|pdf=|usr=015}}
| |
| − | {{tp|p=32179788|t=2020. Ginkgolic acid inhibits fusion of enveloped viruses.|pdf=|usr=015}}
| |
| − | {{tp|p=32448377|t=2020. Stem cell therapy: a potential approach for treatment of influenza virus and coronavirus-induced acute lung injury.|pdf=|usr=015}}
| |
| − | {{tp|p=32318958|t=2020. How to "Detronize" Virus in Crown - Questions to Current Stem Cell Therapies.|pdf=|usr=015}}
| |
| − | {{tp|p=32537523|t=2020. An aurora of natural products-based drug discovery is coming.|pdf=|usr=015}}
| |
| − | {{tp|p=32612804|t=2020. Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents.|pdf=|usr=015}}
| |
| − | {{tp|p=32641977|t=2020. Bioengineering tools to speed up the discovery and preclinical testing of vaccines for SARS-CoV-2 and therapeutic agents for COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=32653199|t=2020. Immunomodulation for the management of corona virus disease (COVID-19).|pdf=|usr=015}}
| |
| − | {{tp|p=32631501|t=2020. Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?|pdf=|usr=015}}
| |
| − | {{tp|p=32620409|t=2020. Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia.|pdf=|usr=015}}
| |
| − | {{tp|p=32636114|t=2020. Extracorporeal blood purification treatment options for COVID-19: The role of immunoadsorption.|pdf=|usr=015}}
| |
| − | {{tp|p=32565057|t=2020. The true historical origin of convalescent plasma therapy.|pdf=|usr=015}}
| |
| − | {{tp|p=32542716|t=2020. Effective coronavirus reduction by various production steps during the manufacture of plasma-derived medicinal products.|pdf=|usr=015}}
| |
| − | {{tp|p=32333396|t=2020. Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light.|pdf=|usr=015}}
| |
| − | {{tp|p=32533558|t=2020. Convalescent plasma - this is no time for competition.|pdf=|usr=015}}
| |
| − | {{tp|p=24117799|t=2014. Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates.|pdf=|usr=015}}
| |
| − | {{tp|p=32504825|t=2020. Innovative highlights of clinical drug trial design.|pdf=|usr=015}}
| |
| − | {{tp|p=32593869|t=2020. Traditional Chinese Herbal Medication for corona-virus 2019.|pdf=|usr=015}}
| |
| − | {{tp|p=32340868|t=2020. Improving Vaccine-Induced Immunity: Can Baseline Predict Outcome?|pdf=|usr=015}}
| |
| − | {{tp|p=32651113|t=2020. Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates.|pdf=|usr=015}}
| |
| − | {{tp|p=32313527|t=2020. Vacunas contra el coronavirus.|pdf=|usr=015}}
| |
| − | {{tp|p=32395638|t=2020. Chloroquine/Hydroxychloroquine Overdose.|pdf=|usr=015}}
| |
| − | {{tp|p=32240549|t=2020. Pivotal role of convalescent plasma in managing emerging infectious diseases.|pdf=|usr=015}}
| |
| − | {{tp|p=12800213|t=2003. Advances in clinical diagnosis and treatment of severe acute respiratory syndrome.|pdf=|usr=015}}
| |
| − | head
| |
| − | {{tp|p=C7357981|t=?. Artemisia and COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7261228|t=?. Vitamin D and COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7234785|t=?. Anti-SARS-CoV-2 hyperimmune immunoglobulins an urgent strategic choice.|pdf=|usr=015}}
| |
| − | {{tp|p=C7345415|t=2020. Isolation and characterization of an exopolymer produced by Bacillus licheniformis: In vitro antiviral activity against enveloped viruses.|pdf=|usr=015}}
| |
| − | {{tp|p=C7340049|t=2020. A review for natural polysaccharides with anti-pulmonary fibrosis properties which may benefit to patients infected by 2019-nCoV.|pdf=|usr=015}}
| |
| − | {{tp|p=C7336955|t=2020. Sulfated polymannuroguluronate TGC161 ameliorates leukopenia by inhibiting CD4+ T cell apoptosis.|pdf=|usr=015}}
| |
| − | {{tp|p=C7275151|t=?. Development of an Inactivated Vaccine Candidate BBIBP-CorV with Potent Protection against SARS-CoV-2.|pdf=|usr=015}}
| |
| − | {{tp|p=32668216|t=2020. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice.|pdf=|usr=015}}
| |
| − | {{tp|p=C7276303|t=2020. Identification of SARS-CoV-2 Vaccine Epitopes Predicted to Induce Long-Term Population-Scale Immunity.|pdf=|usr=015}}
| |
| − | {{tp|p=32693256|t=2020. Efficient degradation of chloroquine drug by electro-Fenton oxidation: Effects of operating conditions and degradation mechanism.|pdf=|usr=015}}
| |
| − | {{tp|p=C7315147|t=2020. SYSTEMATIC REVIEW OF THE ONGOING CLINICAL TRIALS EVALUATING THE DIAGNOSTIC AND THERAPEUTIC INTERVENTIONS TO MANAGE THE RESPIRATORY INFECTION CAUSED BY 2019 NOVEL CORONAVIRUS (2019-NCOV).|pdf=|usr=015}}
| |
| − | {{tp|p=C7343649|t=?. Traditional Chinese medicine played a crucial role in battling COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7266592|t=?. Carry forward advantages of traditional medicines in prevention and control of outbreak of COVID-19 pandemic.|pdf=|usr=015}}
| |
| − | {{tp|p=C7351116|t=2020. Electron beam irradiation on novel coronavirus (COVID-19): A Monte?Carlo simulationProject supported by the National Natural Science Foundation of China (Grant No. 61901360).|pdf=|usr=015}}
| |
| − | {{tp|p=C7292799|t=?. Process integration for emerging challenges: optimal allocation of antivirals under resource constraints.|pdf=|usr=015}}
| |
| − | {{tp|p=C7303657|t=?. Systemic steroids and risk of fecal-oral shedding and increased transmission of SARS-Cov-2 in pemphigus cases???.|pdf=|usr=015}}
| |
| − | {{tp|p=32663514|t=2020. Intestinal microbiome transfer a novel therapeutic strategy for COVID-19 induced hyperinflammation?: In reply to ?COVID-19: Immunology and treatment options? Felsenstein Herbert McNamara et al. 2020?.|pdf=|usr=015}}
| |
| − | {{tp|p=C7314231|t=?. Targeting complement in severe Coronavirus disease 2019 to address microthrombosis.|pdf=|usr=015}}
| |
| − | {{tp|p=32682684|t=?. Successful Use of COVID-19 Convalescent Plasma in a Patient Recently Treated for Follicular Lymphoma.|pdf=|usr=015}}
| |
| − | {{tp|p=32727701|t=?. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib.|pdf=|usr=015}}
| |
| − | {{tp|p=32690179|t=2020. The key role of zinc in elderly immunity: A possible approach in the COVID-19 crisis.|pdf=|usr=015}}
| |
| − | {{tp|p=32690172|t=2020. Foodomics and COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=32690158|t=2020. Home medical nutrition during SARS-CoV-2 pandemic ? A position paper.|pdf=|usr=015}}
| |
| − | {{tp|p=C7128574|t=2020. New thinking in the treatment of 2019 novel coronavirus pneumonia.|pdf=|usr=015}}
| |
| − | {{tp|p=C7282787|t=2020. The combined therapy of a traditional Chinese medicine formula and Western medicine for a critically ill case infected with COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=32658735|t=2020. Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach.|pdf=|usr=015}}
| |
| − | {{tp|p=32658736|t=2020. Bioinformatics studies on a function of the SARS-CoV-2 spike glycoprotein as the binding of host sialic acid glycans.|pdf=|usr=015}}
| |
| − | {{tp|p=32664990|t=2020. Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study.|pdf=|usr=015}}
| |
| − | {{tp|p=32696008|t=2020. The Combination of Tocilizumab and Methylprednisolone Along With Initial Lung Recruitment Strategy in Coronavirus Disease 2019 Patients Requiring Mechanical Ventilation: A Series of 21 Consecutive Cases.|pdf=|usr=015}}
| |
| − | {{tp|p=32696001|t=2020. Less Can Be More When Targeting Interleukin-6-Mediated Cytokine Release Syndrome in Coronavirus Disease 2019.|pdf=|usr=015}}
| |
| − | {{tp|p=32696006|t=2020. Corticosteroid Administration Is Associated With Improved Outcome in Patients With Severe Acute Respiratory Syndrome Coronavirus 2-Related Acute Respiratory Distress Syndrome.|pdf=|usr=015}}
| |
| − | {{tp|p=32661859|t=?. Can Vitamins as Epigenetic Modifiers Enhance Immunity in COVID-19 Patients with Non-communicable Disease?|pdf=|usr=015}}
| |
| − | {{tp|p=C7302922|t=?. COVID-19 Drug Treatment in China.|pdf=|usr=015}}
| |
| − | {{tp|p=32665127|t=?. Are we fully exploiting type I Interferons in today s fight against COVID-19 pandemic?|pdf=|usr=015}}
| |
| − | {{tp|p=C7323099|t=?. Hydroxychloroquine for COVID?19: Myths vs Facts.|pdf=|usr=015}}
| |
| − | {{tp|p=32683320|t=2020. Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19).|pdf=|usr=015}}
| |
| − | {{tp|p=C7356495|t=?. Traditional Chinese Medicine and Clinical Pharmacology.|pdf=|usr=015}}
| |
| − | {{tp|p=C7229886|t=?. Data Monitoring for the Chinese Clinical Trials of Remdesivir in Treating Patients with COVID-19 During the Pandemic Crisis.|pdf=|usr=015}}
| |
| − | {{tp|p=C7238396|t=?. Within a large healthcare system the incidence of positive COVID-19 results and mortality are lower in patients on chronic hydroxychloroquine therapy.|pdf=|usr=015}}
| |
| − | {{tp|p=C7348610|t=?. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study.|pdf=|usr=015}}
| |
| − | {{tp|p=C7329292|t=2020. Subcutaneous tocilizumab treatment in patients with severe COVID-19?related cytokine release syndrome: An observational cohort study.|pdf=|usr=015}}
| |
| − | {{tp|p=32632415|t=2020. Endpoints used in phase III randomized controlled trials of treatment options for COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=32632410|t=2020. Serosurveys and convalescent plasma in COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7332434|t=?. The Efficacy and Safety of Triazavirin for COVID-19: A Trial Protocol.|pdf=|usr=015}}
| |
| − | {{tp|p=C7284238|t=?. Mesenchymal Stem Cells Represent a Potential Therapeutic Option for Coronavirus Disease 2019-Related Acute Respiratory Distress Syndrome.|pdf=|usr=015}}
| |
| − | {{tp|p=C7309930|t=2020. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7329119|t=2020. Special issues raised by evolving areas of clinical research.|pdf=|usr=015}}
| |
| − | {{tp|p=C7298480|t=2020. Ethical issues related to the hydroxychloroquine treatment prescription for Covid-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7337728|t=?. COVID-19 treatment with lopinavir?ritonavir resulting in sick sinus syndrome: a case report.|pdf=|usr=015}}
| |
| − | {{tp|p=32670297|t=2020. Severe COVID-19: NLRP3 Inflammasome Dysregulated.|pdf=|usr=015}}
| |
| − | {{tp|p=32670273|t=2020. Battling COVID-19 Pandemic: Sphingosine-1-Phosphate Analogs as an Adjunctive Therapy?|pdf=|usr=015}}
| |
| − | {{tp|p=32670071|t=2020. Convalescent Plasma Coupled With Medications for the Treatment of a Severe COVID-19 Patient: Drugs Analysis and Pharmaceutical Care Based on the Newly Established Guidelines for COVID-19 Remedy.|pdf=|usr=015}}
| |
| − | {{tp|p=32670091|t=2020. The Modulation of Mucosal Antiviral Immunity by Immunobiotics: Could They Offer Any Benefit in the SARS-CoV-2 Pandemic?|pdf=|usr=015}}
| |
| − | {{tp|p=32662664|t=?. N-acetylcysteine as a potential treatment for novel coronavirus disease 2019.|pdf=|usr=015}}
| |
| − | {{tp|p=32685190|t=?. Better preventing and mitigating the effects of Covid-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7295248|t=?. Possible SARS-coronavirus 2 inhibitor revealed by simulated molecular docking to viral main protease and host toll-like receptor.|pdf=|usr=015}}
| |
| − | {{tp|p=C7249572|t=?. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: let the virus be its own demise.|pdf=|usr=015}}
| |
| − | {{tp|p=C7243912|t=?. Virtual screening of immunomodulatory medicinal compounds as promising anti-SARS-COV-2 inhibitors.|pdf=|usr=015}}
| |
| − | {{tp|p=C7324924|t=2020. mTOR inhibition and p53 activation microRNAs: The possible therapy against pandemic COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7305491|t=?. Known drugs and small molecules in the battle for COVID-19 treatment.|pdf=|usr=015}}
| |
| − | {{tp|p=C7345387|t=?. Chloroquine kills hair cells in zebrafish lateral line and murine cochlear cultures: Implications for ototoxicity.|pdf=|usr=015}}
| |
| − | {{tp|p=C7289101|t=?. QT Interval and Arrhythmic Safety of Hydroxychloroquine Monotherapy in Coronavirus Disease 2019.|pdf=|usr=015}}
| |
| − | {{tp|p=C7318948|t=2020. Early use of tocilizumab in respiratory failure associated with acute COVID -19 pneumonia in recipients with solid organ transplantation.|pdf=|usr=015}}
| |
| − | {{tp|p=32659267|t=2020. Intermittent fasting a possible priming tool for host defense against SARS-CoV-2 infection: Crosstalk among calorie restriction autophagy and immune response.|pdf=|usr=015}}
| |
| − | {{tp|p=C7351562|t=?. Obesity and COVID-19: A Fatal Alliance.|pdf=|usr=015}}
| |
| − | {{tp|p=C7347658|t=?. Novel Stem Cells and Nucleic Acid-Based Vaccine Trials Against Viral Outbreak: A Systematic Evaluation During COVID-2019 Pandemic.|pdf=|usr=015}}
| |
| − | {{tp|p=C7217267|t=?. Does the Bacillus Calmette?Guérin vaccine provide protection from COVID-19?|pdf=|usr=015}}
| |
| − | {{tp|p=C7217270|t=?. Role of poly (ADP) ribose polymerase-1 inhibition by nicotinamide as a possible additive treatment to modulate host immune response and prevention of cytokine storm in COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7239502|t=?. Modified Bhramari Pranayama in Covid 19 Infection.|pdf=|usr=015}}
| |
| − | {{tp|p=C7279711|t=?. Letter to the Editor: Acharya Prafulla Chandra Ray Hydroxychloroquine and COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=32656668|t=?. SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in ?lasso? for the multi-faced virus.|pdf=|usr=015}}
| |
| − | {{tp|p=C7351674|t=2020. Structure-based drug designing towards the identification of potential anti-viral for COVID-19 by targeting endoribonuclease NSP15.|pdf=|usr=015}}
| |
| − | head
| |
| − | {{tp|p=C7348117|t=2020. Remdesivir: Various toxicities: 4 case reports.|pdf=|usr=015}}
| |
| − | {{tp|p=C7348113|t=2020. Multiple drugs interaction: Reduction in drug level and QTc prolongation following off label use: 2 case reports.|pdf=|usr=015}}
| |
| − | {{tp|p=C7348108|t=2020. Tocilizumab: Neutropenia: case report.|pdf=|usr=015}}
| |
| − | {{tp|p=C7348103|t=2020. Hydroxychloroquine: Acute haemolysis that lead to acute renal failure: case report.|pdf=|usr=015}}
| |
| − | {{tp|p=C7348100|t=2020. Multiple drugs: Bradycardia atrioventricular block and off-label use: case report.|pdf=|usr=015}}
| |
| − | {{tp|p=C7346767|t=2020. The use of corticosteroids for COVID-19 infection.|pdf=|usr=015}}
| |
| − | {{tp|p=C7334124|t=2020. Azithromycin/hydroxychloroquine/propofol: Hypoglycaemia and cardiotoxicities following off label use: 2 case reports.|pdf=|usr=015}}
| |
| − | {{tp|p=C7334118|t=2020. Hydroxychloroquine: Corrected QT interval prolongation first degree atrioventricular block and left bundle branch block during an off-label treatment with hydroxychloroquine for COVID-19 pneumonia: 3 case reports.|pdf=|usr=015}}
| |
| − | {{tp|p=C7334116|t=2020. Etanercept/methotrexate: COVID-19: case report.|pdf=|usr=015}}
| |
| − | {{tp|p=C7334127|t=2020. Hydroxychloroquine: QTc prolongation following off-label-use: case report.|pdf=|usr=015}}
| |
| − | {{tp|p=C7334107|t=2020. Azithromycin/hydroxychloroquine: QT prolongation with a notched broad T-wave following off-label therapy: case report.|pdf=|usr=015}}
| |
| − | {{tp|p=C7317081|t=2020. New potential interaction with emergency COVID-19 medicine remdesivir.|pdf=|usr=015}}
| |
| − | {{tp|p=C7302795|t=2020. Bréve : Chloroquine OTC : danger !|pdf=|usr=015}}
| |
| − | {{tp|p=C7296892|t=2020. COVID-19: Wirksamkeit integrativer Medizin?|pdf=|usr=015}}
| |
| − | {{tp|p=C7284681|t=?. Risiken und Chancen von Immuntherapien in Zeiten der Coronavirus-2019-Pandemie.|pdf=|usr=015}}
| |
| − | {{tp|p=C7284280|t=?. Los antimaláricos (cloroquina e hidroxicloroquina) en la pandemia COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7295303|t=2020. Emerging Treatment and Prevention Strategies against COVID-19: A Brief Update.|pdf=|usr=015}}
| |
| − | {{tp|p=C7295283|t=2020. Exploring COVID-19 Therapies: An Extraordinary Global Challenge.|pdf=|usr=015}}
| |
| − | {{tp|p=C7339112|t=2020. Azithromycin ? An Antibiotic to Fight COVID-19?|pdf=|usr=015}}
| |
| − | {{tp|p=C7339103|t=2020. Hydroxychloroquine ? An Antimalarial to Fight COVID-19?|pdf=|usr=015}}
| |
| − | {{tp|p=C7339105|t=2020. ?-Ketoamide Inhibitors of SARS-CoV-2 Main Protease.|pdf=|usr=015}}
| |
| − | {{tp|p=C7239187|t=?. Potential role of oral rinses targeting the viral lipid envelope in SARS-CoV-2 infection.|pdf=|usr=015}}
| |
| − | {{tp|p=C7212254|t=2020. Abemaciclib/fulvestrant: Leucopenia and Covid-19: case report.|pdf=|usr=015}}
| |
| − | {{tp|p=C7212250|t=2020. Prednisone: Coronavirus disease 2019: case report.|pdf=|usr=015}}
| |
| − | {{tp|p=C7212243|t=2020. Evaluation of potential therapies for COVID-19 global pandemic.|pdf=|usr=015}}
| |
| − | {{tp|p=C7212249|t=2020. Demand for potentially hazardous COVID-19 treatments.|pdf=|usr=015}}
| |
| − | {{tp|p=C7212241|t=2020. Hydroxychloroquine-associated QT interval prolongation.|pdf=|usr=015}}
| |
| − | {{tp|p=C7221540|t=2020. Current evidence for directed and supportive investigational therapies against COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7174165|t=?. COVID-19 ACE -inhibitors and angiotensin receptor blockers-: The need to differentiate between early infection and acute lung injury.|pdf=|usr=015}}
| |
| − | {{tp|p=C7227203|t=?. Translation: Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7): National Health Commission National Administration of Traditional Chinese Medicine.|pdf=|usr=015}}
| |
| − | {{tp|p=32639711|t=?. CNS Penetration Ability: A Critical Factor for Drugs in the Treatment of SARS-CoV-2 Brain Infection.|pdf=|usr=015}}
| |
| − | {{tp|p=32665809|t=?. Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment.|pdf=|usr=015}}
| |
| − | {{tp|p=C7269097|t=?. Exploiting Existing Molecular Scaffolds for Long-Term COVID Treatment.|pdf=|usr=015}}
| |
| − | {{tp|p=C7315437|t=2020. Recommender Systems in Antiviral Drug Discovery.|pdf=|usr=015}}
| |
| − | {{tp|p=C7301903|t=?. The Potential of Antimicrobial Peptides as an Antiviral Therapy against COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7319939|t=?. Combating COVID-19 with integrated traditional Chinese and Western medicine in China.|pdf=|usr=015}}
| |
| − | {{tp|p=C7278644|t=?. Bioactive natural compounds against human coronaviruses: a review and perspective.|pdf=|usr=015}}
| |
| − | {{tp|p=C7260574|t=?. Highly pathogenic coronaviruses: thrusting vaccine development in the spotlight.|pdf=|usr=015}}
| |
| − | {{tp|p=C7251357|t=?. Analysis on herbal medicines utilized for treatment of COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7255283|t=?. Letter to the editor: Comment on GLP-1-based drugs and COVID-19 treatment.|pdf=|usr=015}}
| |
| − | {{tp|p=C7252145|t=?. Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model.|pdf=|usr=015}}
| |
| − | {{tp|p=C7252136|t=?. Chinese medicine diagnosis and treatment for COVID-2019: Is China ready for implementing a national guideline?|pdf=|usr=015}}
| |
| − | {{tp|p=C7235485|t=?. Addressing COVID?19 Drug Development with Artificial Intelligence.|pdf=|usr=015}}
| |
| − | {{tp|p=C7239013|t=?. Extent of Prior Lung Irradiation and Mortality in COVID-19 Patients With a Cancer History.|pdf=|usr=015}}
| |
| − | {{tp|p=C7235566|t=?. Covert COVID-19: Cone Beam Computed Tomography Lung Changes in an Asymptomatic Patient Receiving Radiation Therapy.|pdf=|usr=015}}
| |
| − | {{tp|p=32711735|t=2020. Reverse genetic systems: Rational design of coronavirus live attenuated vaccines with immune sequelae.|pdf=|usr=015}}
| |
| − | {{tp|p=32666027|t=2020. Pharmaceutical care of chloroquine phosphate in elderly patients with coronavirus pneumonia (COVID?19).|pdf=|usr=015}}
| |
| − | {{tp|p=C7342052|t=?. The role of Chinese medicine in COVID-19 pneumonia: A systematic review and meta-analysis.|pdf=|usr=015}}
| |
| − | {{tp|p=C7332446|t=?. Traditional chinese medicine and COVID-19: should emergency practitioners use it?|pdf=|usr=015}}
| |
| − | {{tp|p=C7332432|t=?. Convalescent plasma for coronavirus disease 2019 in pregnancy: a case report and review.|pdf=|usr=015}}
| |
| − | {{tp|p=C7314679|t=?. Compassionate use of remdesivir for treatment of severe coronavirus disease 2019 in pregnant women at a United States academic center.|pdf=|usr=015}}
| |
| − | {{tp|p=C7308040|t=?. Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019.|pdf=|usr=015}}
| |
| − | {{tp|p=C7342085|t=?. Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature.|pdf=|usr=015}}
| |
| − | {{tp|p=C7303718|t=2020. Reply to Jakovac: ?COVID-19 and vitamin D?Is there a link and an opportunity for intervention??.|pdf=|usr=015}}
| |
| − | {{tp|p=C7328534|t=?. Tocilizumab in a child with acute lymphoblastic leukaemia and COVID-19-related cytokine release syndrome?.|pdf=|usr=015}}
| |
| − | {{tp|p=C7343652|t=2020. The use of dexamethasone in the treatment of COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7314270|t=2020. Convalescent plasma transfusion a promising therapy for coronavirus diseases 2019 (COVID-19): current updates.|pdf=|usr=015}}
| |
| − | {{tp|p=32659292|t=?. Immunoglobulin fragment F(ab?)2 against RBD potently neutralizes SARS-CoV-2 in vitro.|pdf=|usr=015}}
| |
| − | {{tp|p=32659293|t=2020. Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.|pdf=|usr=015}}
| |
| − | {{tp|p=32675039|t=?. Hydroxychloroquine and Potential Drug Interactions in Older Adults.|pdf=|usr=015}}
| |
| − | {{tp|p=C7340065|t=?. Propiedades antivirales y antiinflamatorias de ivermectina y su potencial uso en COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=32660794|t=?. Response to: Amantadine Treatment for People with COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7335243|t=?. Recent insights for the emerging COVID-19: drug discovery therapeutic options and vaccine development.|pdf=|usr=015}}
| |
| − | {{tp|p=32682671|t=?. Nutrition management for critically and acutely unwell hospitalised patients with coronavirus disease 2019 (COVID-19) in Australia and New Zealand.|pdf=|usr=015}}
| |
| − | {{tp|p=C7342031|t=2020. Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment.|pdf=|usr=015}}
| |
| − | {{tp|p=C7303599|t=2020. Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a.|pdf=|usr=015}}
| |
| − | {{tp|p=C7331567|t=2020. The SARS-CoV-2 main protease as drug target.|pdf=|usr=015}}
| |
| − | {{tp|p=C7346814|t=?. Debate on Bacille Calmette-Guérin vaccination against COVID-19: Is it worth performing clinical trials?|pdf=|usr=015}}
| |
| − | {{tp|p=C7343650|t=?. Molecular targets for COVID-19 drug development: Enlightening Nigerians about the pandemic and future treatment.|pdf=|usr=015}}
| |
| − | {{tp|p=C7358153|t=?. Artemisia et COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7354262|t=?. Vaccinating against COVID-19: The quest for the Grail?|pdf=|usr=015}}
| |
| − | {{tp|p=C7354263|t=?. Thermal cures and COVID-19.|pdf=|usr=015}}
| |
| − | head
| |
| − | {{tp|p=C7323647|t=2020. Coronavirus vaccines.|pdf=|usr=015}}
| |
| − | {{tp|p=C7317079|t=2020. Hydroxychloroquine: QTc prolongation: case report.|pdf=|usr=015}}
| |
| − | {{tp|p=C7317072|t=2020. Methylprednisolone/prednisone: Accelerated viral replication following an off-label treatment: case report.|pdf=|usr=015}}
| |
| − | {{tp|p=C7317070|t=2020. Antibacterials/isavuconazole/voriconazole: Lack of efficacy: case report.|pdf=|usr=015}}
| |
| − | {{tp|p=C7318723|t=2020. Multiklonale Antikörper als Ersatz für Zweitantikörper aus Seren.|pdf=|usr=015}}
| |
| − | {{tp|p=C7318721|t=2020. Rekombinante vollständig humane Antikörper zur Behandlung akuter COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7332229|t=2020. Azaphenantherene derivatives as inhibitor of SARS CoV-2 Mpro: Synthesis physicochemical quantum chemical and molecular docking analysis.|pdf=|usr=015}}
| |
| − | {{tp|p=C7291614|t=2020. COVID-19 und evidenzbasierte Medizin.|pdf=|usr=015}}
| |
| − | {{tp|p=C7291615|t=2020. Remdesivir wohl wirksam bei COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=C7291608|t=2020. Lopinavir-Ritonavir-Kombination nicht wirksam.|pdf=|usr=015}}
| |
| − | {{tp|p=C7303435|t=2020. Azithromycin/hydroxychloroquine: Prolongation of the QT interval: case report.|pdf=|usr=015}}
| |
| − | {{tp|p=C7303433|t=2020. Methylprednisolone: Decrease in T cell count following off label use: case report.|pdf=|usr=015}}
| |
| − | {{tp|p=C7323139|t=2020. Vitamin intervention for cytokine storm in the patients with coronavirus disease 2019.|pdf=|usr=015}}
| |
| − | {{tp|p=C7337782|t=?. Cholesterol-modifying drugs in COVID-19.|pdf=|usr=015}}
| |
| − |
| |
| − | {{tp|p=32596616|t=2020. Extraction, Characterization, and Anticoagulant Activity of a Sulfated Polysaccharide from Bursatella leachii Viscera.|pdf=|usr=015}}
| |
| − | {{tp|p=32579890|t=2020. Targeting drug delivery in the vascular system: Focus on endothelium.|pdf=|usr=015}}
| |
| − | {{tp|p=32654004|t=2020. Comments on: The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality.|pdf=|usr=015}}
| |
| − | {{tp|p=32653224|t=2020. BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic?|pdf=|usr=015}}
| |
| − | {{tp|p=32624192|t=2020. Recent Findings on Cardiovascular Safety With the Use of Chloroquine and Hydroxychloroquine for COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=32502485|t=2020. Hydroxychloroquine for Coronavirus: The Urgent Need for a Moratorium on Prescriptions.|pdf=|usr=015}}
| |
| − | {{tp|p=32653550|t=2020. Treating hypoxemic COVID-19 "ARDS" patients with almitrine: The earlier the better?|pdf=|usr=015}}
| |
| − | {{tp|p=32606531|t=2020. Hydroxychloroquine and Myasthenia Gravis-Can One Take This Risk?|pdf=|usr=015}}
| |
| − | {{tp|p=32637086|t=2020. A severe refractory COVID-19 patient responding to convalescent plasma; A case series.|pdf=|usr=015}}
| |
| − | {{tp|p=32653425|t=2020. Does androgen deprivation therapy protect against severe complications from COVID-19?|pdf=|usr=015}}
| |
| − | {{tp|p=32653452|t=2020. Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions.|pdf=|usr=015}}
| |
| − | {{tp|p=32607398|t=2020. The Application of a Reduced Dye Used in Orthopedics as a Novel Treatment against Coronavirus (COVID-19): A Suggested Therapeutic Protocol.|pdf=|usr=015}}
| |
| − | {{tp|p=32600868|t=2020. Glucose-6-Phosphate Dehydrogenase Deficiency: An Actionable Risk Factor for Patients with COVID-19?|pdf=|usr=015}}
| |
| − | {{tp|p=32611537|t=2020. Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development.|pdf=|usr=015}}
| |
| − | {{tp|p=32603888|t=2020. Clinical implications of nicotine as an antimicrobial agent and immune modulator.|pdf=|usr=015}}
| |
| − | {{tp|p=32626733|t=2020. Effect of Thymoquinone on Acute Kidney Injury Induced by Sepsis in BALB/c Mice.|pdf=|usr=015}}
| |
| − | {{tp|p=32443566|t=2020. Metformin: Sentinel of the Epigenetic Landscapes That Underlie Cell Fate and Identity.|pdf=|usr=015}}
| |
| − | {{tp|p=32120929|t=2020. Antiviral Action of Tryptanthrin Isolated from Strobilanthes cusia Leaf against Human Coronavirus NL63.|pdf=|usr=015}}
| |
| − | {{tp|p=32629280|t=2020. COVID19 inhibitors: A prospective therapeutics.|pdf=|usr=015}}
| |
| − | {{tp|p=22446091|t=2012. Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides.|pdf=|usr=015}}
| |
| − | {{tp|p=32297972|t=2020. Built-in RNA-mediated chaperone (chaperna) for antigen folding tailored to immunized hosts.|pdf=|usr=015}}
| |
| − | {{tp|p=30597533|t=2019. Synthetic biology for bioengineering virus-like particle vaccines.|pdf=|usr=015}}
| |
| − | {{tp|p=26212697|t=2015. Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology.|pdf=|usr=015}}
| |
| − | {{tp|p=20809484|t=2010. Generating stable Chinese hamster ovary cell clones to produce a truncated SARS-CoV spike protein for vaccine development.|pdf=|usr=015}}
| |
| − | {{tp|p=16321039|t=2005. Bioprocess engineering issues that would be faced in producing a DNA vaccine at up to 100 m3 fermentation scale for an influenza pandemic.|pdf=|usr=015}}
| |
| − | {{tp|p=32493296|t=2020. Network pharmacology to dissect the mechanisms of Yinlai Decoction for pneumonia.|pdf=|usr=015}}
| |
| − | {{tp|p=32601089|t=2020. Food is medicine: actions to integrate food and nutrition into healthcare.|pdf=|usr=015}}
| |
| − | {{tp|p=32444705|t=2020. Hydrogen peroxide mouthwash.|pdf=|usr=015}}
| |
| − | {{tp|p=32591697|t=2020. New video will promote silver diamine fluoride to children.|pdf=|usr=015}}
| |
| − | {{tp|p=32591690|t=2020. Chlorhexidine has an antiviral effect against viruses.|pdf=|usr=015}}
| |
| − | {{tp|p=32591675|t=2020. Virucidal activity.|pdf=|usr=015}}
| |
| − | {{tp|p=32591671|t=2020. Povidone iodine gargle and mouthwash.|pdf=|usr=015}}
| |
| − | {{tp|p=32307721|t=2020. Extensive hard palate hyperpigmentation associated with chloroquine use.|pdf=|usr=015}}
| |
| − | {{tp|p=32615072|t=2020. Ivermectin: potential candidate for the treatment of Covid 19.|pdf=|usr=015}}
| |
| − | {{tp|p=32645327|t=2020. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.|pdf=|usr=015}}
| |
| − | {{tp|p=32643603|t=2020. Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment.|pdf=|usr=015}}
| |
| − | {{tp|p=32442424|t=2020. Enhancing the Antiviral Efficacy of RNA-Dependent RNA Polymerase Inhibition by Combination with Modulators of Pyrimidine Metabolism.|pdf=|usr=015}}
| |
| − | {{tp|p=32544459|t=2020. BCG Vaccination in Humans Elicits Trained Immunity via the Hematopoietic Progenitor Compartment.|pdf=|usr=015}}
| |
| − | {{tp|p=32402267|t=2020. Metformin Enhances Autophagy and Normalizes Mitochondrial Function to Alleviate Aging-Associated Inflammation.|pdf=|usr=015}}
| |
| − | {{tp|p=32612152|t=2020. Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=32629149|t=2020. Janus sword actions of chloroquine and hydroxychloroquine against COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=16511823|t=2006. Deciphering the biosynthetic codes for the potent anti-SARS-CoV cyclodepsipeptide valinomycin in Streptomyces tsusimaensis ATCC 15141.|pdf=|usr=015}}
| |
| − | {{tp|p=23788528|t=2013. Synergistic inhibitor binding to the papain-like protease of human SARS coronavirus: mechanistic and inhibitor design implications.|pdf=|usr=015}}
| |
| − | {{tp|p=32533956|t=2020. Impact of Small-N Studies During a Pandemic.|pdf=|usr=015}}
| |
| − | {{tp|p=32505301|t=2020. Adjunctive Therapies in ARDS: The Disconnect Between Clinical Trials and Clinical Practice.|pdf=|usr=015}}
| |
| − | {{tp|p=32632717|t=2020. In Silico Screening of Potential Chinese Herbal Medicine Against COVID-19 by Targeting SARS-CoV-2 3CLpro and Angiotensin Converting Enzyme II Using Molecular Docking.|pdf=|usr=015}}
| |
| − | {{tp|p=32405143|t=2020. Remdesivir - A giant step, or a tiptoe?|pdf=|usr=015}}
| |
| − | {{tp|p=32512231|t=2020. Tuberculosis sepsis after tocilizumab treatment.|pdf=|usr=015}}
| |
| − | {{tp|p=32651020|t=2020. COVID-19: Regulatory Landscape of Medicinal and Medical Device Products for Human Use.|pdf=|usr=015}}
| |
| − | {{tp|p=32613089|t=2020. Low dose anti-inflammatory radiotherapy for the treatment of pneumonia by covid-19: A proposal for a multi-centric prospective trial.|pdf=|usr=015}}
| |
| − | {{tp|p=32402130|t=2020. What Do We Know About Remdesivir Drug Interactions?|pdf=|usr=015}}
| |
| − | {{tp|p=32623357|t=2020. Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors.|pdf=|usr=015}}
| |
| − | {{tp|p=32661494|t=2020. Computational View toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease.|pdf=|usr=015}}
| |
| − | {{tp|p=32653043|t=2020. Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia.|pdf=|usr=015}}
| |
| − | {{tp|p=32653015|t=2020. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.|pdf=|usr=015}}
| |
| − | {{tp|p=32426753|t=2020. Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019.|pdf=|usr=015}}
| |
| − | {{tp|p=32637266|t=2020. Lithium Toxicity in Two Coronavirus Disease 2019 (COVID-19) Patients.|pdf=|usr=015}}
| |
| − | {{tp|p=32626630|t=2020. Serious Adverse Events Associated With Hydroxychloroquine Amidst COVID-19 Pandemic: Case Series and Literature Review.|pdf=|usr=015}}
| |
| − | {{tp|p=32637278|t=2020. Packed Red Blood Cell Transfusion as a Potential Treatment Option in COVID-19 Patients With Hypoxemic Respiratory Failure: A Case Report.|pdf=|usr=015}}
| |
| − | {{tp|p=32656044|t=2020. Pulse Therapy With Corticosteroids and Intravenous Immunoglobulin in the Management of Severe Tocilizumab-Resistant COVID-19: A Report of Three Clinical Cases.|pdf=|usr=015}}
| |
| − | {{tp|p=32615514|t=2020. Docking approaches for modeling multi-molecular assemblies.|pdf=|usr=015}}
| |
| − | {{tp|p=32399388|t=2020. Utilization of Physiologically Based Pharmacokinetic Modeling in Clinical Pharmacology and Therapeutics: an Overview.|pdf=|usr=015}}
| |
| − | {{tp|p=32616467|t=2020. Mesenchymal stem cells in the fight against viruses: Face to face with the invisible enemy.|pdf=|usr=015}}
| |
| − | {{tp|p=32616381|t=2020. A critical evaluation of glucocorticoids in the management of severe COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=32636055|t=2020. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=32227604|t=2020. Repurposing therapeutic agents and herbal medicines to defeat viral nemesis.|pdf=|usr=015}}
| |
| − | {{tp|p=32655654|t=2020. Coronavirus disease 2019 (COVID-19): latest developments in potential treatments.|pdf=|usr=015}}
| |
| − | {{tp|p=32636919|t=2020. Can vitamins and/or supplements provide hope against coronavirus?|pdf=|usr=015}}
| |
| − | {{tp|p=32427191|t=2019. Evaluation of safety, humoral immune response and faecal shedding in horses inoculated with a modified-live bovine coronavirus vaccination.|pdf=|usr=015}}
| |
| − | {{tp|p=32619884|t=2020. Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?|pdf=|usr=015}}
| |
| − | {{tp|p=32506216|t=2020. Serious adverse drug reactions with hydroxychloroquine: a pharmacovigilance study in Vigibase(R).|pdf=|usr=015}}
| |
| − | {{tp|p=32653152|t=2020. Waste in COVID-19 clinical trials conducted in western Europe.|pdf=|usr=015}}
| |
| − | {{tp|p=32651040|t=2020. Linking hydroxychloroquine to hemolysis in a 'suspected' glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection - a critical appraisal.|pdf=|usr=015}}
| |
| − | {{tp|p=32652408|t=2020. Natural and nature-inspired stilbenoids as antiviral agents.|pdf=|usr=015}}
| |
| − | {{tp|p=32616594|t=2020. Cyclophilin Inhibitors Restrict Middle East Respiratory Syndrome Coronavirus Via Interferon lambda In Vitro And In Mice.|pdf=|usr=015}}
| |
| − | {{tp|p=32591664|t=2020. Are hydroxychloroquine and chloroquine effective in the treatment of SARS-COV-2 (COVID-19)?|pdf=|usr=015}}
| |
| − | {{tp|p=32587388|t=2020. Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria.|pdf=|usr=015}}
| |
| − | {{tp|p=32427967|t=2020. Hydroxychloroquine hitting the headlines-retinal considerations.|pdf=|usr=015}}
| |
| − | {{tp|p=32653511|t=2020. Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=32655584|t=2020. Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2.|pdf=|usr=015}}
| |
| − | {{tp|p=32655583|t=2020. Vitamin D Supplementation: A Potential Approach for Coronavirus/COVID-19 Therapeutics?|pdf=|usr=015}}
| |
| − | {{tp|p=32655582|t=2020. Targeting the NLRP3 Inflammasome in Severe COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=32655581|t=2020. Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies.|pdf=|usr=015}}
| |
| − | {{tp|p=32655578|t=2020. Three Decades of Interferon-beta in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?|pdf=|usr=015}}
| |
| − | {{tp|p=32655577|t=2020. Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients.|pdf=|usr=015}}
| |
| − | {{tp|p=32636851|t=2020. Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19).|pdf=|usr=015}}
| |
| − | {{tp|p=32612616|t=2020. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.|pdf=|usr=015}}
| |
| − | {{tp|p=32612613|t=2020. Activation of TLR7 and Innate Immunity as an Efficient Method Against COVID-19 Pandemic: Imiquimod as a Potential Therapy.|pdf=|usr=015}}
| |
| − | {{tp|p=32582186|t=2020. Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs.|pdf=|usr=015}}
| |
| − | {{tp|p=32174911|t=2020. Quantitative Proteomic Analysis Reveals Antiviral and Anti-inflammatory Effects of Puerarin in Piglets Infected With Porcine Epidemic Diarrhea Virus.|pdf=|usr=015}}
| |
| − | {{tp|p=32651936|t=2020. The role played by traditional Chinese medicine in preventing and treating COVID-19 in China.|pdf=|usr=015}}
| |
| − | {{tp|p=32655532|t=2020. Biocides and Novel Antimicrobial Agents for the Mitigation of Coronaviruses.|pdf=|usr=015}}
| |
| − | {{tp|p=32636755|t=2020. Potential Benefits of Tryptophan Metabolism to the Efficacy of Tocilizumab in COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=32636754|t=2020. A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic.|pdf=|usr=015}}
| |
| − | {{tp|p=32390855|t=2020. Traditional Chinese Medicine and Gut Microbiome: Their Respective and Concert Effects on Healthcare.|pdf=|usr=015}}
| |
| − | {{tp|p=32636763|t=2020. The Potential Beneficial Effect of EPA and DHA Supplementation Managing Cytokine Storm in Coronavirus Disease.|pdf=|usr=015}}
| |
| − | {{tp|p=32636762|t=2020. Activation of Ang-(1-7)/Mas Receptor Is a Possible Strategy to Treat Coronavirus (SARS-CoV-2) Infection.|pdf=|usr=015}}
| |
| − | {{tp|p=32352313|t=2020. Incipient need of targeting airway remodeling using advanced drug delivery in chronic respiratory diseases.|pdf=|usr=015}}
| |
| − | {{tp|p=32647807|t=2020. The Emerging Role of Convalescent Plasma in the Treatment of COVID-19.|pdf=|usr=015}}
| |
| − | {{tp|p=32606420|t=2020. The value of targeting recombination as a strategy against coronavirus diseases.|pdf=|usr=015}}
| |
| − |
| |
| − |
| |
| − | {{tp|p=32725866|t=2020. A Pharmacokinetics-Informed Approach to Navigating Hydroxychloroquine Shortages in Patients With Rheumatic Disease During the COVID-19 Pandemic.|pdf=|usr=017}}
| |
| − | {{tp|p=32743211|t=2020. Prediction of Small Molecule Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus-2 RNA-dependent RNA Polymerase.|pdf=|usr=017}}
| |
| − | {{tp|p=32737471|t=2020. Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients.|pdf=|usr=017}}
| |
| − | {{tp|p=32656827|t=2020. Letter: ACE2, Rho kinase inhibition and the potential role of vitamin D against COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32672049|t=2020. Reply to Jakovac: COVID-19, vitamin D, and type I interferon.|pdf=|usr=017}}
| |
| − | {{tp|p=32730105|t=2020. Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.|pdf=|usr=017}}
| |
| − | {{tp|p=32732245|t=2020. Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome.|pdf=|usr=017}}
| |
| − | {{tp|p=32722164|t=2020. Flavonoids Activation of the Transcription Factor Nrf2 as a Hypothesis Approach for the Prevention and Modulation of SARS-CoV-2 Infection Severity.|pdf=|usr=017}}
| |
| − | {{tp|p=32739404|t=2020. The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro.|pdf=|usr=017}}
| |
| − | {{tp|p=32740801|t=2020. Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32741139|t=2020. Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-analysis.|pdf=|usr=017}}
| |
| − | {{tp|p=32739342|t=2020. COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials.|pdf=|usr=017}}
| |
| − | {{tp|p=32743022|t=2020. Targeting the cholinergic anti-inflammatory pathway with vagus nerve stimulation in patients with Covid-19?|pdf=|usr=017}}
| |
| − | {{tp|p=32731331|t=2020. The Antiviral Properties of Cyclosporine. Focus on Coronavirus, Hepatitis C Virus, Influenza Virus, and Human Immunodeficiency Virus Infections.|pdf=|usr=017}}
| |
| − | {{tp|p=32736237|t=2020. Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: A single-center experience.|pdf=|usr=017}}
| |
| − | {{tp|p=32718376|t=2020. Clozapine and COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32731913|t=2020. Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment.|pdf=|usr=017}}
| |
| − | {{tp|p=32732190|t=2020. Drug treatments for covid-19: living systematic review and network meta-analysis.|pdf=|usr=017}}
| |
| − | {{tp|p=32734502|t=2020. Anakinra for the Treatment of COVID-19-Associated Pericarditis: A Case Report.|pdf=|usr=017}}
| |
| − | {{tp|p=32678443|t=2020. Cardiovascular diseases, lipid-lowering therapies and European registries in the COVID-19 pandemic.|pdf=|usr=017}}
| |
| − | {{tp|p=32745670|t=2020. New disease old vaccine: Is recombinant BCG vaccine an answer for COVID-19?|pdf=|usr=017}}
| |
| − | {{tp|p=32728202|t=2020. Immune monitoring of interleukin-7 compassionate use in a critically ill COVID-19 patient.|pdf=|usr=017}}
| |
| − | {{tp|p=32721383|t=2020. Computationally Optimized SARS-CoV-2 MHC Class I and II Vaccine Formulations Predicted to Target Human Haplotype Distributions.|pdf=|usr=017}}
| |
| − | {{tp|p=32735799|t=2020. Roles of flavonoids against coronavirus infection.|pdf=|usr=017}}
| |
| − | {{tp|p=32740825|t=2020. In Silico Screening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy.|pdf=|usr=017}}
| |
| − | {{tp|p=32728975|t=2020. Physical exercise as a tool to help the immune system against COVID-19: an integrative review of the current literature.|pdf=|usr=017}}
| |
| − | {{tp|p=32721580|t=2020. Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019.|pdf=|usr=017}}
| |
| − | {{tp|p=32735655|t=2020. The Multidimensional Challenge of Treating COVID-19: Remdesivir is a Foot in the Door.|pdf=|usr=017}}
| |
| − | {{tp|p=32725382|t=2020. Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents.|pdf=|usr=017}}
| |
| − | {{tp|p=32728438|t=2020. Safety and potential efficacy of cyclooxygenase-2 inhibitors in coronavirus disease 2019.|pdf=|usr=017}}
| |
| − | {{tp|p=32738628|t=2020. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32718345|t=2020. Inhibiting IL-6 in COVID-19: we are not sure.|pdf=|usr=017}}
| |
| − | {{tp|p=32734518|t=2020. Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection.|pdf=|usr=017}}
| |
| − | {{tp|p=32740972|t=2020. Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes.|pdf=|usr=017}}
| |
| − | {{tp|p=32735689|t=2020. Dihydroorotate dehydrogenase inhibitors in SARS-CoV-2 infection.|pdf=|usr=017}}
| |
| − | {{tp|p=32730844|t=2020. Structure-based drug repositioning over the human TMPRSS2 protease domain: search for chemical probes able to repress SARS-CoV-2 Spike protein cleavages.|pdf=|usr=017}}
| |
| − | {{tp|p=32725454|t=2020. Liver injury in remdesivir-treated COVID-19 patients.|pdf=|usr=017}}
| |
| − | {{tp|p=32681497|t=2020. COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy.|pdf=|usr=017}}
| |
| − | {{tp|p=32740858|t=2020. The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse.|pdf=|usr=017}}
| |
| − | {{tp|p=32745811|t=2020. Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2.|pdf=|usr=017}}
| |
| − | {{tp|p=32739476|t=2020. Repurposing of host-based therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19): a link between antiviral and anticancer mechanisms?|pdf=|usr=017}}
| |
| − | {{tp|p=32738307|t=2020. Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32738306|t=2020. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.|pdf=|usr=017}}
| |
| − | {{tp|p=32738305|t=2020. Lactoferrin as potential preventative and adjunct treatment for COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32745548|t=2020. Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening.|pdf=|usr=017}}
| |
| − | {{tp|p=32745629|t=2020. A sound approach: Hydroxychloroquine reduces mortality in severe COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32738492|t=2020. Problems with the analysis in "Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19".|pdf=|usr=017}}
| |
| − | {{tp|p=32738491|t=2020. Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?|pdf=|usr=017}}
| |
| − | {{tp|p=32738483|t=2020. Clarifying the record on hydroxychloroquine for the treatment of patients hospitalized with COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32726724|t=2020. Appropriate use of Tocilizumab in COVID-19 Infection.|pdf=|usr=017}}
| |
| − | {{tp|p=32721534|t=2020. Adsorptive granulocyte and monocyte apheresis: A potentially relevant therapeutic option for COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32721528|t=2020. Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge.|pdf=|usr=017}}
| |
| − | {{tp|p=32731361|t=2020. Computational Studies of SARS-CoV-2 3CLpro: Insights from MD Simulations.|pdf=|usr=017}}
| |
| − | {{tp|p=32727145|t=2020. Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?|pdf=|usr=017}}
| |
| − | {{tp|p=32718020|t=2020. Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials.|pdf=|usr=017}}
| |
| − | {{tp|p=32727996|t=2020. Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019: A Case Report.|pdf=|usr=017}}
| |
| − | {{tp|p=32727845|t=2020. Identification of an anti-SARS-CoV-2 receptor binding domain directed human monoclonal antibody from a naive semi-synthetic library.|pdf=|usr=017}}
| |
| − | {{tp|p=32741313|t=2020. Identification of potential drug candidates to combat COVID-19: a structural study using the main protease (mpro) of SARS-CoV-2.|pdf=|usr=017}}
| |
| − | {{tp|p=32727069|t=2020. A Cell-Based Reporter Assay for Screening Inhibitors of MERS Coronavirus RNA-Dependent RNA Polymerase Activity.|pdf=|usr=017}}
| |
| − | {{tp|p=32726951|t=2020. Efficacy of Corticosteroids in Patients with SARS, MERS and COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=017}}
| |
| − | {{tp|p=32741525|t=2020. Attenuating hyperinflammation in COVID-19: A change in paradigm?|pdf=|usr=017}}
| |
| − | {{tp|p=32726446|t=2020. Plasmodium falciparum infection may protect a population from SARS-CoV-2 infection.|pdf=|usr=017}}
| |
| − | {{tp|p=32726430|t=2020. Virucidal efficacy of different oral rinses against SARS-CoV-2.|pdf=|usr=017}}
| |
| − | {{tp|p=32745348|t=2020. Use of the IL-6R Antagonist Tocilizumab in Hospitalized COVID-19 Patients.|pdf=|usr=017}}
| |
| − | {{tp|p=32744399|t=2020. Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study.|pdf=|usr=017}}
| |
| − | {{tp|p=32745925|t=2020. Polyacylated anthocyanins constructively network with catalytic dyad residues of 3CL(pro) of 2019-nCoV than monomeric anthocyanins: A structural-relationship activity study with 10 anthocyanins using in-silico approaches.|pdf=|usr=017}}
| |
| − | {{tp|p=32739642|t=2020. Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment.|pdf=|usr=017}}
| |
| − | {{tp|p=32676670|t=2020. Considerations and Future Directions for Conducting Clinical Research With Pediatric Populations During the COVID-19 Pandemic.|pdf=|usr=017}}
| |
| − | {{tp|p=32729620|t=2020. Mesenchymal Stem Cells in COVID-19: A Journey from Bench to Bedside.|pdf=|usr=017}}
| |
| − | {{tp|p=32726783|t=2020. JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients.|pdf=|usr=017}}
| |
| − | {{tp|p=32726479|t=2020. Bacillus Calmette-Guerin vaccination and socioeconomic variables vs COVID-19 global features: Clearing up a controversial issue.|pdf=|usr=017}}
| |
| − | {{tp|p=32729180|t=2020. Molecular Insights into Small Molecule Drug Discovery for SARS-CoV-2.|pdf=|usr=017}}
| |
| − | {{tp|p=32735169|t=2020. Deploying Randomized Controlled Trials during the COVID-19 Pandemic: Reason and Bayesian Designs.|pdf=|usr=017}}
| |
| − | {{tp|p=32737112|t=2020. Targeting IL-6 in COVID-19. Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma.|pdf=|usr=017}}
| |
| − | {{tp|p=32737108|t=2020. Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma.|pdf=|usr=017}}
| |
| − | {{tp|p=32737107|t=2020. More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia.|pdf=|usr=017}}
| |
| − | {{tp|p=32737106|t=2020. Rational use of tocilizumab in COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32737105|t=2020. Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli.|pdf=|usr=017}}
| |
| − | {{tp|p=32744511|t=2020. Evaluation of drugs for potential repurposing against COVID-19 using a tier-based scoring system.|pdf=|usr=017}}
| |
| − | {{tp|p=32725790|t=2020. Synergy between cytokines and risk factors in the cytokine storm of Covid-19: protection from the chronic use of cytokine inhibitors?|pdf=|usr=017}}
| |
| − | {{tp|p=32735127|t=2020. Point-of-care and utility in clinical trials: making quicker decisions to transform patient care and drug development.|pdf=|usr=017}}
| |
| − | {{tp|p=32732352|t=2020. Remdesivir for severe covid-19: a clinical practice guideline.|pdf=|usr=017}}
| |
| − | {{tp|p=32732277|t=2020. Covid-19: Remdesivir probably reduces recovery time, but evidence is uncertain, panel finds.|pdf=|usr=017}}
| |
| − | {{tp|p=32719054|t=2020. Sacubitril, valsartan and SARS-CoV-2.|pdf=|usr=017}}
| |
| − | {{tp|p=32723436|t=2020. COVID-19: disCOVering the role of complement system.|pdf=|usr=017}}
| |
| − | {{tp|p=32745524|t=2020. Critical COVID-19 disease, homeostasis, and the "surprise" of effective glucocorticoid therapy.|pdf=|usr=017}}
| |
| − | {{tp|p=32723229|t=2020. Could Targeting HMGB1 be useful for the Clinical Management of COVID-19 Infection?|pdf=|usr=017}}
| |
| − | {{tp|p=32729428|t=2020. The Promise of Mesenchymal stem cells therapy for acute Respiratory Distress Syndrome Caused by COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32729640|t=2020. Probing 3CL protease: Rationally designed chemical moieties for COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32739174|t=2020. Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection.|pdf=|usr=017}}
| |
| − | {{tp|p=32744917|t=2020. Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects.|pdf=|usr=017}}
| |
| − | {{tp|p=32729363|t=2020. Development and progress of clinical trials of Coronavirus Disease 2019 antiviral drugs.|pdf=|usr=017}}
| |
| − | {{tp|p=32734777|t=2020. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis.|pdf=|usr=017}}
| |
| − | {{tp|p=32745502|t=2020. Probing antiviral drugs against SARS-CoV-2 through virus-drug association prediction based on the KATZ method.|pdf=|usr=017}}
| |
| − | {{tp|p=32742008|t=2020. Repurposed Drugs Against COVID-19: Safety Concerns and Stockout.|pdf=|usr=017}}
| |
| − | {{tp|p=32718300|t=2020. In Silico Identification of a Potent Arsenic Based Approved Drug Darinaparsin against SARS-CoV-2: Inhibitor of RNA Dependent RNA polymerase (RdRp) and Essential Proteases.|pdf=|usr=017}}
| |
| − | {{tp|p=32744166|t=2020. Is vitamin C an effective agent for the prevention of COVID-19 and treatment of severe infection in the ICU?|pdf=|usr=017}}
| |
| − | {{tp|p=32744052|t=2020. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra).|pdf=|usr=017}}
| |
| − | {{tp|p=32734828|t=2020. Tackling COVID-19: identification of potential main protease inhibitors via structural analysis, virtual screening, molecular docking and MM-PBSA calculations.|pdf=|usr=017}}
| |
| − | {{tp|p=32729392|t=2020. Antiviral potential of some novel structural analogs of standard drugs repurposed for the treatment of COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32741322|t=2020. Identification of promising drug candidates against NSP16 of SARS-CoV-2 through computational drug repurposing study.|pdf=|usr=017}}
| |
| − | {{tp|p=32741312|t=2020. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.|pdf=|usr=017}}
| |
| − | {{tp|p=32741259|t=2020. Identification of potential anti-TMPRSS2 natural products through homology modelling, virtual screening and molecular dynamics simulation studies.|pdf=|usr=017}}
| |
| − | {{tp|p=32740262|t=2020. Understanding COVID-19 Vaccines and Their Development.|pdf=|usr=017}}
| |
| − | {{tp|p=32740441|t=2020. Low hospitalization rate without severe arrhythmias: a prospective survey on 350 patients early home treated with hydroxychloroquine during COVID-19 pandemia.|pdf=|usr=017}}
| |
| − | {{tp|p=32734670|t=2020. Characteristics of Clinical Trials relating to COVID-19 registered at ClinicalTrials.gov.|pdf=|usr=017}}
| |
| − | {{tp|p=32729947|t=2020. Could an acute respiratory distress syndrome in COVID-19 infected patients be calmed down simply by iron withdrawal from lung tissues?|pdf=|usr=017}}
| |
| − | {{tp|p=32730617|t=2020. Characteristics and Strength of Evidence of COVID-19 Studies Registered on ClinicalTrials.gov.|pdf=|usr=017}}
| |
| − | {{tp|p=32744622|t=2020. The Uncertain Role of Corticosteroids in the Treatment of COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32744600|t=2020. The Uncertain Role of Corticosteroids in the Treatment of COVID-19-Reply.|pdf=|usr=017}}
| |
| − | {{tp|p=32744591|t=2020. The Uncertain Role of Corticosteroids in the Treatment of COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32722777|t=2020. Benefits and Safety of Nasal Saline Irrigations in a Pandemic-Washing COVID-19 Away.|pdf=|usr=017}}
| |
| − |
| |
| − | {{tp|p=32761294|t=2020. The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation.|pdf=|usr=017}}
| |
| − | {{tp|p=32765941|t=2020. Bioactive Lipids as Mediators of the Beneficial Action(s) of Mesenchymal Stem Cells in COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32765939|t=2020. COVID-19 and Senotherapeutics: Any Role for the Naturally-occurring Dipeptide Carnosine?|pdf=|usr=017}}
| |
| − | {{tp|p=32765938|t=2020. Potential Using of Fat-derived Stromal Cells in the Treatment of Active Disease, and also, in Both Pre- and Post-Periods in COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32767400|t=2020. Dupilumab, severe asthma airway responses, and SARS-CoV-2 serology.|pdf=|usr=017}}
| |
| − | {{tp|p=32762135|t=2020. Cabbage and fermented vegetables: from death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32774998|t=2020. Principles and treatment strategies for the use of Chinese herbal medicine in patients at different stages of coronavirus infection.|pdf=|usr=017}}
| |
| − | {{tp|p=32616373|t=2020. The influence of corticosteroid on patients with COVID-19 infection: A meta-analysis.|pdf=|usr=017}}
| |
| − | {{tp|p=32744592|t=2020. Searching for COVID-19 treatments: First, do no harm.|pdf=|usr=017}}
| |
| − | {{tp|p=32761732|t=2020. The COVID-19 liquid gold rush: Critical perspectives of human milk and SARS-CoV-2 infection.|pdf=|usr=017}}
| |
| − | {{tp|p=32755302|t=2020. MAY PHYTOTHERAPY WITH POLYPHENOLS SERVE AS A POWERFUL APPROACH FOR THE PREVENTION AND THERAPY TOOL OF NOVEL CORONAVIRUS DISEASE 2019 (COVID-19)?|pdf=|usr=017}}
| |
| − | {{tp|p=32778354|t=2020. Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention.|pdf=|usr=017}}
| |
| − | {{tp|p=32541234|t=2020. The Impact of COVID-19 on Clinical Trials.|pdf=|usr=017}}
| |
| − | {{tp|p=32763313|t=2020. Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses.|pdf=|usr=017}}
| |
| − | {{tp|p=32723524|t=2020. Response to: Amantadine, COVID-19 and Parkinsonism.|pdf=|usr=017}}
| |
| − | {{tp|p=32779737|t=2020. The absorbing filter Oxiris in severe COVID-19 patients: A case series.|pdf=|usr=017}}
| |
| − | {{tp|p=32674226|t=2020. Covid-19 and dietary socioecology: Risk minimisation.|pdf=|usr=017}}
| |
| − | {{tp|p=32773989|t=2020. Repurposing of known anti-virals as potential inhibitors for SARS-CoV-2 main protease using molecular docking analysis.|pdf=|usr=017}}
| |
| − | {{tp|p=32754003|t=2020. Potential Drugs and Remedies for the Treatment of COVID-19: a Critical Review.|pdf=|usr=017}}
| |
| − | {{tp|p=32763818|t=2020. Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32768882|t=2020. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies.|pdf=|usr=017}}
| |
| − | {{tp|p=32764129|t=2020. Patient-centric research in the time of COVID-19: conducting ethical COVID-19 research in Africa.|pdf=|usr=017}}
| |
| − | {{tp|p=32779815|t=2020. Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32776354|t=2020. The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing.|pdf=|usr=017}}
| |
| − | {{tp|p=32778225|t=2020. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.|pdf=|usr=017}}
| |
| − | {{tp|p=32767687|t=2020. Stem cell therapy for COVID-19: Possibilities and challenges.|pdf=|usr=017}}
| |
| − | {{tp|p=32772307|t=2020. Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?|pdf=|usr=017}}
| |
| − | {{tp|p=32779609|t=2020. Glucocorticoid-Induced Bacterial Endocarditis in COVID-19 Pneumonia- Something to Be Concerned About?|pdf=|usr=017}}
| |
| − | {{tp|p=32771488|t=2020. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32772069|t=2020. Clinical Outcomes Associated with Methylprednisolone in Mechanically Ventilated Patients with COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32770240|t=2020. AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial.|pdf=|usr=017}}
| |
| − | {{tp|p=32780788|t=2020. Gut microbiota and COVID-19: A superfluous diagnostic biomarker or therapeutic target?|pdf=|usr=017}}
| |
| − | {{tp|p=32767755|t=2020. Physiologically-Based Pharmacokinetic Modeling to Predict the Clinical Efficacy of the Coadministration of Lopinavir and Ritonavir against SARS-CoV-2.|pdf=|usr=017}}
| |
| − | {{tp|p=32771054|t=2020. Therapeutic plasma exchange in patients with COVID-19 pneumonia in intensive care unit: a retrospective study.|pdf=|usr=017}}
| |
| − | {{tp|p=32766569|t=2020. Treatment for Severe Coronavirus Disease 2019 With the Seraph-100 Microbind Affinity Blood Filter.|pdf=|usr=017}}
| |
| − | {{tp|p=32779824|t=2020. Volatile molecules for COVID-19: A possible pharmacological strategy?|pdf=|usr=017}}
| |
| − | {{tp|p=32770567|t=2020. Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study.|pdf=|usr=017}}
| |
| − | {{tp|p=32761647|t=2020. Snake venom-derived bradykinin-potentiating peptides: A promising therapy for COVID-19?|pdf=|usr=017}}
| |
| − | {{tp|p=32777537|t=2020. Global clinical trial mobilization for COVID-19: higher, faster, stronger.|pdf=|usr=017}}
| |
| − | {{tp|p=32753375|t=2020. BET 1: The role of remdesivir in COVID-19 infection.|pdf=|usr=017}}
| |
| − | {{tp|p=32730568|t=2020. Estradiol, Progesterone, Immunomodulation, and COVID-19 Outcomes.|pdf=|usr=017}}
| |
| − | {{tp|p=32780229|t=2020. Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials.|pdf=|usr=017}}
| |
| − | {{tp|p=32780273|t=2020. Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention.|pdf=|usr=017}}
| |
| − | {{tp|p=32725286|t=2020. Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?|pdf=|usr=017}}
| |
| − | {{tp|p=32735546|t=2020. The Anatomy of the SARS-CoV-2 Biomedical Literature: Introducing the CovidX Network Algorithm for Drug Repurposing Recommendation.|pdf=|usr=017}}
| |
| − | {{tp|p=32723801|t=2020. Drug discovery strategies for SARS-CoV-2.|pdf=|usr=017}}
| |
| − | {{tp|p=32735992|t=2020. Design of an engineered ACE2 as a novel therapeutics against COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32738928|t=2020. Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?|pdf=|usr=017}}
| |
| − | {{tp|p=32738360|t=2020. Computational guided drug repurposing for targeting 2'-O-ribose methyltransferase of SARS-CoV-2.|pdf=|usr=017}}
| |
| − | {{tp|p=32727107|t=2020. Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS.|pdf=|usr=017}}
| |
| − | {{tp|p=32722020|t=2020. Low Albumin Levels Are Associated with Poorer Outcomes in a Case Series of COVID-19 Patients in Spain: A Retrospective Cohort Study.|pdf=|usr=017}}
| |
| − | {{tp|p=32737681|t=2020. Identification of potential Mpro inhibitors for the treatment of COVID-19 by using systematic virtual screening approach.|pdf=|usr=017}}
| |
| − | {{tp|p=32722908|t=2020. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.|pdf=|usr=017}}
| |
| − | {{tp|p=32715661|t=2020. Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients.|pdf=|usr=017}}
| |
| − | {{tp|p=32726304|t=2020. Developing a low-cost and accessible COVID-19 vaccine for global health.|pdf=|usr=017}}
| |
| − | {{tp|p=32735326|t=2020. Potential role of hypovitaminosis D and Vitamin D supplementation during COVID-19 pandemic.|pdf=|usr=017}}
| |
| − | {{tp|p=32703908|t=2020. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody.|pdf=|usr=017}}
| |
| − | {{tp|p=32740890|t=2020. Stem Cells Therapy as a Possible Therapeutic Option in Treating COVID-19 Patients.|pdf=|usr=017}}
| |
| − | {{tp|p=32739472|t=2020. Apparent inefficacy of hydroxychloroquine combined with azithromycin on SARS-CoV-2 clearance in an incident cohort of geriatric patients with COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32718128|t=2020. Perspectives for the immune plasma treatment of COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32731461|t=2020. Vaccine Design from the Ensemble of Surface Glycoprotein Epitopes of SARS-CoV-2: An Immunoinformatics Approach.|pdf=|usr=017}}
| |
| − | {{tp|p=32717854|t=2020. Immunogenic SARS-CoV-2 Epitopes: In Silico Study Towards Better Understanding of COVID-19 Disease-Paving the Way for Vaccine Development.|pdf=|usr=017}}
| |
| − | {{tp|p=32717346|t=2020. Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy.|pdf=|usr=017}}
| |
| − | {{tp|p=32722574|t=2020. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.|pdf=|usr=017}}
| |
| − | {{tp|p=32734479|t=2020. Partially ionized medical oxygen as a supplementary treatment for COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32668969|t=2020. Potential Targets for Treatment of Coronavirus Disease 2019 (COVID-19): A Review of Qing-Fei-Pai-Du-Tang and Its Major Herbs.|pdf=|usr=017}}
| |
| − | {{tp|p=32631576|t=2020. Carvedilol and COVID-19: A Potential Role in Reducing Infectivity and Infection Severity of SARS-CoV-2.|pdf=|usr=017}}
| |
| − | {{tp|p=32622469|t=2020. Is Inhaled Furosemide a Potential Therapeutic for COVID-19?|pdf=|usr=017}}
| |
| − | {{tp|p=32750259|t=2020. COVID-19: Clean up on IL-6.|pdf=|usr=017}}
| |
| − | {{tp|p=32749854|t=2020. Reply to: Does Vaping Increase Susceptibility to COVID-19?|pdf=|usr=017}}
| |
| − | {{tp|p=32753413|t=2020. To immunosuppress: whom, when and how? That is the question with COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32719045|t=2020. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.|pdf=|usr=017}}
| |
| − | {{tp|p=32737111|t=2020. COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine.|pdf=|usr=017}}
| |
| − | {{tp|p=32737109|t=2020. Response to: 'COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine' by Teh et al.|pdf=|usr=017}}
| |
| − | {{tp|p=32732244|t=2020. Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials - a real-world district general hospital experience.|pdf=|usr=017}}
| |
| − | {{tp|p=32732243|t=2020. Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M et al.|pdf=|usr=017}}
| |
| − | {{tp|p=32769154|t=2020. Correspondence on 'Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist' by Graef et al.|pdf=|usr=017}}
| |
| − | {{tp|p=32769153|t=2020. Mild COVID-19 in ANCA-associated vasculitis treated with rituximab.|pdf=|usr=017}}
| |
| − | {{tp|p=32769149|t=2020. Response to: 'Correspondence on 'Festina lente: hydroxychloroquine, COVID-19and the role of the rheumatologist' by Graef et al' by Lo et al.|pdf=|usr=017}}
| |
| − | {{tp|p=32759263|t=2020. Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis.|pdf=|usr=017}}
| |
| − | {{tp|p=32759257|t=2020. Response to: 'Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis' by Singer et al.|pdf=|usr=017}}
| |
| − | {{tp|p=32759267|t=2020. Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production.|pdf=|usr=017}}
| |
| − | {{tp|p=32701630|t=2020. Treatment of Cytokine Storm in COVID-19 Patients with Immunomodulatory Therapy.|pdf=|usr=017}}
| |
| − | {{tp|p=32740072|t=2020. Re: Chloroquine (CQ) and Hydroxychloroquine (HQ) Retinal Toxicity Consideration in the Treatment of the Coronavirus Disease 2019 (COVID-19).|pdf=|usr=017}}
| |
| − | {{tp|p=32740071|t=2020. A Word of Caution in the Use of Hydroxychloroquine in the Elderly COVID-19 Population.|pdf=|usr=017}}
| |
| − | {{tp|p=32740070|t=2020. Chloroquine, Hydroxychloroquine, Retinal Toxicity, and COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32761219|t=2020. Convalescent plasma to treat COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32759299|t=2020. Covid-19: Where are we on immunity and vaccines?|pdf=|usr=017}}
| |
| − | {{tp|p=32758306|t=2020. Selenium and viral infection: are there lessons for COVID-19?|pdf=|usr=017}}
| |
| − | {{tp|p=32769401|t=2020. Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe?|pdf=|usr=017}}
| |
| − | {{tp|p=32773440|t=2020. A Review of Remdesivir for COVID-19: Data to Date.|pdf=|usr=017}}
| |
| − | {{tp|p=32756614|t=2020. Discovery of sandwich type COVID-19 nucleocapsid protein DNA aptamers.|pdf=|usr=017}}
| |
| − | {{tp|p=32755466|t=2020. Human Cardiac Mesenchymal Stem Cells Remodel in Disease and Can Regulate Arrhythmia Substrates.|pdf=|usr=017}}
| |
| − | {{tp|p=32748740|t=2020. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking Screening.|pdf=|usr=017}}
| |
| − | {{tp|p=32767929|t=2020. Theoretical Study of the Molecular Mechanism of Maxingyigan Decoction Against COVID-19: Network Pharmacology-based Strategy.|pdf=|usr=017}}
| |
| − | {{tp|p=32769050|t=2020. Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design.|pdf=|usr=017}}
| |
| − | {{tp|p=32693756|t=2020. Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32767920|t=2020. The Plausible role of Indian Traditional Medicine in combating Corona Virus (SARS-CoV 2): a mini-review.|pdf=|usr=017}}
| |
| − | {{tp|p=32758037|t=2020. Antiviral drugs and plasma therapy used for Covid-19 treatment: a nationwide Turkish algorithm.|pdf=|usr=017}}
| |
| − | {{tp|p=32742146|t=Summ. Impact of COVID-19 on Clinical Research and Inclusion of Diverse Populations.|pdf=|usr=017}}
| |
| − | {{tp|p=32742147|t=2020. Applying Community-Partnered Participatory Research Approaches to Develop COVID-19 Solutions.|pdf=|usr=017}}
| |
| − | {{tp|p=32734625|t=2020. BCG vaccination early in life does not improve COVID-19 outcome of elderly populations, based on nationally reported data.|pdf=|usr=017}}
| |
| − | {{tp|p=32722864|t=2020. In silico Drug Repurposing for COVID-19: Targeting SARS-CoV-2 Proteins through Docking and Consensus Ranking.|pdf=|usr=017}}
| |
| − | {{tp|p=32726549|t=2020. Audio Interview: New SARS-CoV-2 Vaccine Results, with Peter Piot.|pdf=|usr=017}}
| |
| − | {{tp|p=32704139|t=2020. Next-generation vaccine platforms for COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32704138|t=2020. COVID-19 therapies and vaccine landscape.|pdf=|usr=017}}
| |
| − | {{tp|p=32737466|t=2020. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.|pdf=|usr=017}}
| |
| − | {{tp|p=32731258|t=2020. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.|pdf=|usr=017}}
| |
| − | {{tp|p=32731257|t=2020. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques.|pdf=|usr=017}}
| |
| − | {{tp|p=32726802|t=2020. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.|pdf=|usr=017}}
| |
| − | {{tp|p=32726800|t=2020. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis.|pdf=|usr=017}}
| |
| − | {{tp|p=32710694|t=2020. Potential limitations of plasmapheresis in treatment of COVID-19 patients: How to overcome them?|pdf=|usr=017}}
| |
| − |
| |
| − | {{tp|p=32755604|t=2020. Teaching Old Drugs New Tricks: Statins for COVID-19?|pdf=|usr=017}}
| |
| − | {{tp|p=32755598|t=2020. A Carbohydrate-Binding Protein from the Edible Lablab Beans Effectively Blocks the Infections of Influenza Viruses and SARS-CoV-2.|pdf=|usr=017}}
| |
| − | {{tp|p=32759966|t=2020. A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2.|pdf=|usr=017}}
| |
| − | {{tp|p=32761452|t=2020. Sex differences in COVID-19 mortality: opportunity to develop HSP27 (HSPB1) immunotherapy to treat hyper-inflammation?|pdf=|usr=017}}
| |
| − | {{tp|p=32761336|t=2020. Role of Complementary and Alternative Medicine in Prevention and Treatment of COVID-19: An Overhyped Hope.|pdf=|usr=017}}
| |
| − | {{tp|p=32754224|t=2020. Potential mechanism prediction of Cold-Damp Plague Formula against COVID-19 via network pharmacology analysis and molecular docking.|pdf=|usr=017}}
| |
| − | {{tp|p=32759176|t=2020. Convalescent plasma for COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32671831|t=2020. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases.|pdf=|usr=017}}
| |
| − | {{tp|p=32702224|t=2020. Clozapine in the Time of COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32736332|t=2020. Determination of an optimal control strategy for vaccine administration in COVID-19 pandemic treatment.|pdf=|usr=017}}
| |
| − | {{tp|p=32654163|t=2020. First case of DRESS syndrome caused by hydroxychloroquine with a positive patch test.|pdf=|usr=017}}
| |
| − | {{tp|p=32753056|t=2020. Plasma exchange in critically ill COVID-19 patients.|pdf=|usr=017}}
| |
| − | {{tp|p=32754408|t=2020. The Potential Vaccine Component for COVID-19: A Comprehensive Review of Global Vaccine Development Efforts.|pdf=|usr=017}}
| |
| − | {{tp|p=32754388|t=2020. Potential Treatment Options for COVID-19: A Comprehensive Review of Global Pharmacological Development Efforts.|pdf=|usr=017}}
| |
| − | {{tp|p=32699671|t=2020. Debunking Cannabidiol as a Treatment for COVID-19: Time for the FDA to Adopt a Focused Deterrence Model?|pdf=|usr=017}}
| |
| − | {{tp|p=32685300|t=2020. The Role of Interleukin-6 Inhibitors in the Treatment of COVID-19 Infections: A Case Series.|pdf=|usr=017}}
| |
| − | {{tp|p=32750451|t=2020. Metformin and COVID-19: From cellular mechanisms to reduced mortality.|pdf=|usr=017}}
| |
| − | {{tp|p=32771797|t=2020. Potential treatment methods targeting 2019-nCoV infection.|pdf=|usr=017}}
| |
| − | {{tp|p=32777212|t=2020. What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results.|pdf=|usr=017}}
| |
| − | {{tp|p=32768505|t=2020. COVID-19: A review of the proposed pharmacological treatments.|pdf=|usr=017}}
| |
| − | {{tp|p=32768503|t=2020. In silico pharmacokinetic and molecular docking studies of natural flavonoids and synthetic indole chalcones against essential proteins of SARS-CoV-2.|pdf=|usr=017}}
| |
| − | {{tp|p=32763302|t=2020. Coronavirus diseases 2019: Current biological situation and potential therapeutic perspective.|pdf=|usr=017}}
| |
| − | {{tp|p=32763298|t=2020. Molecular effects and retinopathy induced by hydroxychloroquine during SARS-CoV-2 therapy: Role of CYP450 isoforms and epigenetic modulations.|pdf=|usr=017}}
| |
| − | {{tp|p=32764115|t=2020. SARS-CoV2 disrupts clinical research - the role of a rare disease-specific trial network.|pdf=|usr=017}}
| |
| − | {{tp|p=32779213|t=2020. COVID-19 and Vitamin D: A lesson from the skin.|pdf=|usr=017}}
| |
| − | {{tp|p=32762581|t=2020. Immunotherapy for SARS-CoV-2: potential opportunities.|pdf=|usr=017}}
| |
| − | {{tp|p=32780893|t=2020. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32777281|t=2020. What underlies the benefit of famotidine formulations used during COVID-19?|pdf=|usr=017}}
| |
| − | {{tp|p=32771622|t=2020. Global multi-omics and systems pharmacological strategy unravel the multi-targeted therapeutic potential of natural bioactive molecules against COVID-19: An in silico approach.|pdf=|usr=017}}
| |
| − | {{tp|p=32767854|t=2020. Letter to the Editors: Statins and COVID-19: Efficacy Still to Be Proven.|pdf=|usr=017}}
| |
| − | {{tp|p=32780299|t=2020. Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective.|pdf=|usr=017}}
| |
| − | {{tp|p=32774508|t=2020. Chloroquine and COVID-19: Should We Care about Ototoxicity?|pdf=|usr=017}}
| |
| − | {{tp|p=32777263|t=2020. Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results.|pdf=|usr=017}}
| |
| − | {{tp|p=32767379|t=2020. Biologic drugs during COVID-19 outbreak.|pdf=|usr=017}}
| |
| − | {{tp|p=32771630|t=2020. Comment on Arshad et al: Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32768697|t=2020. Vitamin D3 and K2 and their potential contribution to reducing the COVID-19 mortality rate.|pdf=|usr=017}}
| |
| − | {{tp|p=32768701|t=2020. Low-Dose Subcutaneous Tocilizumab to Prevent Disease Progression in Patients with Moderate COVID-19 Pneumonia and Hyperinflammation.|pdf=|usr=017}}
| |
| − | {{tp|p=32768698|t=2020. Hydroxychloroquine in COVID-19: taking care of statistic to take care of patients.|pdf=|usr=017}}
| |
| − | {{tp|p=32768694|t=2020. Re: Arshad S, Kilgore P, Chaudhry ZS et al. Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19. Int J Infect Dis: 2020. Epub 2020 Jul 1 http://doi.org/10.1016/j.ijid.2020.06.099.|pdf=|usr=017}}
| |
| − | {{tp|p=32768693|t=2020. Early Identification of COVID-19 Cytokine Storm and Treatment with Anakinra or Tocilizumab.|pdf=|usr=017}}
| |
| − | {{tp|p=32766679|t=2020. Comment on: Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.|pdf=|usr=017}}
| |
| − | {{tp|p=32750131|t=2020. Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.|pdf=|usr=017}}
| |
| − | {{tp|p=32770858|t=2020. Updated information on new coronavirus disease 2019 occurrence, drugs, and prediction of a potential receptor.|pdf=|usr=017}}
| |
| − | {{tp|p=32779770|t=2020. QTc prolongation during antiviral therapy in two COVID-19 patients.|pdf=|usr=017}}
| |
| − | {{tp|p=32779201|t=2020. Immunomodulatory Therapeutic Proteins in COVID-19: Current Clinical Development and Clinical Pharmacology Considerations.|pdf=|usr=017}}
| |
| − | {{tp|p=32773258|t=2020. Therapeutic plasma exchange resolving COVID-19 related ARDS.|pdf=|usr=017}}
| |
| − | {{tp|p=32777441|t=2020. Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-COV-2 infection?|pdf=|usr=017}}
| |
| − | {{tp|p=32763357|t=2020. Hydroxychloroquine use in Hospitalized Patients with COVID-19: An observational matched cohort study.|pdf=|usr=017}}
| |
| − | {{tp|p=32763262|t=2020. The proper use of corticosteroids for 2019-nCov pneumonia: Towards promising results?|pdf=|usr=017}}
| |
| − | {{tp|p=32777038|t=2020. Convalescent Plasma Therapy on Patients with Severe or Life-Threatening COVID-19: A Metadata Analysis.|pdf=|usr=017}}
| |
| − | {{tp|p=32773212|t=2020. Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review.|pdf=|usr=017}}
| |
| − | {{tp|p=32762368|t=2020. Prolonged QT Interval in a Patient With Coronavirus Disease-2019: Beyond Hydroxychloroquine and Azithromycin.|pdf=|usr=017}}
| |
| − | {{tp|p=32779755|t=2020. Hydroxychloroquine treatment in COVID-19: a descriptive observational analysis of 30 cases from a single center in Wuhan, China.|pdf=|usr=017}}
| |
| − | {{tp|p=32767684|t=2020. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells.|pdf=|usr=017}}
| |
| − | {{tp|p=32749708|t=2020. Can aldosterone increase interleukin-6 levels in Covid-19 pneumonia?|pdf=|usr=017}}
| |
| − | {{tp|p=32749702|t=2020. Targeting human TLRs to combat COVID-19: A solution?|pdf=|usr=017}}
| |
| − | {{tp|p=32776550|t=2020. Clinical trials of inhaled beclomethasone and mometasone for COVID-19 should be conducted.|pdf=|usr=017}}
| |
| − | {{tp|p=32776534|t=2020. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study.|pdf=|usr=017}}
| |
| − | {{tp|p=32735768|t=2020. Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2.|pdf=|usr=017}}
| |
| − | {{tp|p=32770854|t=2020. Clinical trial to test the efficacy of melatonin in COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32765615|t=2020. Glucocorticoids in COVID19; a friend not foe.|pdf=|usr=017}}
| |
| − | {{tp|p=32748578|t=2020. Interferon-alpha2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study.|pdf=|usr=017}}
| |
| − | {{tp|p=32776022|t=2020. Structural Basis for Designing Multiepitope Vaccines Against COVID-19 Infection: In Silico Vaccine Design and Validation.|pdf=|usr=017}}
| |
| − | {{tp|p=32777300|t=2020. Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study.|pdf=|usr=017}}
| |
| − | {{tp|p=32763660|t=2020. Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content.|pdf=|usr=017}}
| |
| − | {{tp|p=32768893|t=2020. The possible immunoregulatory and anti-inflammatory effects of selective serotonin reuptake inhibitors in coronavirus disease patients.|pdf=|usr=017}}
| |
| − | {{tp|p=32755992|t=2020. MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32633332|t=2020. The complement inhibitors in COVID-19: future expectations.|pdf=|usr=017}}
| |
| − | {{tp|p=32744716|t=2020. SARS-CoV-2 vs. SARS-CoV-1 management: antibiotics and inflammasome modulators potential.|pdf=|usr=017}}
| |
| − | {{tp|p=32744711|t=2020. Molecular modelling of the antiviral action of Resveratrol derivatives against the activity of two novel SARS CoV-2 and 2019-nCoV receptors.|pdf=|usr=017}}
| |
| − | {{tp|p=32767353|t=2020. Morning vs. evening administration of antiviral therapy in COVID-19 patients. A preliminary retrospective study in Ferrara, Italy.|pdf=|usr=017}}
| |
| − | {{tp|p=32767349|t=2020. Corticosteroid therapy for patients with severe novel Coronavirus disease 2019.|pdf=|usr=017}}
| |
| − | {{tp|p=32767348|t=2020. Inhibitory effects of Vitamin D on inflammation and IL-6 release. A further support for COVID-19 management?|pdf=|usr=017}}
| |
| − | {{tp|p=32767316|t=2020. Hydroxychloroquine (HCQ) use in G6PD deficient COVID-19 patients and the risk of Acute Hemeolytic Anaemia (AHA).|pdf=|usr=017}}
| |
| − | {{tp|p=32752970|t=2020. The trade-off dilemma in pharmacotherapy of COVID-19: systematic review, meta-analysis, and implications.|pdf=|usr=017}}
| |
| − | {{tp|p=32746653|t=2020. Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges.|pdf=|usr=017}}
| |
| − | {{tp|p=32762516|t=2020. Are BCG-induced non-specific effects adequate to provide protection against COVID-19?|pdf=|usr=017}}
| |
| − | {{tp|p=32773415|t=2020. Hydroxychloroquine for chemoprophylaxis in COVID-19: A case of motivated perception?|pdf=|usr=017}}
| |
| − | {{tp|p=32773410|t=2020. Hydroxychloroquine prophylaxis for SARS-CoV-2 infection among healthcare workers.|pdf=|usr=017}}
| |
| − | {{tp|p=32644027|t=2020. Tocilizumab for COVID-19: a real 'miracle drug'?|pdf=|usr=017}}
| |
| − | {{tp|p=32696730|t=2020. Newly Emergent 2019-nCoV and New Uses of an Old Medicine, Doxycycline; A Hypothesis.|pdf=|usr=017}}
| |
| − | {{tp|p=32758675|t=2020. Immunoinformatic construction of an adenovirus-based modular vaccine platform and its application in the design of a SARS-CoV-2 vaccine.|pdf=|usr=017}}
| |
| − | {{tp|p=32729823|t=2020. Drug evaluation and pharmaceutical care in a critically ill COVID-19 patient.|pdf=|usr=017}}
| |
| − | {{tp|p=32718410|t=2020. Bacille Calmette-Guerin (BCG) vaccine and the COVID-19 pandemic: responsible stewardship is needed.|pdf=|usr=017}}
| |
| − | {{tp|p=32740371|t=2020. A retrospective evaluation on the efficacy of Lopinavir/ritonavir and chloroquine to treat non-severe COVID-19 patients.|pdf=|usr=017}}
| |
| − | {{tp|p=32735036|t=2020. COVID-19 in Nursing Homes: Calming the Perfect Storm.|pdf=|usr=017}}
| |
| − | {{tp|p=32610879|t=2020. Hydroxychloroquine for COVID-19: What is our Current State of Knowledge?|pdf=|usr=017}}
| |
| − | {{tp|p=32610873|t=2020. Characteristics, Treatment Outcomes and Role of Hydroxychloroquine among 522 COVID-19 hospitalized patients in Jaipur City: An Epidemio-Clinical Study.|pdf=|usr=017}}
| |
| − | {{tp|p=32738852|t=2020. Hydroxychloroquin for COVID-19 Why was so much hype?|pdf=|usr=017}}
| |
| − | {{tp|p=32762537|t=2020. In silico virtual screening, characterization, docking and molecular dynamics studies of crucial SARS-CoV-2 proteins.|pdf=|usr=017}}
| |
| − | {{tp|p=32762511|t=2020. In silico investigation of phytoconstituents from Indian medicinal herb 'Tinospora cordifolia (giloy)' against SARS-CoV-2 (COVID-19) by molecular dynamics approach.|pdf=|usr=017}}
| |
| − | {{tp|p=32762411|t=2020. Identification of polyphenols from Broussonetia papyrifera as SARS CoV-2 main protease inhibitors using in silico docking and molecular dynamics simulation approaches.|pdf=|usr=017}}
| |
| − | {{tp|p=32752951|t=2020. Molecular docking, molecular dynamics simulations and reactivity, studies on approved drugs library targeting ACE2 and SARS-CoV-2 binding with ACE2.|pdf=|usr=017}}
| |
| − | {{tp|p=32752947|t=2020. Predictive modeling by deep learning, virtual screening and molecular dynamics study of natural compounds against SARS-CoV-2 main protease.|pdf=|usr=017}}
| |
| − | {{tp|p=32752944|t=2020. Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2.|pdf=|usr=017}}
| |
| − | {{tp|p=32752938|t=2020. In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials.|pdf=|usr=017}}
| |
| − | {{tp|p=32772895|t=2020. Structural insight to hydroxychloroquine-3C-like proteinase complexation from SARS-CoV-2: inhibitor modelling study through molecular docking and MD-simulation study.|pdf=|usr=017}}
| |
| − | {{tp|p=32772892|t=2020. In silico designing of multi-epitope vaccine construct against human coronavirus infections.|pdf=|usr=017}}
| |
| − | {{tp|p=32723468|t=2020. Convalescent Plasma: Promise for COVID-19 Pandemic.|pdf=|usr=017}}
| |
| − | {{tp|p=32723461|t=2020. Chloroquine and Hydroxychloroquine in COVID-19: Challenges and the Need for Caution in Low-Resource Settings.|pdf=|usr=017}}
| |
| − | {{tp|p=32763058|t=2020. Therapeutic plasma exchange in adult critically ill patients with life-threatening SARS-CoV-2 disease: A pilot study.|pdf=|usr=017}}
| |
| − | {{tp|p=32746637|t=2020. Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro.|pdf=|usr=017}}
| |
| − | {{tp|p=32769686|t=2020. Association between hypertension and pneumonia caused by SARS-CoV-2 in Mexican population.|pdf=|usr=017}}
| |
| − | {{tp|p=32711596|t=2020. Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.|pdf=|usr=017}}
| |
| − | {{tp|p=32692185|t=2020. Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32761166|t=2020. COVID-19 and Dexamethasone: A Potential Strategy to Avoid Steroid-Related Strongyloides Hyperinfection.|pdf=|usr=017}}
| |
| − | {{tp|p=32720611|t=2020. [Use of Statins, Anticoagulants, Antiaggregants and Antiarrhythmic Drugs in Patients With COVID-19. The Agreed Experts' Position of Russian Society of Cardiology, Eurasian Association of Therapists, National Society on Atherothrombosis, Societies of Experts in Urgent Cardiology, Eurasian Arrhythmology Association].|pdf=|usr=017}}
| |
| − | {{tp|p=32747135|t=2020. Should estrogen be used in the co-treatment of COVID-19 patients? What is the rationale?|pdf=|usr=017}}
| |
| − | {{tp|p=32747134|t=2020. Response to "Should estrogen be used in the co-treatment of COVID-19 patients?"|pdf=|usr=017}}
| |
| − | {{tp|p=32679422|t=2020. Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis?|pdf=|usr=017}}
| |
| − | {{tp|p=32759894|t=2020. Vitamin C for COVID-19: A living systematic review.|pdf=|usr=017}}
| |
| − | {{tp|p=32558474|t=2020. Amplifying RNA Vaccine Development.|pdf=|usr=017}}
| |
| − |
| |
| − | {{tp|p=32755836|t=2020. Vaccine development against coronavirus (2003 to present): An overview, recent advances, current scenario, opportunities and challenges.|pdf=|usr=017}}
| |
| − | {{tp|p=32749644|t=2020. ACE2 and SARS-CoV-2 Infection: Might GLP-1 Receptor Agonists Play a Role?|pdf=|usr=017}}
| |
| − | {{tp|p=32748035|t=2020. Nanotechnology-based antiviral therapeutics.|pdf=|usr=017}}
| |
| − | {{tp|p=32753842|t=2020. Plasmapheresis, Anti-ACE2 and Anti-FcgammaRII Monoclonal Antibodies: A Possible Treatment for Severe Cases of COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32669523|t=2020. Traditional Chinese medicine to treat COVID-19: the importance of evidence-based research.|pdf=|usr=017}}
| |
| − | {{tp|p=32669519|t=2020. Re-tasking the use of pre-existing medications and potential therapeutic options for coronavirus disease (COVID-19): systematic review of clinical studies.|pdf=|usr=017}}
| |
| − | {{tp|p=32742294|t=2020. Hydroxychloroquine-induced hyperpigmentation in a 14-year-old female with systemic lupus erythematosus.|pdf=|usr=017}}
| |
| − | {{tp|p=32766547|t=2020. A vaccine for SARS-CoV-2: goals and promises.|pdf=|usr=017}}
| |
| − | {{tp|p=32758569|t=2020. In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2.|pdf=|usr=017}}
| |
| − | {{tp|p=32750366|t=2020. An overview of the pathogenic mechanisms involved in severe cases of COVID-19 infection, and the proposal of salicyl-carnosine as a potential drug for its treatment.|pdf=|usr=017}}
| |
| − | {{tp|p=32700670|t=2020. Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020.|pdf=|usr=017}}
| |
| − | {{tp|p=32765844|t=2020. In silico screening of known small molecules to bind ACE2 specific RBD on Spike glycoprotein of SARS-CoV-2 for repurposing against COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32742639|t=2020. Turning up the heat on COVID-19: heat as a therapeutic intervention.|pdf=|usr=017}}
| |
| − | {{tp|p=32704354|t=2020. Coronavirus disease 2019 drug discovery through molecular docking.|pdf=|usr=017}}
| |
| − | {{tp|p=32704352|t=2020. Recruiting the innate immune system with GM-CSF to fight viral diseases, including West Nile Virus encephalitis and COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32752217|t=2020. Food and COVID-19: Preventive/Co-therapeutic Strategies Explored by Current Clinical Trials and in Silico Studies.|pdf=|usr=017}}
| |
| − | {{tp|p=32766256|t=2020. Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm?|pdf=|usr=017}}
| |
| − | {{tp|p=32766251|t=2020. The Coronavirus Pandemic (SARS-CoV-2): New Problems Demand New Solutions, the Alternative of Mesenchymal (Stem) Stromal Cells.|pdf=|usr=017}}
| |
| − | {{tp|p=32719799|t=2020. Current Findings Regarding Natural Components With Potential Anti-2019-nCoV Activity.|pdf=|usr=017}}
| |
| − | {{tp|p=32760409|t=2020. Could the Induction of Trained Immunity by beta-Glucan Serve as a Defense Against COVID-19?|pdf=|usr=017}}
| |
| − | {{tp|p=32760408|t=2020. Prevention of Severe Coronavirus Disease 2019 Outcomes by Reducing Low-Grade Inflammation in High-Risk Categories.|pdf=|usr=017}}
| |
| − | {{tp|p=32760407|t=2020. High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects.|pdf=|usr=017}}
| |
| − | {{tp|p=32754165|t=2020. A Hypothesis for the Possible Role of Zinc in the Immunological Pathways Related to COVID-19 Infection.|pdf=|usr=017}}
| |
| − | {{tp|p=32754164|t=2020. The Potential Impact of Zinc Supplementation on COVID-19 Pathogenesis.|pdf=|usr=017}}
| |
| − | {{tp|p=32754163|t=2020. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies.|pdf=|usr=017}}
| |
| − | {{tp|p=32754161|t=2020. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using in silico Structure-Based Virtual Screening Approach.|pdf=|usr=017}}
| |
| − | {{tp|p=32754160|t=2020. Designing Multi-Epitope Vaccines to Combat Emerging Coronavirus Disease 2019 (COVID-19) by Employing Immuno-Informatics Approach.|pdf=|usr=017}}
| |
| − | {{tp|p=32733489|t=2020. Complement Inhibition in Coronavirus Disease (COVID)-19: A Neglected Therapeutic Option.|pdf=|usr=017}}
| |
| − | {{tp|p=32733488|t=2020. Potential Fast COVID-19 Containment With Trehalose.|pdf=|usr=017}}
| |
| − | {{tp|p=32733487|t=2020. Role of Immune Dysregulation in Increased Mortality Among a Specific Subset of COVID-19 Patients and Immune-Enhancement Strategies for Combatting Through Nutritional Supplements.|pdf=|usr=017}}
| |
| − | {{tp|p=32719685|t=2020. Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies.|pdf=|usr=017}}
| |
| − | {{tp|p=32719684|t=2020. COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning.|pdf=|usr=017}}
| |
| − | {{tp|p=32719683|t=2020. Mesenchymal Stem Cells: A New Piece in the Puzzle of COVID-19 Treatment.|pdf=|usr=017}}
| |
| − | {{tp|p=32761491|t=2020. Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32766266|t=2020. Administration of Immunoglobulins in SARS-CoV-2-Positive Patient Is Associated With Fast Clinical and Radiological Healing: Case Report.|pdf=|usr=017}}
| |
| − | {{tp|p=32733907|t=2020. Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32765482|t=2020. Therapeutic Strategies Against COVID-19 and Structural Characterization of SARS-CoV-2: A Review.|pdf=|usr=017}}
| |
| − | {{tp|p=32754147|t=2020. Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro.|pdf=|usr=017}}
| |
| − | {{tp|p=32765279|t=2020. Selective Estrogen Receptor Modulators in COVID-19: A Possible Therapeutic Option?|pdf=|usr=017}}
| |
| − | {{tp|p=32765274|t=2020. No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study.|pdf=|usr=017}}
| |
| − | {{tp|p=32754036|t=2020. BCG Against SARS-CoV-2: Second Youth of an Old Age Vaccine?|pdf=|usr=017}}
| |
| − | {{tp|p=32733287|t=2020. Resistance Training in Face of the Coronavirus Outbreak: Time to Think Outside the Box.|pdf=|usr=017}}
| |
| − | {{tp|p=32719619|t=2020. While We Wait for a Vaccine Against SARS-CoV-2, Why Not Think About Available Drugs?|pdf=|usr=017}}
| |
| − | {{tp|p=32754571|t=2020. Novel Coronavirus Pneumonia Treatment With Traditional Chinese Medicine: Response Philosophy in Another Culture.|pdf=|usr=017}}
| |
| − | {{tp|p=32754570|t=2020. Recent Advancements in the Diagnosis, Prevention, and Prospective Drug Therapy of COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32733842|t=2020. Progress in the Research and Development of Anti-COVID-19 Drugs.|pdf=|usr=017}}
| |
| − | {{tp|p=32733837|t=2020. A Perspective on Emerging Therapeutic Interventions for COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32719766|t=2020. Clinical Use of Short-Course and Low-Dose Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia Progression.|pdf=|usr=017}}
| |
| − | {{tp|p=32750187|t=2020. Insights on 3D Structures of Potential Drug-Targeting Proteins of SARS-CoV-2: Application of Cavity Search and Molecular Docking.|pdf=|usr=017}}
| |
| − | {{tp|p=32763844|t=2020. The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients.|pdf=|usr=017}}
| |
| − | {{tp|p=32772313|t=2020. Anthraquinone Derivatives as an Immune Booster and their Therapeutic Option Against COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32778829|t=2020. After 62 years of regulating immunity, dexamethasone meets COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32770341|t=2020. Use of a Novel Negative-Pressure Tent During Bedside Tracheostomy in COVID-19 Patients.|pdf=|usr=017}}
| |
| − | {{tp|p=32667665|t=2020. Transcriptome-based drug repositioning for coronavirus disease 2019 (COVID-19).|pdf=|usr=017}}
| |
| − | {{tp|p=32778962|t=2020. Repurposing of Kinase Inhibitors for Treatment of COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32781283|t=2020. Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial.|pdf=|usr=017}}
| |
| − | {{tp|p=32776317|t=2020. Low dose radiation therapy for COVID-19 pneumonia: brief review of the evidence.|pdf=|usr=017}}
| |
| − | {{tp|p=32773257|t=2020. Potential influence of Nagella sativa (Black cumin) in reinforcing immune system: A hope to decelerate the COVID-19 pandemic.|pdf=|usr=017}}
| |
| − | {{tp|p=32754955|t=2020. Astaxanthin, COVID-19 and immune response: Focus on oxidative stress, apoptosis and autophagy.|pdf=|usr=017}}
| |
| − | {{tp|p=32748969|t=2020. Evaluation of medicinal herbs as a potential therapeutic option against SARS-CoV-2 targeting its main protease.|pdf=|usr=017}}
| |
| − | {{tp|p=32779305|t=2020. High affinity interaction of Solanum tuberosum and Brassica juncea residue smoke water compounds with proteins involved in coronavirus infection.|pdf=|usr=017}}
| |
| − | {{tp|p=32778507|t=2020. COVID-19 and steroid therapy: Impact on diabetes.|pdf=|usr=017}}
| |
| − | {{tp|p=32779326|t=2020. Drugs against SARS-CoV-2: What do we know about their mode of action?|pdf=|usr=017}}
| |
| − | {{tp|p=32773341|t=2020. Could the antipsychotic chlorpromazine be a potential treatment for SARS-CoV-2?|pdf=|usr=017}}
| |
| − | {{tp|p=32779878|t=2020. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect.|pdf=|usr=017}}
| |
| − | {{tp|p=32778854|t=2020. COVID-19: should oral vaccination strategies be given more consideration?|pdf=|usr=017}}
| |
| − | {{tp|p=32771272|t=2020. A Scoping Review of Registered Clinical Trials of Convalescent Plasma for COVID-19 and a Framework for Accelerated Synthesis of Trial Evidence (FAST Evidence).|pdf=|usr=017}}
| |
| − | {{tp|p=32770691|t=2020. Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32748963|t=2020. Rapid establishment of a COVID-19 convalescent plasma program in a regional health care delivery network.|pdf=|usr=017}}
| |
| − | {{tp|p=32777902|t=2020. Melatonin, Aging and COVID-19: Could melatonin be beneficial for COVID-19 treatment in elderly?|pdf=|usr=017}}
| |
| − | {{tp|p=32773245|t=2020. Influenza immunization and COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32747214|t=2020. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.|pdf=|usr=017}}
| |
| − | {{tp|p=32776298|t=2020. Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort.|pdf=|usr=017}}
| |
| − | {{tp|p=32767940|t=2020. Recent Discovery for Inhibitors Targeting in SARS-CoV-2 and Developed anti-NCP.|pdf=|usr=017}}
| |
| − | {{tp|p=32760027|t=2020. Focus shifts to antibody cocktails for COVID-19 cytokine storm.|pdf=|usr=017}}
| |
| − | {{tp|p=32770162|t=2020. Seeds of hope in COVID-19 vaccine preliminary data.|pdf=|usr=017}}
| |
| − | {{tp|p=32747742|t=2020. Dexamethasone nanomedicines for COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32760013|t=2020. Anti-IL-6Rs falter in COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32760011|t=2020. COVID-19 vaccine guidelines.|pdf=|usr=017}}
| |
| − | {{tp|p=32756549|t=2020. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.|pdf=|usr=017}}
| |
| − | {{tp|p=32698192|t=2020. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.|pdf=|usr=017}}
| |
| − | {{tp|p=32749808|t=2020. Hydroxychloroquine en chloroquine bij COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32639122|t=2020. COVID-19 Pandemic - Nephrology Experiences.|pdf=|usr=017}}
| |
| − | {{tp|p=32732294|t=2020. Brain death evaluation during the pandemic.|pdf=|usr=017}}
| |
| − | {{tp|p=32738510|t=2020. Parenteral fish oil: An adjuvant pharmacotherapy for coronavirus disease 2019?|pdf=|usr=017}}
| |
| − | {{tp|p=32769659|t=2020. Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19).|pdf=|usr=017}}
| |
| − | {{tp|p=32757981|t=2020. In silico Potential of Approved Antimalarial Drugs for Repurposing Against COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32758635|t=2020. COVID-19: Pharmacology and kinetics of viral clearance.|pdf=|usr=017}}
| |
| − | {{tp|p=32758336|t=2020. Avoiding COVID-19 complications with diabetic patients could be achieved by multi-dose Bacillus Calmette-Guerin vaccine: a case study of beta cells regeneration.|pdf=|usr=017}}
| |
| − | {{tp|p=32764148|t=2020. Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2.|pdf=|usr=017}}
| |
| − | {{tp|p=32657706|t=2020. Benefit v. risk when using chloroquine in patients with severe COVID-19 disease.|pdf=|usr=017}}
| |
| − | {{tp|p=32657716|t=2020. Critical care triaging in the shadow of COVID-19: Ethics considerations.|pdf=|usr=017}}
| |
| − | {{tp|p=32747425|t=2020. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.|pdf=|usr=017}}
| |
| − | {{tp|p=32554572|t=2020. Pandemic vaccines are about to face the real test.|pdf=|usr=017}}
| |
| − | {{tp|p=32631874|t=2020. The line starts to form for a coronavirus vaccine.|pdf=|usr=017}}
| |
| − | {{tp|p=32646976|t=2020. U.K. megatrial outshines other drug studies.|pdf=|usr=017}}
| |
| − | {{tp|p=32753553|t=2020. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.|pdf=|usr=017}}
| |
| − | {{tp|p=32739134|t=2020. Tratamiento farmacologico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32692266|t=2020. Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status.|pdf=|usr=017}}
| |
| − | {{tp|p=32773244|t=2020. Ensuring access and affordability through COVID-19 vaccine research and development investments: A proposal for the options market for vaccines.|pdf=|usr=017}}
| |
| − | {{tp|p=32684497|t=2020. Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus.|pdf=|usr=017}}
| |
| − | {{tp|p=32696759|t=2020. [Discussion and prospect of infusion of NK cells in the treatment of SARS-CoV-2 infection].|pdf=|usr=017}}
| |
| − | {{tp|p=32762168|t=2020. [Nutritional support for critically ill patients with COVID-19].|pdf=|usr=017}}
| |
| − | {{tp|p=32648389|t=2020. [Exploration of fire needling therapy on coronavirus disease 2019].|pdf=|usr=017}}
| |
| − | {{tp|p=32726008|t=2020. [Analysis of potential role of Chinese classic prescriptions in treatment of COVID-19 based on TCMATCOV platform].|pdf=|usr=017}}
| |
| − | {{tp|p=32726006|t=2020. [Analysis on formula of Mongolian medicine for prevention of COVID-19].|pdf=|usr=017}}
| |
| − | {{tp|p=32726005|t=2020. [Analysis of medication regularity and pharmacodynamic characteristics of traditional Chinese medicine treatment in 444 severe cases of COVID-19].|pdf=|usr=017}}
| |
| − | {{tp|p=32726004|t=2020. [Analysis of traditional Chinese medicine from patent information sharing platform of coronavirus disease 2019 (COVID-19)].|pdf=|usr=017}}
| |
| − | {{tp|p=32726003|t=2020. [Large- scale prospective clinical study on prophylactic intervention of COVID-19 in community population using Huoxiang Zhengqi Oral Liquid and Jinhao Jiere Granules].|pdf=|usr=017}}
| |
| − | {{tp|p=32727176|t=2020. [Analysis of clinical characteristics of 49 cases of COVID-19].|pdf=|usr=017}}
| |
| − | {{tp|p=32385989|t=2020. [Glucocorticoid for coronavirus disease 2019: a dilemma].|pdf=|usr=017}}
| |
| − | {{tp|p=32684211|t=2020. [A comparative study on clinical effects of dexmedetomidine and midazolam on patients with severe coronavirus disease 2019 on non-invasive ventilation].|pdf=|usr=017}}
| |
| − |
| |
| − | {{tp|p=32733775|t=2020. Ascorbate as Prophylaxis and Therapy for COVID-19-Update From Shanghai and U.S. Medical Institutions.|pdf=|usr=017}}
| |
| − | {{tp|p=32748329|t=2020. Comment on "Possible prophylactic or preventive role of topical povidone iodine during accidental ocular exposure to 2019-nCoV".|pdf=|usr=017}}
| |
| − | {{tp|p=32754651|t=2020. SARS-CoV-2 RNA Dependent RNA polymerase (RdRp) - A drug repurposing study.|pdf=|usr=017}}
| |
| − | {{tp|p=32719218|t=2020. Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort study.|pdf=|usr=017}}
| |
| − | {{tp|p=32757500|t=2020. Clinical Experience with Use of Remdesivir in the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2: a Case Series.|pdf=|usr=017}}
| |
| − | {{tp|p=32757497|t=2020. Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication.|pdf=|usr=017}}
| |
| − | {{tp|p=32741372|t=2020. Bioinformatics analysis of epitope-based vaccine design against the novel SARS-CoV-2.|pdf=|usr=017}}
| |
| − | {{tp|p=32760915|t=2020. Glucocorticoids save lives in COVID-19 patients.|pdf=|usr=017}}
| |
| − | {{tp|p=32760206|t=2020. Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels.|pdf=|usr=017}}
| |
| − | {{tp|p=32676542|t=2020. Insights into Potential Mechanisms of Injury and Treatment Targets in COVID-19, SARS-Cov-2 Infection.|pdf=|usr=017}}
| |
| − | {{tp|p=32756371|t=2020. BCG Vaccination and Mortality of COVID-19 across 173 Countries: An Ecological Study.|pdf=|usr=017}}
| |
| − | {{tp|p=32758689|t=2020. SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial.|pdf=|usr=017}}
| |
| − | {{tp|p=32756480|t=2020. COVID-19: The Immune Responses and Clinical Therapy Candidates.|pdf=|usr=017}}
| |
| − | {{tp|p=32766115|t=2020. Enlightenment from clinical trials on Chinese medicine for coronavirus disease 2019 (COVID-19).|pdf=|usr=017}}
| |
| − | {{tp|p=32766114|t=2020. Home-based traditional Chinese medicine nursing interventions for discharged patients with COVID-19: a rapid review of Chinese guidelines.|pdf=|usr=017}}
| |
| − | {{tp|p=32766113|t=2020. The role of Korean Medicine in the post-COVID-19 era: an online panel discussion part 1 - Clinical research.|pdf=|usr=017}}
| |
| − | {{tp|p=32766112|t=2020. Evidence map on the contributions of traditional, complementary and integrative medicines for health care in times of COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32742920|t=2020. Could herbal medicine (Soshihotang) be a new treatment option for COVID-19?: a narrative review.|pdf=|usr=017}}
| |
| − | {{tp|p=32742919|t=2020. Is the traditional Chinese herb "Artemisia annua" possible to fight against COVID-19?|pdf=|usr=017}}
| |
| − | {{tp|p=32738617|t=2020. ACE2 Co-evolutionary Pattern Suggests Targets for Pharmaceutical Intervention in the COVID-19 Pandemic.|pdf=|usr=017}}
| |
| − | {{tp|p=32713863|t=2020. Computational search for potential COVID-19 drugs from FDAapproved drugs and small molecules of natural origin identifies several anti-virals and plant products.|pdf=|usr=017}}
| |
| − | {{tp|p=32764200|t=2020. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population.|pdf=|usr=017}}
| |
| − | {{tp|p=32678432|t=2020. Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32754463|t=2020. Preventive and treatment strategies of COVID-19: From community to clinical trials.|pdf=|usr=017}}
| |
| − | {{tp|p=32627758|t=2020. Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses.|pdf=|usr=017}}
| |
| − | {{tp|p=32658285|t=2020. Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic.|pdf=|usr=017}}
| |
| − | {{tp|p=32758429|t=2020. Vitamin D for COVID-19: a case to answer?|pdf=|usr=017}}
| |
| − | {{tp|p=32750438|t=2020. The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32759013|t=2020. High dose folic acid is a potential treatment for pulmonary hypertension, including when associated with COVID-19 pneumonia.|pdf=|usr=017}}
| |
| − | {{tp|p=32758904|t=2020. N-acetycysteine: A potential therapeutic agent in COVID-19 infection.|pdf=|usr=017}}
| |
| − | {{tp|p=32658853|t=2020. Uso de plasma de convalecientes para tratamiento de COVID-19. Historia y evidencia.|pdf=|usr=017}}
| |
| − | {{tp|p=32752010|t=2020. Is Antioxidant Therapy a Useful Complementary Measure for Covid-19 Treatment? An Algorithm for Its Application.|pdf=|usr=017}}
| |
| − | {{tp|p=32756215|t=2020. Therapeutic response to corticosteroids in a critically ill patient with COVID-19: A case report.|pdf=|usr=017}}
| |
| − | {{tp|p=32769922|t=2020. A systematic review and meta-analysis of the efficacy and safety of western medicine routine treatment combined with Chinese herbal medicine in the treatment of COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32729248|t=2020. In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression.|pdf=|usr=017}}
| |
| − | {{tp|p=32751194|t=2020. Newcastle Disease Virus as a Vaccine Vector for SARS-CoV-2.|pdf=|usr=017}}
| |
| − | {{tp|p=32721181|t=2020. Immunometabolic Status of COVID-19 Cancer Patients.|pdf=|usr=017}}
| |
| − | {{tp|p=32639219|t=2020. Anti-protease Treatments Targeting Plasmin(ogen) and Neutrophil Elastase May Be Beneficial in Fighting COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32741697|t=2020. Antiviral activity of green tea and black tea polyphenols in prophylaxis and treatment of COVID-19: A review.|pdf=|usr=017}}
| |
| − | {{tp|p=32756606|t=2020. Development and simulation of fully glycosylated molecular models of ACE2-Fc fusion proteins and their interaction with the SARS-CoV-2 spike protein binding domain.|pdf=|usr=017}}
| |
| − | {{tp|p=32761523|t=2020. Potential treatment of COVID-19 by inhibitors of human dihydroorotate dehydrogenase.|pdf=|usr=017}}
| |
| − | {{tp|p=32754890|t=2020. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.|pdf=|usr=017}}
| |
| − | {{tp|p=32759053|t=2020. A severe COVID-19 despite ongoing treatment with Lopinavir-Ritonavir.|pdf=|usr=017}}
| |
| − | {{tp|p=32747923|t=2020. Ethical review of patient safety and public health in EU clinical trials legislation: impact of COVID-19 pandemic.|pdf=|usr=017}}
| |
| − | {{tp|p=32761451|t=2020. Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs.|pdf=|usr=017}}
| |
| − | {{tp|p=32753646|t=2020. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication.|pdf=|usr=017}}
| |
| − | {{tp|p=32742241|t=2020. Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes.|pdf=|usr=017}}
| |
| − | {{tp|p=32714112|t=2020. A SARS-CoV-2 Vaccination Strategy Focused on Population-Scale Immunity.|pdf=|usr=017}}
| |
| − | {{tp|p=32748331|t=2020. Physiological Relevance of Angiotensin Converting Enzyme 2 As a Metabolic Linker and Therapeutic Implication of Mesenchymal Stem Cells in COVID-19 and Hypertension.|pdf=|usr=017}}
| |
| − | {{tp|p=32746913|t=2020. Clinical practice guidelines and experts' consensuses of traditional Chinese herbal medicine for novel coronavirus (COVID-19): protocol of a systematic review.|pdf=|usr=017}}
| |
| − | {{tp|p=32684095|t=2020. Worrying situation regarding the use of dexamethasone for COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32662203|t=2020. Hypothetical targets and plausible drugs of coronavirus infection caused by SARS-CoV-2.|pdf=|usr=017}}
| |
| − | {{tp|p=32713627|t=2020. Convalescent plasma for covid19 - How long should a donor be excluded from donation?|pdf=|usr=017}}
| |
| − | {{tp|p=32711925|t=2020. Can Activation of NRF2 Be a Strategy against COVID-19?|pdf=|usr=017}}
| |
| − | {{tp|p=32707833|t=2020. COVID-19: Mechanisms of Vaccination and Immunity.|pdf=|usr=017}}
| |
| − | {{tp|p=32730781|t=2020. Immunometabolism pathways as the basis for innovative anti-viral strategies (INITIATE): A Marie Sklodowska-Curie innovative training network.|pdf=|usr=017}}
| |
| − | {{tp|p=32726231|t=2020. Addendum to Systematic Review of Remdesivir for the Treatment of COVID-19.|pdf=|usr=017}}
| |
| − | {{tp|p=32726230|t=2020. Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature.|pdf=|usr=017}}
| |
| − | {{tp|p=32726238|t=2020. Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management.|pdf=|usr=017}}
| |
| − | {{tp|p=32742564|t=2020. Stem cell therapy for COVID-19 and other respiratory diseases: Global trends of clinical trials.|pdf=|usr=017}}
| |
| − | {{tp|p=32684209|t=2020. [Meta-analysis of single-group rate of the distribution of traditional Chinese medicine syndromes in 2 139 patients with coronavirus disease 2019].|pdf=|usr=017}}
| |
| − | {{tp|p=32684206|t=2020. [Application of convalescent plasma for the treatment of adult patients with coronavirus disease 2019].|pdf=|usr=017}}
| |
| − | {{tp|p=32684205|t=2020. [Expert opinion on diagnosis and treatment of coronavirus disease 2019 with traditional Chinese medicine based on "three syndromes and three methods"].|pdf=|usr=017}}
| |
